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1.1 Introduction 
This thesis is about the application of immunological insights and techniques to 
improve diagnosis, treatment and follow-up of inflammatory skin diseases, like 
allergic contact dermatitis (ACD) and allergic drug eruptions (ADE). The cells and 
mediators involved in cutaneous inflammation, allergic skin reactions in particular, 
will be discussed below. In chapter 1.2 and 1.3, clinical, epidemiological and im-
munological aspects of ACD and ADE, respectively, will be discussed. Finally, the 
various immunological techniques used in this thesis will be summarized in chap· 
ter 1.4. 
Cutaneous inflammation 
Healthy, uninflamed skin, with the horny layer as the first barrier, protects the body 
from loss of cells, fluids and electrolytes and from penetration of harmful sub-
stances like chemicals and infectious agents. In inflammatory skin conditions, such 
as psoriasis, contact allergy and wound healing, this barrier is disrupted or indi· 
rectly disturbed by an inflammatory infiltrate in the epidermis. Usually, inflamma-
ti on is an effective response. It is the basic reaction of living tissue to several types 
of injuries leading to its complete or incomplete healing. The classical signs of 
inflammation, irrespective of the tissue(s) involved, are rubor, calor, dolor, tumor 
and functio laesa, Le. redness, heat, pain, swelling and disturbed function, respec-
tively. However, inflammatory skin disease may become 50 severe and widespread 
that it intervenes with physiological functions of the skin, like protection against 
external agents, prevention of water and heat loss, and, in a broader sense, psy-
chosocial functions of the affected individu al. 
In inflammatory skin diseases, allergic skin reactions included, various resident, 
recruited and/or recirculating ce lis and their mediators participate. Together they 
constitute the Skin Immune System (SIS) [1, 2J. The SIS includes cells of the 
epidermis, the dermis, the blood vessels, the Iymphatics, and their mediators. The 
cutaneous nervous system interacts with several of these components of the SIS. 
The various constituents mentioned will now be looked at more closely in the 
following sections. 
1.1.1 Cells involved in cutaneous inflammation 
The cellular component of the SIS consists of keratinocytes (KC), Langerhans 
cells (LC), melanocytes, Iymphocytes, cells from the monocyte/macrophage 
lineage, granulocytes, mast cells (MC) and endothelial cells (EN). 
Keratinocytes 
KC make up 95 percent of the epidermis and produce keratins which give the skin 
its strength. The innermost or basal KC actively proliferate. They differentiate and 
give rise to, subsequentiy, the stratum basale, stratum spinosum, stratum 
granulosum, stratum lucidum and stratum corneum. The stratum corneum is the 
outermost layer which consists of cornified and flattened KC and forms the prin· 
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ciple barrier to exogenous agents. Unlike Iymphocytes, monocytes and LC, KC 
are sessile. They grow, differentiate and constitutively produce some cytokines, 
even in the absence of stimuli [3]. Wh en stimulated, however, they produce and 
release a wide array of biologically active substances, such as proteolytic en-
zymes (e.g. acid phosphatase and proteases), growth factors, proinflammatory 
cytokines (e.g. interleukin(IL)-1, IL-6 and tumor necrosis factor(TNF)-a), chemokines 
and inhibitory substances like IL-10, prostaglandin(PG)-E" hydroxy-eicosa-
tetraenoic acids (HETE), transforming growth factor(TGF)-~ and a-melanocyte 
stimulating hormone (MSH) [1,4-8]. On their cell membranes KC express cytokine 
receptors and hu man leukocyte antigen (HLA) class I. When exposed to 
interferon(IFN)-y, KC express HLA class 11, adhesion molecules (e.g. intercellular 
adhesion molecule (ICAM)) and B7-3, but not B7-1 or B7-2 [4, 8-10]. There is 
increasing evidence that such 'activated' KC can act as non-professional antigen 
(Ag) presenting cells (APC) and activate T cells in a direct or indirect manner via 
adhesion molecules (e.g.ICAM-1), cytokines (e.g.IL-1 and IL-1 0) and costimulatory 
molecules (e.g. B7-3) [11, 12]. In contrast, Tcell anergy following interaction be-
tween T cells and KC has also been noted [10]. 
Langerhans cells 
Epidermal LC are distinct tissue dendritic cells (DC). They develop from bone 
marrow-derived precursor cells, that are related to monocytes and circulate in the 
peripheral blood [13-15]. In human skin, LC represent the key APC that control the 
T cell response to Ag [12, 16]. They possess the characteristic Birbeck granules 
and express a distinct pattern of phenotypic markers, such as CD1 a (a specific LC 
marker), band c, CD15s (Iigand for E-selectin (CD62e)), CD45, the adhesion 
molecules CD18 (~-chain of Iymphocyte function-associated antigen(LFA)-1) and 
CD58 (LFA-3), high and low (CD23) affinity Fc receptors for IgE and for IgG (CD32), 
HLA class land class 11 molecules and the cutaneous Iymphocyte-associated 
antigen (CLA) [15]. The HLA class land 11 molecules are part of the human major 
histocompatibility complex (MHC). This is a highly polymorphic cluster of genes 
that code lor MHC molecules on the cell surface of APC, B cells and activated T 
cells (HLA class 11) or all nucleated cells (HLA class I). The HLA molecules repre-
sent 'sell' during presentation of (foreign) Ag to T ce lis (see below). 
LC produce a variety of cytokines, including IL-1 and IL-6. As such, LC are opti-
mally equipped for their task as professional APC of the skin. They take up offend-
ing Ag th at has passed the stratum corneum and process it into small peptides 
which associate intracellularly with HLA class 11. Subsequently, the LC migrate via 
afferent Iymphatics from the skin to the paracortical area of the draining Iymph 
node [17, 18] and differentiate into B7 expressing DC with potent costimulatory 
activity. The peptide-HLA complex is expressed on the cell surface, ready for 
recognition by the T cell receptor (TcR). 
Lymphocytes 
B Iymphocytes are sporadically observed in either healthy or inflamed human skin. 
They can produce antibodies (Ab) but normally do not infiltrate the skin. T cells, on 
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the other hand, are present in healthy skin. Naive T cells may live lor many years 
without dividing. They can be induced to differentiate into at least three lunction-
ally different effector T cells: T helper type 1 (Th,), T helper type 2 (Th,) and CD8' 
cytotoxic T cells. What causes differentiation into Th, or Th, ce lis is not lully under-
stood. The decision may be directed by the type and density ol Ag-HLA com-
plexes, the costimulatory properties ol the APC and by paracrine or hormon al 
effects ol cytokines produced by other ce lis involved in the immune reaction [19]. 
Naive T cells leave the blood and enter the Iymph nodes via interaction ol L -selectin 
and mucin-like vascular addressins (e.g. CD34 and GlyCAM-1) in high endothelial 
venules. In the T cell areas, they can bind transiently to prolessional APC. This 
binding is mediated by LFA-1 and CD2 on the T cell and adhesion molecules ol 
the immunoglobulin superfamily (e.g. ICAM-1, -2 and -3 and LFA-3) on the APC. 
During this period ol contact the HLA class 11 on the APC is sampled lor a specilic 
peptide. In many cases a specilic peptide is not lound and the T cell separates 
Irom the APC. Il the Ag is recognized in the absence ol adequate costimulation, 
anergic T cells are induced which are unable to produce IL-2. This anergy ensures 
T cell tolerance to sell tissue Ag. Alter recognition, intracellular signaling through 
the T cell receptor (TcR) leads to higher affinity ol LFA-1 lor its ligands. If the 
appropriate costimulatory signa I to CD28 on the T cell is provided simultaneously 
through 87 on the same APC, the naive T cell is activated. Interactions between 
CD40L on the activated T cell and CD40 on the APC may sustain, enhance or 
pro long the presentation ol 87-1 or 87-2 on the APC and th us prevent the induc-
tion ol anergy and ineffective or abortive T-cell stimulation [20]. Synthesis ol the 
T cell growth lactor IL-2, and its high affinity receptor (IL-2R), is induced via in-
creased transcription and stabilization ol IL-2 mRNA. The T cell re-enters the cell 
cycle, starts to proliferate and its progeny differentiates into effector T ce lis. Upon 
renewed presentation and recognition ol the Ag, the ellector T cells will produce 
cytokines and initiate an inflammatory response without the need lor costimulation. 
Due to loss ol L -selectin and expresssion ol very late activating antigen(VLA)-4, 
they no longer recirculate and as a result ol increased levels ol LFA-1 and CD2, 
they display more effective adhesion to target cells. Also, their TcR signal trans-
duction is more efficient due to altered conlormation by CD45RO and the increased 
expression ol CTLA-4, another receptor lor 87. All effector T cells mediate their 
lunction through expression ol membrane-bound (e.g. CD40 ligand, Fas ligand) or 
secreted (cytokines, cytotoxins) molecules. In inflammatory skin diseases, such 
as psoriasis, contact dermatitis, drug eruptions, (late phase) atopic dermatitis, 
bullous diseases, cutaneous T celilymphoma and lichen plan us, T ce lis are abun-
dantly present in the skin. At such sites ol cutaneous inflammation, almost all 
T cells bear the skin homing receptor CLA which is the major T celiligand lor the 
vascular adhesion molecule E-selectin on dermal postcapillary venules [21, 22]. 
Other Iymphocytes (specific lor unrelated Ag), granulocyles and macrophages 
are also recruited, and augment the inflammatory reaction. The prominent role ol 
T cells in allergic contact dermatitis will be discussed in chapter 1.2. 
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Monocytes 
Monocytes are bone marrow-derived cells which circulate in the peripheral blood 
until they exit and differentiate into tissue macrophages and OC [13, 14]. Ouring 
their differentiation, the number and properties of their abundant membrane re-
ceptors, secretory products and phagocytic capacity change. The main functions 
of macrophages are ingestion and degradation or storage of foreign particles (in-
cluding micro-organisms) and tissue debris. Many of their specialized degrading 
enzymes are stored in the Iysosomes and released during inflammation. After 
processing, antigenic peptides are presented in the MHC class I or 11 groove to 
Tcells.ln addition, arachidonic acid derivatives and cytokines like IL-1, TNF and 
I FN-aJp are synthesized and secreted. When chronically activated, as in myco-
bacterial infections, they may become epitheloid cells or get incorporated into 
giant cells. 
Granulocytes 
Neutrophil granulocytes are the earliest (within a few hours) bone marrow-derived 
ce lis found at sites of inflammation. Their main function is ingestion, digestion and 
removal of microbes and tissue debris. The cytoplasm of the neutrophil contains 
numero us granules filled with degradative enzym es and other bioactive substances. 
Following ingestion, bactericidal H20 2 and O2- are formed from oxygen in the res-
piratory burst. Additionally, neutrophils can synthesize inflammatory mediators, 
such as platelet activating factor (PAF), 5-HETE, thromboxanes and leukotrienes 
(LT). They express membrane receptors for a.o. Fcy (the constant part of IgG), 
complement and cytokines. 
Eosinophil granulocytes are also phagocytic but only weakly bactericidal. Their 
numbers are increased in norm al wound healing, allergic conditions associated 
with high IgE, parasitic infestations and some neoplasias. Their differentiation 
and activation is mediated by a.o. IL-5 and they are responsive to chemotactic 
factors, PAF, LTS4., PG02 , and granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF). Their membranes contain receptors for IgE, complement, cytokines 
and glucocorticoids. In addition, eosinophils produce a multitude of inflammatory 
mediators that contribute to the micromilieu for local and infiltrating cells, such as 
cytokines, eosinophil cationic protein (ECP), major basic protein (MSP), 
eosinophil-derived neurotoxin (EON), several degradative enzymes, LT and PAF. 
Sasophil granulocytes contribute to wound healing, participate in delayed hyper-
sensitivity reactions and are increased in atopic individuals. They express recep-
tors for IgE (FceRI) and can be activated by specific Ag, anti-lgE, complement and 
eosinophil MSP. 
Mast cells 
MC participate in wound healing, acute inflammatory skin diseases (a.o. allergy) 
and chronic conditions like cutaneous systemic mastocytosis. They express a.o. 
FceRI and receptors for neuropeptides and cytokines [23, 24] and contain more 
preformed inflammatory mediators than basophils. Activated MC synthesize and 
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release TNF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, PG, LT and GM-CSF [25]. MC 
are a heterogenous group of cells. On the basis of their neutra I serine protease 
content, human MC can be divided into two phenotypes: (1) the 'connective-
tissue-type' MC, which is tryptase and chymase positive (MCTe), is present in 
human dermis and contains IL-4 and little IL-5 or IL-6, and (2) Us counterpart, the 
tryptase positive, chymase negative 'mucosal-type' MC which contains IL-4, IL-5 
and IL-6 and gene rally is not present in skin. 
Endothelial cells 
EN, especially of the postcapillary venules, play a critical role in controlling ad he-
sion and subsequent extravasation of leukocytes. In a multistep process, circulat-
ing leukocytes decelerate, become activated, adhere to, and finally pass the EN 
layer [1]. This process is mediated by a number of adhesion molecules on EN, 
such as E-selectin, P-selectin, ICAM-1, ICAM-2, and vascular cell adhesion 
molecule(VCAM)-1, and soluble adhesion molecules like sE-selectin and sICAM-1 , 
th at interact with counter adhesion molecules like CLA, LFA-1 and VLA-4 on granu-
locytes, monocytes and T cells. The density of the adhesion molecules is 
upregulated by inflammatory mediators such as IL-1, TNF-a and IFN-y. 
1.1.2 Cytokines involved in cutaneous inflammation 
Cytokines are smalI, soluble polypeptide molecules th at are produced by virtually 
every cell type in response to exogenous stimuli. They interact with specific recep-
tors to mediate intercellular or intracellular communication. Being active in picomolar 
concentrations, cytokines regulate the amplitude and duration of inflammation by 
acling locallyon nearby cells (paracrine actions), on the same ce lis th at secreted 
them (autocrine) and occasionally via the circulation on distant target ce lis (en do-
crine). Cytokines may display both pleiotropy (one cylokine induces several differ-
ent biologica I effects) and redundancy (different cytokines induce similar biologi-
cal effects). The biologica I response to cytokines reflects a balance between their 
production, their half-lile (decay), the expression of cytokine receptors on the tar-
get cells, and the influence of natural inhibitors. Epidermal cells (EC) are capable 
of producing a wide array of mutually interacting cytokines. 
In Table I, epidermal cytokines which are important in cutaneous inflammation 
[1, 5, 6, 26-29] are grouped into proinflammatory, chemotactic and immuno-
modulatory cytokines and discussed below. 
Proinflammatory cytokines 
The so-called proinflammatory cytokines include IL-1, IL-6 and TNF-a. IL-1 was 
originally denoted by different nam es such as Iymphocyte activating factor (LAF) 
and EC-derived thymocyte aclivating factor (ETAF). In human skin it is produced 
by macrophages, KC, EN and fibroblasts (FB). Different isoforms of IL-1, termed 
IL-1a, IL-1~, IL-1yand IL-1ra have been identified. While IL-1a is biologically ac-
tive, IL-1~ is not until it is proteolytically processed by IL-1~ converting enzyme 
(ICE). In contrast to monocytes and macrophages, which mainly produce IL-1 p, 
Table I. Three classes of cytokines important in cutaneous inflammation. 
Cytokine Stimulus Producer Target Effect 
I. Proinflammatory 
IL-1 LPS, PMA, UV, M<p,KC, EN, FB KC prol, IL-1, IL-6, IL-8, ICAM 
injury, bacterial LC diff 
products, heat T act, IL-2(R), IL-4, IFN-y 
shock proteins, B act 
cytokines NK act 
M<p act, IL-1, IL-6, TNF-()( 
FB WOl, IL-6, ICAM-1 
EN CAM-1 
IL-6 LPS, PMA, UV, KC, FB, M<p KC prol 
injury, cytokines, T act, prol 
TOd B act, prol, diff, Ig-prod 
NK act 
M<p act 
TNF-()( LPS, TPA, Uv, M<p, KC, T KC cY.l0static, ICAM-1 
uroshiol, Ti.l.ct LC dlff 
FB prol 
EN ICAM-1, ELAM-1, VCAM-1 
/I. Chemotactic 
IL-8 IL-1, TNF-()( KC, FB, EN T, Neutro chem 
Gro-()( IL-1, TNF-()( KC, FB, EN T, Neutro chem 
IP-10 IFN-y KC, EN T,Mo chem 
Table I. Three classes of cytokines important in cutaneous inflammation (continued). 
Cytokine 
111. Immunomodulatory 
IL-2 
IL-4 
IFN-y 
Stimulus 
CD28-B7 
interaction 
Toa 
TOd 
Producer 
Th" CTL 
Th" Mc,.c 
Th" CTL 
Target 
KC 
T 
B 
NK 
KC 
T 
B 
M<p 
KC 
LC 
T 
B 
NK 
M<p 
Effect 
? 
act, prol, IL-2R 
prol 
prol 
IL-6, prol 
prol, surv 
prol, act, IgE, MHC 
act, MHC 
ICAM-1, HLA-DR, IP-10 
MHC 
prol, diff 
diff, IgG" 
act 
act, MHC 
act, activation; B, B cell; chem, chemotaxis; diff, differentiation; ELAM, endothelialleukocyte adhesion molecule; EN, 
endothelial cell; FB, fibroblast; ICAM, intercellular adhesion molecule; IP-10, IFN-y-inducable protein 10; IFN, inter-
feron; Ig, immunoglobulin; IL, interleukin; KC, keratinocyte; LC, Langerhans cell; lPS, lipopolysaccharide; MCTC, tryptase 
and chymase posltive mast cell; M<p, macrophage; MHC, major histocompatibility complex; Mo, monocyte; NK, natural 
killer cell; Neutro, neutrophil; PMA, phorbol myristate acetate; prod, production; prol, proliferation; R, receptor; surv, 
survival;T, T cell;T,", T cell activation;Th, T helper;TNF, tumor necrosis factor; TPA, 12-0-tetradecanoylphorbol-13-
acetate; UV, ultraviolet; VCAM, vascular cell adhesion molecule. 
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KC predominantly produce IL-Ia which they release after injury. They are capable 
of producing IL-Ip, but do not use classicallCE to process it into the biologically 
active form. Released pro-IL-I p may be processed by infiltrating inflammatory cells. 
Also, some evidence for activation of human epidermallL-I p by proteinases other 
than ICE has recently been reported [30J. The multiple functions of IL-I (see Table I) 
support the notion of ils central role in inflammation and immunity [5,27, 31J. 
IL-6, another multifunctional proinflammatory cytokine, is also released by mono-
cytes, FB, EN and KC (see Table I). After stimulation, KC produce several biologi-
callyactive IL-6 isoforms. IL-6 participates in both physiological and pathological 
cutaneous processes as part of a cytokine network which consists of IL-I, TNF, 
epidermal growth factor (EGF), platelet-derived growth factor (PDGF), IFN-y, TGF-a 
and TGF-p. In addition, locally produced IL-6 can diffuse into the peripheral circula-
tion, and mediate systemic features of the acute phase response [5J. 
TNF comprises two forms with similar biologica I activity: TNF-a, originally named 
cachectin, and TNF-p or Iymphotoxin. TNF acts on 2 receptors, i.e. a 55 kDa TNFRI 
and a 75 kDa TNFRII. TNF-a is produced by macrophages, activated T cells, MC 
and KC. Together with IL-I, it may indirecily (via induction of B7-I/B7-2 on APC) 
and directly enhance the clonal expansion of Ag-stimulated T cells [32J. Environ-
mental stimuli, like UV-B radiation and contact allergens, may induce TNF-a pro-
duction by KC and consequently increased ICAM-I and VCAM-I expression on 
KC and EN [5, 7J. 
Chemokines 
The family of chemotactic cytokines, or chemokines, are partly responsible for the 
disease-characteristic tissue infiltrate composition and T cell accumulation seen 
in chronic skin diseases. Members of the C-X-C type subfamily (a chemokines), 
like IL-8, Gro-a and IP-IO, are selectively chemotactic forTcelis and neutrophils 
but not for eosinophils, basophils or monocytes. IL-8 and Gro-a are produced in 
the skin by KC, FB and EN after stimulation with IL-Ia, IL-Ip and TNF-a and 
regulate recruitment ofT cells and neutrophils to the skin. Uke IL -I a, I L -8 is prob-
ably preformed and released in diseased skin. IP-IO is expressed in KC after 
stimulation with IFN-y. Members of the C-C type subfamily (P chemokines) attract 
monocyt es, certain T cell subsets, eosinophils and basophils, but not neutrophils. 
They include monocyte-chemotactic and activating factor (MCP-I/MCAF), the factor 
Regulated And Normal T cell Expressed and Secreted (RANTES) and macro-
phage inflammatory protein(MIP)-1 a and p. UWe is known about the role of C-C 
chemokines in the skin, but RANTES may play an important role in delayed type 
hypersensitivity (DTH) reactions [I, 6J. 
Immunomodulatory cytokines 
Typical immunomodulatory cytokines include IL-2, IL-4 and IFN-y. IL-2 plays a key 
role in T cell activation and Tand B cell proliferation. Both IL-2 and its receptor 
(IL-2R) are synthesized by activatedT ce lis after Ag presentation. Ugands binding 
to the surface receptor CD2 can also induce IL-2 production. 
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IL-4 is a Til, cytokine, but it is also produced by MC.lt enhances T cell proliferation 
and induces class 11 MHC expression and the IgG to IgE isotype switch ol B cells. 
IL-4 may directiy induce prolileration ol KC, independent ol IL-6 [33], suppresses 
TIl,-mediated immune responses and is an important down-regulator ol skin in-
flammation [34J. 
IFN-y is produced by Th, cells. It induces activation ol macrophages. IFN-y also 
induces or upregulates class 11 MHC expression on macrophages, LC and KC, 
and the production ol IP-10 and expression ol ICAM-1 by KC. 
Besides the classica I proinflammatory and immunomodulatory cytokines men-
tioned in Table land described above, in recent years the importance ol IL-1 0 and 
IL-12 as additional immunomodulatory cytokines has become clear. Both cytokines 
may be produced by a.o. activated KC and play a critical role in the polarization ol 
immune reactions towards Th, or Th, responses [1, 19J. 
O/her media/ors af inflammatian 
In addition to the cytokines and chemokines mentioned, the humoral component 
ol the SIS comprises several other mediators ol inllammation, such as anti micro-
bial peptides, complement, immunoglobulins, eicosanoids and neuropeptides. The 
enzymes acid phosphatase and cathepsins are released by epidermal cells and 
contribute lurther to inflammation. Neuropeptides like calcitonin gene-relaled pro-
tein (CGRP), substance P (SP), neurokinin A (NKA) and somatostatin (SOM) are 
thought to mediale the complex interplay between the cutaneous nervous system 
and several components ol the SIS. For instance, intradermal injection ol SP is 
known to induce wheal and flare reactions [35J and CGRP has been lound to 
inhibit the induction ol contact hypersensitivity in mice [36J. 
Other inllammatory mediators tllat derive Irom the cells ol damaged tissue, infil-
trating leukocytes or plasma, such as histamine, PG, LT, PAF, and acute phase 
proteins are beyond the scope ol this thesis and will not be discussed here. 
1.1.3 Allergic skin reactions 
Allergic skin reactions are inflammatory skin conditions initially caused by a spe-
citic immune response to an Ag. Normally, the adaptive immune response against 
inlectious agents is benelicial. However, adaptive immune responses mayalso be 
directed against harmiess Ag th at are not associated with inlectious agents, caus-
ing serious disease like allergy, autoimmunity or tissue rejection. Coombs and Geil 
have introduced a classilication in which the immune responses are divided into 
lour main reaction types depending on the Ag and mechanism involved [37J. Many 
skin reactions are good examples ol these immune reactions at work: lor example, 
type I reactions in urticaria and angioedema, type 11 reactions in pemphigus and 
pemphigoid, type 111 reactions in the Arthus reaction and vasculitis, and type IV 
reactions in allergic contact dermatitis and granulomatous reactions in tuberculo-
sis, leprosy, leishmaniasis or due to zirconium and beryllium. Although some re-
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spons es cannot be readily classified into a single reaction type, the classification 
is very useful for didactic and mechanistic purposes. The allergic reaction types !-IV 
will now be looked at more closely. 
Type I or immediate allergic reactions are IgE-mediated responses. They can be 
detected by intracutaneous skin tests and in vi/ra assays like the radioallergo-
sorbent test (RAST) and the basophil degranulation test. The reaction is triggered 
by an allergen that crosslinks two IgE Ab bound to FceR 1 on the same Me, lead-
ing to its activation and consequently the release ol preformed histamine. Later 
on, LT, IL-3, IL-4, IL-5 and TNF-a are also produced, leading to an influx ol mono-
cytes, T cells and eosinophils. These cells dominate the so-called late-phase re-
action. The clinical signs and symptams of a type I reaction are dependent on the 
dose ol the allergen and its route of administration. If given systemically, or even 
locally in the case of a potent allergen and a highly sensitized individual, connec-
tive tissue Me throughout the body may become activated. As a result, histamine 
and other mediators are systemically released causing systemic anaphylaxis. Insect 
venoms and drugs may cause this type ol reaction. Local administration of small 
amounts of allergen in the skin, as done in intracutaneous skin tests, induces activation 
ol local Me resulting in a wheal and flare reaction. Inhalation of allergen may induce 
activation of local mucosal Me causing allergic rhinitis or allergic asthma. Finally, 
ingestion ol allergen may cause activation of local mucosal MC and de ep skin con-
nective tissue MC leading to vomiting, diarrhea and urticaria. 
Type 11 allergic reactions are mediated by IgG or IgM Ab. These Ab bind to cell-
surlace or matrix-associated Ag (for example a drug), leading to activation ol 
complement and FcR' accessory cells, and lysis of the Ag-modified cell. Erythro-
cytes and thrombocytes are particularly vulnerable to this type of response. Asso-
ciated clinical syndromes are hemolytic anemia and thrombocytopenia, but also 
pemphigus and pemphigoid. 
Type 111 allergic reactions are caused by deposition ol Ag-Ab immune complexes 
in many tissues. The Ag to Ab ratio controls the size and precipitation ol the com-
plexes. The dose and route ol Ag administration determine the pat hogen ic poten-
tial. Systemically delivered drugs may in duce serum-sickness-like reactions. Local 
injection into the skin may result in an Arthus reaction. Vasculitis allergica and 
extrinsic allergic alveolitis, or hypersensitivity pneumonitis due to certain inhaled 
Ag, are examples of type 111 reactions. 
Type IV or DTH reactions are mediated by specifically sensitized T cells. This re-
action type is described in greater detail in chapter 1.2 and in chapter 2 on allergic 
contact dermatitis. 
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1.2 Allergie contact dermatitis 
1.2.1 Clinical and epidemiological aspects 
Introduction 
Contact dermatitis (CD) is an inllammatory skin disease that may occur after re-
peated contact with a broad array ol chemical compounds .. lt is a world-wide prob-
lem and a major cause ol occupational disease, interfering with work, household 
and recreational activities [1-5]. 
Based on etiology, two different types ol CD can be distinguished, Le. irritant and 
allergie CD. Morphologically, they are very similar. The main dillerenee is th at aller-
gie CD (ACD) is mediated by specilically sensitized T cells, whereas irritant CD 
(lCD) is not. ACD will be the locus ol this chapter. ft is a classic type IV reaction 
and clinically characterized by erythema, induration, pap ui es, vesicles and itch-
ing. Additionally, lissuring and lichenilication may develop in chronic cases. The 
hands are most commonly affected and the symptoms usually remain restricted to 
the area ol contact. However, secondary lesions may develop elsewhere. Histo-
logically, ACD is characterized bya predominantly mononuclear infiltrate and spon-
giosis ol the epidermis. 
The incapacitating ability ol ACD and the constantly increasing number ol poten-
tial contact allergens are important motives lor intense research into its immuno-
logical background and lor searching new strategies to counteract or prevent this 
unwanted immune response. 
Prevalenee 
Incidence ligures lor CD among the general population are grossly lacking. The 
majority ol the available studies are cross-sectional and among patient popula-
tions ol dermatology clinics and thus provide only estimates ol the prevalence. 
The populations studied often differ in many respects. Differences in the study 
period, the distribution of age and gender, the localization ol the eczema, occupa-
tional and environmental exposure and the type of allergen make comparison ol 
those studies extremely difficult [1]. Reliable comparison is complicated even more 
by the use of different diagnostic criteria lor contact dermatitis, which vary lrom 
self-administered questionnaires or routine examination to lull medical and expo-
sure history, including clinical examination and patch testing. With these limita-
tions in mind, estimates ol the prevalence ol contact dermatitis in the general 
population range between 1 % and 10% [1, 5], with a preponderance ol lCD. How-
ever, in many dermatology clinics the Irequency ol ACD is often higher than that of 
lCD. This may be explained by the more severe and persisting symptoms ol ACD 
and consequently a tendency to seek medical care more often. 
The likelihood ol ACD is tightly correlated with the presence or absence ol certain 
risk lactors [1, 2J. Several ol such possible risk lactors for ACD are shown in Table I, 
grouped into patient, environment, and allergen-related factors. 
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Table I. Pos si bie risk lactors for allergie contact dermatitis. 
Patient 
(susceptibility) 
- age 
- gender 
- genetic predisposition / atopy? 
- pre-existent skin injury 
(e.g. ear-piercing, dryness) 
Environment 
(exposure) 
~ sensitizers I irrilants 
- concentration; frequency 
- site of exposure 
- low humidity 
- high temperature 
Mocclusion 
- sweating 
Allergen 
(sensitizing potential) 
- chemical reactivity 
- vehiele / alloy 
- cross-reactivity 
In most studies, the prevalence of ACD among women is approximately twice as 
high as among men [1,6,7]. The highest prevalence of ACD is seen among young 
women, between 20 and 30 years of age [1, 2]. In men, no clear age trend is seen. 
As ear piercing and wearing of inexpensive jewelry have become very popular, the 
prevalence of nickel sensitivity is increasing, especially among schoolgirls [6, 8, 9]. 
Sweat and especially plasma were found to be very effective in releasing nickel 
from jewelry [10]. Among Norwegian school children between 7 and 12 years of 
age, 17% had proven contact allergy to one or more metals. Among these aller-
gies, nickel was the most common allergen (86%). Girls were affected twice as 
frequent as boys (10% and 4.5%, respectively). Also, nickel sensitivity in girls with 
pierced ears was 2 times more frequent than in those without, and increased with 
the number of holes in the earlobes. Posilive metaltests among atopie girls were 
2 times more frequent than among non-atopics [6]. The poor barrier function of 
atopic skin may explain the higher incidence of ACD in atopic individuals. How-
ever, the role of atopy in the development of ACD is still controversial as lower 
sensitization rates among atopics have also been reported [1]. Possible explana-
tions for the latler observation could be (1) a change in the immunological reactiv-
ity favoring a T helper (Th) type 2 reaction over a Th type 1 reaction, or (2) a 
behavioral change leading to effective avoidance of nickel exposure. 
High occupational exposure occurs in wet work, like household duties, hairdress-
ing / cosmetics, the cleaning industry, food industry and health services, but also 
in dry work, like the rubber, chemical, metal and construction industry. Frequent 
and prolonged exposure to water, soaps, perfumes, dyes, bleaches or other ag-
gressive chemicals and metal equipment facilitate the development of both irritant 
and allergie contact dermatitis. Among fe male cleaners [4] and hairdressers [11] 
CD is a major problem. Sensilization to the allergens in the hairdressers' series, as 
recommended by the International Contact Dermatitis Research Group (ICDRG) 
and its European counterpartthe EECDRG, was seen in up to 51% of European 
hairdressers [11]. 
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Many risk lactors are tightly interrelated. For example, certain types ol 'risky' work 
are al most exclusively performed by young women. Gender-related differences 
may thus be based on differences in occupational exposure instead ol susceptibil-
ity. Additionally, negative risk lactors mayalso exist. For example, early oral expo-
sure to nickellrom dental braces was lound to reduce sensitization rates upon 
subsequent ear piercing in a retrospective study among patients attending patch 
test clinics [12J. 
The number ol possible contact allergens is constantly increasing with some sub-
stances disappearing but more newly developed substances appearing. The sen-
sitization rate ol an allergen in a population is determined mainly by the combina-
tion ol its inherent sensitizing potential and its Irequency ol occurrence or intensity 
ol exposure. In Table 11 the European standard series ol commonly encountered 
contact allergens is summarized along with some estimated sensitization rates 
based on European studies among suspected ACD patients [13J. 
Nickel, chromium and cobalt are the highest ranking sensitizers in many popula-
tion-based and patient-based studies in Europe as weil as in the United States [1 J. 
Sensitivity to nickel was lound in 86% ol conlirmed metal allergies in Norwegian 
school children [6J. Even supposedly inert metals, such as gold, gold salts [14, 15J 
and platinum, have been recognized as contact sensitizers. In chapter 2.1 the 
contact allergen nickel is discussed in greater detail. 
Cosmetics are also a Irequent eau se ol CD, in lemales as weil as in males, and 
amount to 2-4% ol dermatologie consultations [16J. The permanent wave ingredi-
ent glyceryl-monothioglycolate and hair dye ingredient p-phenylenediamine have 
been reported as the leading sensitizers among European hairdressers in 19% 
and 15%, respectively [11 J. 
Acrylates are increasingly used in the medica I, dental, industrial and domestic 
environment (a.o. nail varnish). Occupational contact sensitivity to acrylates has 
been reported in up to 13%, especially among dental laboratory technicians [3, 
17, 18J. 
Latex is increasingly used in health care, a.o. in disposable latex protective gloves, 
catheters, IV tubes, and injection caps. The preventive measures related to the 
HIV epidemie have lead to a rise in prevalenee ol latex allergy up to 10 percent, 
which is comparable to the prevalenee among the highly exposed group ol operat-
ing theater personnel [3, 19-26J. Spina bilida patients are also at risk due to long-
term exposure to latex containing gloves, catheters and tubes [19, 27]. Clinical 
manilestations range Irom mild delayed eczematous skin reactions to severe, even 
lethal, systemic reactions [19J. Most ol the reactions are, however, caused by 
irritation or type I allergy. 
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Table 11. European standard series and sensitization rates among 
suspected ACD patients. 
Contact allergen 
Meta!s 
Nickel sulfate 
Cobalt chloride 
Potassium dichromate 
Cosmetics 
Fragrance mix 
Balsam of Peru 
Isothiazolinone 
Formaldehyde 
p-phenylenediamine dihydrochloride 
Quaternium-15 
Pharmaceutica!s 
Neomycin sulfate 
Colophony 
Wool alcohols 
Benzocaine 
Ethylenediamine dihydrochloride 
Parabens 
Quinolone mix 
Rubber chemica!s 
Carba mix 
Thiuram mix 
Mercapto mix 
Black rubber mix 
Miscelfaneous 
p-tert-butylphenolformaldehyde resin 
Epoxy resin 
Primin 
Modified from Wilkinson and Rycroft [13J. 
ACD, allergie contact dermatitis. 
Diagnosis 
Percentage of ACD 
13-19 
4.6-9.0 
1.4-8.1 
6.4-9.4 
4.0-6.7 
0.9-8.4 
1.4-5.2 
0.3-4.9 
0.3-2.2 
1.3-6.9 
1.7-4.7 
1.2-3.9 
0.4-3.3 
0.6-2.7 
0.5-2.6 
0.7-2.2 
0.8-4.7 
2.0-2.6 
0.6-1.2 
0.3-1.3 
0.3-1.4 
0.6-1.1 
0.3-1.4 
Every suspected contact allergy should be evaluated thoroughly, starting with a 
detailed history and physical examination in which the previously described risk 
factors should be considered. However, the assessment of a causal relation be-
tween exposure to an allergen and its supposed contact allergie reaction is not a 
light task, especially if exposure to multiple allergens occurs. Still, precise details 
on the frequency and type of exposure, the type of allergen involved, the risk 
factors present, and the localization of the eczema are of great practical impor-
tance because they may influence prognosis, as measured by persistenee of symp-
toms, tendency for medical consultation, sick leave and permanent disability [1,2, 13]. 
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Indications on the role of specific allergens in the etiology of ACD can be obtained 
from patch testing. For optimal comparison between different clinics, standard 
patch test (PT) series should be performed according to guidelines of the ICDRG 
[13J. As an example, the European standard series of contact allergens is shown 
in Table 11. A positive PT for an allergen is not sufficient for the clinical diagnosis of 
ACD. Sensitization to one or more allergens is not exceptional in the general popu-
lation and is not necessarily followed by clinically overt ACD. Therefore, the rel-
evance of a positive PT should always be judged by the exposure history [1 J. The 
combination of a positive exposure history and a positive PT for the same allergen 
is highly significant for the clinical diagnosis and relevance of ACD. 
Additional evidence of sensitization to an allergen can be obtained from in vitro 
Iymphocyte proliferation assays (LPA) [28, 29J. In chapter 2.2, the skin PT and the 
LPA are described as parameters for monitoring a hyposensitization procedure in 
nickel ACD patients. 
Predictive testing, to assess the risk of future ACD in an individual case, is not 
(yet) possible. 
Treatment 
Satisfactory treatment of CD is often difficult. Despite improvements in diagnosis 
and treatment of CD, the outcome does not appear to have changed much over 
the past 30 years, especially in occupational CD [2J. 
Rigorous reduction of allergen exposure should be the primary goal in prevention 
of occupational dermatitis [11 J sin ce even occasional contact with the allergen in 
the home or working environment is sufficient to maintain the condition [1 J. Ex-
amples of successfully reduced exposure are the addition of ferrous sulfate to 
cement which significantly reduced skin problems related to chromium exposure 
from cement, and the legal measures in Denmark to prevent nickel exposure from 
a.o. jewelry. Since damaged skin is more susceptible to developing CD, protection 
of the skin with gloves and creams mayalso be helpful. However, .Ihe wearing of 
gloves is not popular and may induce its own skin problems. 
Emollients, topical or even systemic corticosteroids and phototherapy mayalso 
be beneficial. For some contact allergens, e.g. nickel, restriction of dietary intake 
mayalso be useful. In chapter 2.1 the presence of nickel in daily used objects and 
in food is discussed. In chapter 2.2 a possible hyposensitization procedure for 
nickel ACD is described [29J. 
Rigorous avoidance of exposure normally leads to resolution of the clinical signs 
of acute allergie or irritant CD. However, for chronic CD the outcome is less favor-
able.ln a prospective study 1-16 years after the initial presentation, 70% of irritant 
hand dermatitis patients still had active disease [30J. Reported percentages for 
remission or significant improvement of ACD are 30% after 6 years [31 J and 27% 
after 10 years [32J. 
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Exposure and gender are the main predictors associated with outcome. Although 
more frequently affected, women may have a bet1er outcome [2J. However, as 
mentioned earlier many risk factors are tightly interrelated, which may mask their 
individual effe cts. 
1.2.2 Immunological aspects 
In chapter 1.1, the cells and mediators involved in cutaneous inflammation and 
allergic skin reactions in general were discussed. In the following section, the 
immunopathophysiology of ACD will be discussed in greater detail. 
Allergic contact dermatitis is a classica I type IV or delayed type hypersensitivity 
(DTH) reaction. This unwanted immune response is mediated by T cells previ-
ously sensitized to one or more contact allergens. It nicely illustrates the ten sion 
that exists between protective immunity against non-self and reactivity to modified 
self due to reactive chemica Is that may converl normally tolerated proteins into 
highly immunogenic substances [33J. 
Substances capable of inducing ACD are generally low molecular weight chemi-
cally reactive compounds, ca lied haptens. They can penetrate the skin and bind to 
skin- or non-skin-related proteins to form a complete antigen (Ag), capable of 
inducing an immune response. Metal haptens such as nickel mayalso bind 
directly to, and modify, particular self peptides in the MHC groove [15J. Nickel as a 
contact allergen is discussed in chapter 2.1. 
The sequence of events leading to ACD following first and second exposures to a 
reactive hapten can be organized into two phases, i.e. the induction or acquisition 
phase .and the elicitation or expression phase [33J. Table 111 summarizes these 
events and some of their mediators. 
In the afferent limb Ag is taken up, processed and presented in the groove of HI.-A 
class 11 on the surface of Ag presenting cells (APC). Alter migration to the regional 
Iymph nodes, the HLA-peptide complex on the APC can be recognized by the TcR 
of specific T cells, leading to their activation. However, for optimal T cell activation 
and IL-2 production a second signal, the so-called costimulation, is needed. Mul-
tiple accessory signals may be involved in costimulation, including IL-1 and inter-
action of LFA-1, CD28 (and other 87 counter receptors) and CD40L on the T cell 
and ICAM-1, 87-1 (CDBO), 87-2 (CDB6) and CD40 on the APC [34J. Lack of 
costimulation can result in prolonged unresponsiveness of the T cell (anergy) or 
its death. 
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Table 111. Events leading to ACD and same of their mediators. 
Event 
I. Induction phase 
Penetration of hapten and formation of complete Ag 
Uptake and processing of Ag by LC 
Migration of LC to regional Iymph nodes 
Activation of specific T cells via 
Apposition of LC and T cell 
- Presentation of Ag-fragment 
- Costimulation 
- Activation and clonal expansion of selected Th, 
Recirculation and migration of memory T cells 
11. Elicitation phase 
Penetration of hapten and formation of complete Ag 
Recruitment and activation of specific and nonspecific 
CD4' and CD8' T cells and M<p via 
- expression of chemokines by LC, KC and EN 
expression of adhesion molecules and HLA class 11 
by LC, KC and EN 
Modulation of ACD by cutaneous innervation 
Down-regulation of ACD by reg uia tory cytokines 
Mediators involved 
IL-lp, IL-12, PGE, 
chemokines 
ICAM-l/LFA-l, CD3/LFA-2 
HLA class IIlTcR 
IL-l, B7/CD28, CD40/CD40L 
IL-2 
CLA 
CLA 
IFN-y, IL-l, TNF-a. 
IFN-y, TNF-a. 
neuropeptides 
IL-4, IL-l0 
ACD, allergic contact dermatitis; Ag, antigen; CLA, cutaneous Iymphocyte-associated anti-
gen; EN, endothelial cell; HLA, human leukocyte antigen; ICAM, intercellular adhesion mole-
cule; IFN, interferon; IL, interleukin; KC, keratinocyte; LC, Langerhans cell; LFA, Iymphocyte-
associated antigen; M<p, macrophage; PGE, prostaglandin E;TcR, T cell receptor; Th, T helper; 
TNF, tumor necrosis factor. 
In the efferent limb the previously sensitized Ag-specific C04+ T helper type 1 and 
C08+ cytotoxic TeelIs migrate to the skin where they may get activated upon re-
newed Ag presentation. Cutaneous Iymphocyte-associated antigen (CLA) may 
play a prominent role in this homing behavior [35]. Release ol cytokines and 
chemokines like IFN-y, TNF-p, IL-3, GM-CSF, MIP and MCP/MCAF leads to re-
eruitment and activation ol other TeelIs, specilic lor unrelated Ag, and macro-
phages which amplily the ACO response. 
It has been shown that the skin is essential in the development ol ACO. Therelore, 
many ol its intrinsic cell types, cytokines and other cellular constituents have been 
studied extensively lor their roles in the induction, elicitation and down-modulation 
ol ACO. Most ol these ce lis and mediators have already been discussed in chapter 
1.1. In addition, application ol allergen to the epidermis was lound to cause an up-
regulation ol HLA class 11 on epidermal LC [36, 37], an allergen-specilic cytokine 
pattern consisting ol early epidermal LC-produced IL-1p and KC-produced IL-la 
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and IP-10, and non-specifically induced cytokines Iike KC-produced TNF-o: and 
T cell derived IFN-y [38,39], Administration of the Th,-promoting cytol<ine IL-12 
during hapten sensilization was found to in duce effector CD4' T cells that pro-
duced IFN-y, but not IL-4 in response to T cell receptor-mediated stimulation [40], 
On the other hand, KC-derived IL-10, which is specifically induced by contact 
allergens, inhibits the APC function of LC via inhibition of costimulatory signals 
and thereby enables counter-regulation of ACD and even tolerance induction [39, 41], 
In addition, KC can also activate T ce lis as non-professional APC, thereby inducing 
T cell anergy due to the absence of proper costimulatory signals [42, 43], 
In chapter 2, allergic contact dermatitis due to nickel wiJl be described in greater 
detail. 
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1.3 Allergie drug eruptions 
1.3.1 Clinical and epidemiological aspects 
Introduction 
Allergic drug reactions are a small but important part of the broad range of ad-
verse drug reactions (ADR). An accepted definition of ADR is: any undesired and 
unintended response that occurs at certain doses of a drug given for therapeutic, 
diagnostic or prophylactic benefit of the patient [1]. An ADR can be considered 
allergic if it is mediated by an antigen(Ag)-dependent immunological mechanism, 
i.e. via antibodies (Ab) or T cells. Although 'hypersensitivity' is widely used as a 
synonym, we prefer the term 'allergy' as it indicates an underlying immunological 
mechanism, whereas 'hypersensitivity' does not. Table I shows drug allergy in the 
context of a classification of all ADR based on the predictability and dose-depen-
dency of the reaction. 
Table I. Classifiealion of adverse drug reaclions. 
Predictabie Unpredictable 
( dose-dependent / in normal palients ) ( dose-independent / in susceplible palients ) 
- overdose / toxicity ~ intolerance 
- side effects - idiosyncrasy 
- secondary / indirect effects - allergy 
- drug interaclions - pseudoallergy 
Modified trom DeSwarte [1 J. 
The two main categories of ADR are predictabie reactions, which are usually dose-
dependent and occur in otherwise healthy patients, and unpredictable reactions, 
which are often dose-independent and limited to a small group of susceptible 
patients. Among the predictabie reactions, side effects are the most common ac-
counting for up to 80% of ADR. 
Unpredictable ADR comprise intolerance, idiosyncrasy, allergy and pseudoallergy. 
The term intolerance is used for quantitatively increased, pharmacologically char-
acteristic effects ot a drug, often at unusually small doses. Idiosyncrasy is re-
served for qualitatively abnormal responses to a drug, unrelated to its ph ar ma co-
logical actions and not the result of an immune response. Pseudoallergy is used 
for qualitatively abn or mal reactions to a drug that may resem bie an allergic ADR in 
any aspect. Especially type I allergic reactions (Coombs and Geil) are often mim-
icked but the main difference trom true allergy is that interaction of specific Ab or 
sensitized T ce lis with the drug is not involved. Likewise, a sensitization period is 
absent and skin tests are not helptul. Finally, drug allergy, which comprises about 
5 to 10% ot ADR, will now be looked at more closely. 
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Allergie ADR mayor may not follow the well-known allergie reaction types origi-
nally described by Coombs and Geil [2J, which are reviewed in section 1.3.2. Actu-
ally, drug allergy may mimic many diseases that range from mild to even fatal 
conditions. The majority of allergie ADR, however, involve the skin [1 J and are 
consequently also termed allergie drug eruptions. They may be accompanied by 
fever, hematologieal, hepatic, renal, museuloskeletal, eardiorespiratory, autoim-
mune or other systemic manifestations. The variety of dermatological appearances 
includes exanthematous and eczematous eruptions, urtiearia and angioedema, 
(photo)allergie contact dermatitis, fixed drug eruptions, exfoliative dermatitis, 
Stevens-Johnson syndrome and toxic epidermal neerolysis (TEN) [1, 3-5J. 
Prevalenee 
Data on drug eruptions are voluntarily reported and recorded in Europe [6J. Sim i-
lar reporting and registration systems are maintained elsewhere, e.g. by the Food 
and Drug Administration in the United States, and are vital for detection, notifica-
tion, and epidemiologieal purposes [7-9J. Nonetheless, systematic studies on the 
incidence and prevalenee of allergie ADR in a general population are grossly lack-
ing [3J. Currently available studies are often difficuIt to compare as they differ with 
respect to the drugs and populations studied, and the criteria used for the diagno-
sis of drug allergy. Additionally, these studies are likely to be biased due to the 
voluntary reporting system used. 
Reported frequeneies of ADR (allergie and nonallergie) range from 0.3% to 30% 
per drug treatment [10J. Allergie ADR are estimated to account for 5-10% of all 
observed ADR [5, 10]. For most eommon drugs, however, the risk of an allergie 
reaction is between 1 % and 3% [1]. Reported frequencies of hospitalization due to 
ADR vary signifieantly from 0.2% to 29%. The frequeney of drug-attributed deaths 
is estimated at 0.1-0.01 % of inpatients [1J. 
The likelihood of an allergie ADR is tightly correlated with the presenee or ab-
sence of certain risk factors [1, 4, 5, 10]. A number of risk factors thaI have been 
identified for drug allergy are shown in Table 11 and grouped into patient, treatment, 
and drug-related factors. 
Age is an example of a patient-related risk factor: the incidence of drug allergy in 
children and the aged is lower than that in adults. A familial predisposition to drug 
allergy has also been noted but the genetic factors involved have not yet been 
elucidated [1, 5]. Whether atopy represents a risk factor for allergie ADR is still 
eontroversial [1, 3, 11 J. Previous allergie, and possibly even nonallergie ADR, are 
also a risk for the development of new ADR. 
Treatment-related factors include dose and duration of treatment and concomitant 
use of multiple drugs [10]. High dose and long-term drug therapy increase expo-
sure and therefore the risk of allergie ADR. 
Allergic drug eruptions 
Table 11. Risk factors for allergic adverse drug reactions. 
Patient 
(susceptibility) 
- age 
- gender 
- genetic predisposition I atopy? 
- previous (non)allergic ADR 
~ concurrent disease 
Treatment 
(exposure) 
- current drug exposure 
(dose; frequency; duration) 
- previous exposure 
- route of administration 
- polypharmacy 
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Drug 
(or metabolite) 
- molecular size 
- chemical reactivity 
- cross-reactivity 
The route of drug administration is another risk-determining factor. For example, 
topical application of some drugs (e.g. antibiotics and antihistamines) may induce 
allergic contact dermatitis, and oral therapy is considerably less likely to induce 
severe reactions, such as anaphylaxis, than parenteral administration [5]. 
Chemical reactivity is a cru cia I drug-related risk factor, since it determines the 
likelihood that a drug will bind to a carrier molecule, turning it into a multivalent 
complete allergen [4J. Certain drugs induce allergic ADR more frequently than 
others. Commonly used allergenic drug groups are antibiotics (including penicil-
lins, cephalosporins and sulfonamides), anti-epileptic drugs (AED), anesthetics 
(including muscle relaxants and thiopental), hormones (a.o. insulin), immunoglo-
bulins and vaccines [4, SJ. In an interview-based Canadian study among patients 
scheduled for surgery, antibiotics (50%), opioids (27%), non-steroidal anti-inflam-
matory drugs (NSAID) (10%) and sedatives (5%) were found to account for more 
than 90% of reported drug allergies [1 OJ. 
The large influence of risk factors and diagnostic criteria on the reported frequency 
of drug allergy is illustrated by the following data on penicillin allergy. The inci-
dence of penicillin 'allergy' as reported by patients was found seven times higher 
(7.8%) than the actual figure (1.1 %) as judged from a detailed history in a British 
study among hospital patients [12]. Among patients on long-term antibiotic treat-
ment for cystic fibrosis, allergy to beta-Iactam antibiotics, as defined by drug-
induced fever and rash, was seen in 29% [13]. In another study, penicillin allergy, 
as determined by skin tests and radioallergosorbent test (RAST), was found in 
19.4% of patients with a history of a cutaneous reaction following penicillin admin-
istration [14]. Among patients with a previous history of penicillin allergy, positive 
skin tests with major determinant benzylpenicilloyl polylysine and a minor-deter-
minant mixture were seen in 7.1%, as opposed to 1.7% of subjects negative by 
history. Acute allergic reactions upon subsequent penicillin administration to 
individuals with negative skin tests were seen in 2.9% of subjects positive by 
history as opposed to 0.5% of patients negative by history [11 J. 
The incidence of anaphylactic shock, the most severe type of allergic ADR, is 
estimated at 1 in 1,000-10,000 treatments. lts main symptom is a drop in blood 
pressure immediately or within 1 hour after administration of the drug. PeniciJlin is 
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its main elicitor, but preparations used lor hyposensitization and blood or plasma-
derived components mayalso provoke this type ol reaction. Fatal cases ol severe 
generalized anaphylaxis due to penicillin are estimated at 1 in 50.000-100.000. 
Over half ol these occur in patients with no previous history ol penicillin allergy [1, 
3, 5]. Nonimmediate reactions, as evidenced by a positive delayed response to 
direct challenge with penicillin intramuscularly and orally, were seen in 7.6% ol 
patients with a history ol a cutaneous reaction lollowing penicillin administration. 
Immunological mechanisms were demonstrated by a positive delayed skin test in 
65% ol these patients [14]. 
AED also Irequently cause ADR, including allergy. They will be discussed in depth 
in chapter 3. 
Pseudoallergic reactions may mimick true drug allergy in any aspect, sometimes 
posing serious differential diagnostic difficulties.ln the next sections, pseudoallergic 
reactions to NSAID and iodinated contrast media are discussed. 
Pseudoallergic ADR to mild analgesics or NSAID were seen in less than 1 % in a 
Swiss survey ol over 19,000 exposed patients [7]. Pseudoallergic bronchoconstrictive 
reactions and urticaria to aspirin and other NSAI D occur especially in asthmatics 
[4, 5]. The Irequency ol such aspirin 'intolerance' increases with age and is slightly 
higher in lemales [3]. The underlying mechanism is not entirely clear but direct 
non-specific release ol histamine lrom basophils or mast cells, and inhibition ol 
cyclooxygenase have been suggested as possible mechanisms [1, 4]. 
lodinated contrast media mayalso induce pseudoallergic or anaphylactoid reac-
ti ons. These reactions are usually mild and self-limited, but serious reactions do 
occur in about 0.1% ol radiocontrast procedures [4]. Nonionic contrast material 
has been shown to induce lewer and less severe adverse reactions. As such, they 
are a suitable alternative lor patients with previous serious or life-threatening reac-
tions to the hyperosmolar iodinated contrast materials [15, 16]. 
Diagnosis 
Drug allergy is often suspected but rarely properly analyzed, proven and docu-
mented. The patients statement ol being allergic is often accepted without lurther 
investigation [10, 12]. Also, the assessment ol causality between a drug and its 
supposed allergic reaction is not a light task, especially il multiple drugs are pre-
scribed. Discrimination between allergic and other ADR, however, is essential since 
it inlluences luture drug administration. Incorrect labeling ol a patient as allergic 
may lead to substitution ol benelicial medication lor other possibly less effective 
more dangerous andfor more expensive drugs [10]. Therelore, suspected allergic 
ADR should be evaluated thoroughly, starting with a detailed history and physical 
examination in which the previously described risk lactors should be taken into 
consideration. 
In Table 111 the variety ol drug induced cutaneous manilestations are classified 
with respect to the likeliness ol an underlying allergic mechanism [1]. 
Alfergie drug eruptions 
Table 111. Cutaneous manifestations of drug allergy. 
I. Likelyalfergie 
M exanthema 
- urticaria / angioedema 
- contact dermatitis' and photosensitivity 
- fixed drug eruption 
- erythema multiforme 
- exfoliative dermatitis 
- vasculitis 
- toxic epidermal necrolysis (TEN) 
- erythema nodosum 
11. Possibly alfergic 
- eczematous eruptions 
- vesiculobullous reactions 
- lichen planus 
- pityriasis rosea 
111. Not allergie 
- acneiform eruptions 
- pigmentary changes 
- alopecia 
- tumors 
'allergie contact dermatitis is discussed in chapter 1.2. 
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Additional clinical and laboratory criteria suggestive of drug allergy are summa-
rized in Table IV. These clinical criteria are often insufficient for a elear distinction 
between allergic and non-allergic ADR. However, such distinction is highly relevant 
as it influences future drug administration. Therefore, additional tests are often 
needed. Predictive tests, to assess the risk of future drug allergy in an individual 
case, are not (yet) available, despite many attempts [1, 17]. Several diagnostic 
tests have been suggested. However, the lack of a 'golden standard' for the diag-
nosis of allergic ADR seriously hampers the proper validation of such tests. 
Rechallenge is the most definite test but it may be hazardous and a life-threaten-
ing anaphylactic reaction can be the result. It should therefore be restricted to 
cases in which no alternatives exist and may only be executed after informed 
consent, in an intensive care setting, and by experienced physicians [5]. 
Skin tests, like intradermal and patch tests (PT), and În vi/ra tests, like the RAST, 
the enzyme-linked immunosorbent assay (ELISA), the basophil degranulation test, 
and the Iymphocyte proliferation assay (LPA), have all been practiced. However, 
the suitability of these tests is highly dependent on the drug involved. In addition, 
many tests are time critica I and may be disturbed by concurrent symptomatic drug 
therapy, like antihistamines and corticosteroids. Proper positive and negative con-
trols should therefore always be ineluded. 
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Table IV. Clinical and laboratory criteria suggestive ol drug allergy. 
- occurrence in minority of (susceptibie) patients 
- sensilization period > 1 week (no prior exposure) 
- manifestations unrelated to pharmacological actions of the drug 
- manilestations matching known allergic reaction types 
(e.g. anaphylaxis, urticaria, serum sickness-like reaetions) 
- blood / tissue eosinophilia 
- demonstration of drug·speeific antibodies or sensitized TeelIs 
- disappearance within several days after discontinuation 
- reproduction by minute doses of the same or immunochemically related drugs 
Modified from DeSwarte [1 J. 
A suitable diagnostie test for allergie ADR should be quick, inexpensive, able to 
demonstrate either specific Ab or sensitized TeelIs (which may be the only differ-
ence between a true allergie and a pseudoallergie ADR), and above all safe. In 
vitro tests are likely to be the safest alternatives to rechallenge. Skin tests seem 
quite safe as gene rally mild self-limited adverse reactions to skin tests with major 
and minor determinants of penicillin were seen in only 1.2% of patients with a 
positive history. The safety could be increased even more by doing preliminary 
scratch tests before intradermal tests [11 J. 
Demonstration of drug-specific Ab, as was often the only analysis in the past, may 
be suggestive for sensitization but is not sufficient for the clinical diagnosis allergie 
ADR. Actually, many people have penicillin-specific IgG and IgM without develop-
ing clinically overt allergy to the drug [1, 12J. However, the concomitant presence 
of suggestive clinical and immunological parameters are highly significant for the 
diagnosis. 
In chapter 3, the skin PT and the LPA are investigated for their suitability to detect 
allergy to the AED carbamazepine and its metabolites. A flow diagram for diagnos-
ing anti-epileptic drug allergy is also proposed. 
Trealmenl 
For didactic purposes, treatment is discussed here after diagnosis. However, in 
suspected allergie ADR the offending drug should be discontinued as soon as 
possible, usually before extensive di agnost ie exploration can be done. In most 
cases prompt withdrawal of the causative drug will halt the allergie response. A 
non-cross-reactive substitute drug may be started if needed. Symptomatic treat-
ment with corticosteroids or antihistamines can be of help. Systemic adrenaline 
and/or antihistamines may be needed in more severe cases. 
Table V. Classification of drug allergie reaction types according to Coombs and Geil [2]. 
Reaction type 
I. Immediate 
1/. Antibody-dependent 
cytotoxic 
111. Immune complex 
IV. Cel/-mediated, DTH 
Mechanism 
drug cross-links specific IgE on mast cells 
and basophils resulting in degranulation 
antibody (lgG/lgM) binds to drug or drug-
altered cell membrane resulting in com-
plement-mediated cytotoxicity 
drug-antibody (lgG) complexes are depo-
sited in blood vessel walls and basement 
membranes leading to complement-
mediated tissue damage 
tissue damage is mediated directly by cyto-
toxie T cells, or indirectly via release of in-
flammatory cytokines by activated Th, cells 
Manifestations 
anaphylaxis, urticaria I angioedema 
bronchoconstriction 
hemolytic anemia, thrombocytopenia, 
leukocytopenia 
serum sickness (urticaria / rash, fever, 
arthritis, Iymphadenrtis), vasculrtis, 
nephritis, hemolytic anemia, thrombo-
cytopenia, drug-induced LE 
allergie contact dermatitis, allergie 
photodermatitis, hepatocellular injury 
DTH, delayed type hypersensitivity; Ig, immunoglobulin; LE, lupus erythematosus; Th, T helper. 
Examples of drugs involved 
penicillin, antisera, hypo-
sensitization preparations 
penicillin, cephalosporins, 
quinine, c<-methyldopa 
penicillin, carbamazepine 
penicillin, antihistamines 
(also topically applied), 
carbamazepine 
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For some drugs (e.g. penicillin and insulin) rush desensitization, as used lor bee or 
wasp allergy, has been successlul. However, the procedure is not without risk and 
should only be undertaken if no alternative is available [4, 12J. The mechanism ol 
action ol desensitization is unclear but generation ol so-called blocking Ab and 
gradual and subclinical mast cell degranulation and thus depletion have been sug-
gested [5J. The restrictions described earlier lor rechallenge are also valid lor de-
sensitization. 
1.3.2 Immunological aspects 
In chapter 1.1, the cells and mediators involved in cutaneous inflammation and 
allergie skin reactions in general were discussed. In the lollowing section, the 
immunopathophysiology ol allergie ADR will be discussed in greater detail. 
Allergie ADR depend on a drug-specific immune response. However, most drugs 
are low molecular substances and consequentiy they cannot induce such an im-
mune response on their own. The drug itsell, or one ol its (mostiy reactive) me-
tabolites lirst needs to bind covalently to carrier molecules, fike proteins 
(e.g. albumin), glycoproteins and sometimes polysaccharides or cell membranes 
(e.g. erythrocytes and platelets). This need lor binding to certain carrier molecules 
may explain why allergic reactions to some drugs remain restricted to particular 
tissues or organs, and why detection ol allergy to same drugs may lail since such 
a carrier molecule is not present in in vi/ra test conditions [1 J. 
The actual response ol the immune system is dependent on the relative concen-
trations ol multivalent drug-carrier complexes and univalent Iree drug or metabo-
lite molecules. The multivalent hapten-carrier complexes, or complete Ag, are th en 
processed (or not [18]) and presented by APC to T cells. II the Ag is recognized, 
prolileration and lormation ol effector and memory TeelIs or production ol specilic 
Ab by B cells lollows. As ol now the patient is sensitized and renewed contact with 
the allergen may lead to an allergic reaction. The underlying immune responses 
may lollow one or more ol the allergic reaction types I-IV as originally described by 
Coombs and Geil [2J. These 'prototype' allergic reactions were discussed in detail 
in chapter 1.1. In Table V, they are brielly summarized lor drug allergy along with 
their mechanisms, clinical manifestations, and some examples ol drugs involved. 
In chapter 3, symptoms, diagnosis and treatment ol allergic reactions to ca rba-
mazepine (CBZ) and other AED, are described in detail. 
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1.4 Inlroduclion 10 Ihe experimenlal work 
In this chapter the various immunological techniques used in this thesis wil! be put 
into perspective. Their purpose, procedure, possibilities and limitations will be dis-
cussed. However, only a broad outline of each procedure wil! be given here. For 
details the reader is referred to the methods section of each chapter. First, the 
methods used in each chapter will be briefly mentioned. Alter that, each method 
will be discussed in greater detail. 
Most of the immunological techniques described below focus on T cell function. In 
chapter 2.2 the patch test (PT), the /ymphocyte pro/i'eration assay (LPA) and flow 
cytometric analysis are used for monitoring immunological parameters during hy-
posensitization treatment of nickel allergie contact dermatitis (ACO) patients. The 
details of the hyposensitization procedure are given in chapter 2.2 and will be 
discussed in chapter 4.ln chapter 2.3 immunohistochemistry (/He) and computer-
assisted image ana/ysis (IA) are used for detection of cytokines and other markers 
of inflammation in inflammatory skin sections. In the chapters 3.2, 3.3 and 3.4 the 
PT and the LPA are validated and used to support the diagnosis of allergie adverse 
drug reactions (AOR) to the anti-epileptic drugs carbamazepine and its metabolites, 
and to bromocriptine. 
Patch test 
Purpose. PT are used as an aid in detecting the antigen (Ag) or drug that caused 
ACO or allergie AOR. 
Procedure. PT chambers with the suspected contact allergens are applied to the 
skin of the back. Alter 48 hours the chambers are removed. At 48 and 72 hours, 
the skin reaction to each allergen is read and scored according to international 
standard criteria. The resulting score can be - (negative), 1 +, 2+, 3+, and occa-
sionally 4+. 
Possibilities. A large number of pos si bie contact allergens can be tested at on ce 
for their relevance. The severity of the allergy is reflected in the height of the PT 
score. The method is safe, quick and cheap. 
Umitations. PT are not suitable for diagnosing type I, 11 and 111 allergie reactions. 
Reproducible and reliable application and reading of PT requires proper training. 
Irritant reactions, induced by some substances, can mimic allergie reactions. Nega-
tive as weil as positive control subjects and Ag should be included for internal 
standardization. Sunbathing can make proper PT analysis less reliable due to the 
immunosuppressive action of ultraviolet radiation. Sporadically, the local allergie 
skin reaction develops into a more generalized allergie reaction or a reactivation of 
previously affected areas. 
Lymphocyle proliferation assay 
Purpose. The LPA is used to demonstrate Iymphocyte reactivity to allergens in 
patients with suspected allergy. 
Procedure. Peripheral blood mononuciear ce lis (PBMC, i.e.lymphocytes and mono-
cytes) are isolated from venous blood of the patient, cultured and exposed to 
suspected Ag. If the Ag is recognized, T Iymphocytes start proliferating. Alter several 
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days of culture the proliferation rate of exposed Iymphocytes is measured and 
compared to that of unexposed Iymphocytes. 
Passibilities. The difference in proliferation rates between exposed and unexposed 
Iymphocytes is a measure of the severity of the allergy or the degree of sensitiza-
tion. As the Iymphocyte exposure to Ag is done entirely in vi/ra, i.e. outside the 
body, the risk of a generalized allergie reaction to the test is completely absent. 
Limita/ians. Negative as weil as positive control subjects and Ag should be in-
cluded for internal standardization. The number of Ag that can be tested at once is 
limited due to the relatively large number of PBMC that is needed per Ag. Ag need 
to be water soluble at the desired concentrations. Seemingly false positive results 
can be found as the LPA can detect Iymphocyte reactivity to an Ag before clinically 
overt allergy manifests itsel!. Finally, the LPA requires extensive laboratory facili-
ties and expertise, is labor intensive and costly. 
Flow cytometric analysis 
Purpase. Flow cytometric analysis is used to rapidly extract objective and repro-
ducible qualitative and quantitative information about the presence of particular 
cell types, structures or produets from a large number of immunofluorescently 
stained cells in suspension. In this thesis it is used to type PBMC as an immuno-
logical parameter during hyposensitization of nickel ACD patients. 
Procedure. Cell samples are processed into suspensions and exposed to mono-
clonal and/or polyclonal antibodies (Ab) that were raised specifically against the 
Ag to be demonstrated, and directly or indirectly coupled to an immunofluorescent 
or otherwise detectable marker substance. After calibration, the aUributes of inter-
est (e.g. forward and side scatter, stain, cell number, etc.) are measured and the 
resulting data are stored for later processing. 
Passibilities. The presence of certain Ag in or on a large number of cells in suspen-
sion, its frequency and its quantity can be rapidly measured with a high degree of 
objectivity and accuracy. 
Limitatians. Because samples are processed into suspensions, information about 
the localization of the Ag is lost. The possibility of non-specific reactivity with other 
ce lis requires a large number of method controls (i.e. positive and negative con trol 
Ab and cell samples) and reduces the applicability of many Ab. Some Ag cannot 
(yet) be detected as they structurally change, disappear or cannot be reached by 
Ab in the staining procedure. High quality flow cytometric analysis requires expen-
sive software and computer equipment. 
Immunohistochemistry 
Purpase. IHC is used to demonstrate particular cell types and structures or prod-
ucts that may be present in certain types of tissue. In this thesis it is used to detect 
cytokines and other markers of inflammation in inflammatory skin of ACD and 
psoriasis patients. 
Procedure. Skin samples are taken by biopsy, prepared into sm all tissue sections 
and mounted onto microscope glass slides. The tissue sections are then exposed 
to monoclonal and/or polyclonal Ab that were raised specifically against the Ag to 
be demonstrated, and directly or indirectly coupled to a visually or otherwise de-
tectable marker substance. 
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Possibililies. The presence and localization of certain Ag in the tissue, and an 
indication of its quantity, can be determined by microscopie analysis. 
Limitalions. The possibility of non-specific reactivity with other tissue components 
requires a large number of method controls (i.e. positive and negative con trol Ab 
and tissue samples) and reduces the applicability of many Ab. Since the method is 
highly sensitive to small known or unknown deviations from the protocol, all samples 
that need to be compared should be processed in one run. Some Ag cannot (yet) 
be detected as they structurally change, disappear or cannot be reached by Ab in 
the IHC procedure. Finally, because the quality of the resulting slides decreases 
with time, microscopical analysis and scoring should be done within a relatively 
short period. 
Computer-assisted image analysis 
Purpose. IA strives to extract objective and reproducible qualitative and/or quanti-
tative information from images that is not immediately obvious from visual inspec-
tion alone. 
Procedure. The images that need analysis are digitized and stored electronically. 
After calibration and pre-analysis image optimization, the attributes of interest 
(e.g. distances, areas, shapes, color, intensity, etc.) are measured and the result-
ing data are stored for later processing. 
Possibililies. Digital storage guarantees absolute conservation of image quality. If 
IA is performed weil, a high degree of objectivity and accuracy can be reached. 
Limitalions. The handling of high quality digital images (high resolution and true 
color) requires expensive image analysis software and computer equipment with 
large memory and storage capacities. Because some of the methods and algo-
rithms are still under development, reliable IA requires caution and a sound under-
standing of information theory and computer technology. 
In both ACD and allergic ADR, the skin is the target organ of immunological reac-
tivity to an allergen. This thesis describes the application of immunological in-
sights and techniques to improve the diagnosis, treatment and follow-up of ACD 
and allergie ADR. In the following chapters, the techniques described above are 
used for the following aims: (1) to monitor clinical and immunological parameters 
during hyposensitization treatment of nickel ACD patients (chapter 2.2), (2) to 
improve quantification of immunostained skin sections in inflammatory skin dis-
eases like ACD and psoriasis (chapter 2.3), and (3) to assess immunological reac-
tivity to the drugs carbamazepine, oxcarbazepine, phenytoin and bromocriptine in 
patients with a possibly allergic ADR to one of these drugs (chapters 3.2,3.3 and 3.4). 
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In this short chapter our locus will be mainly on nickel as a contact sensitizer. This 
metal deserves special attention lor a number ol reasons discussed below. 
Nickel, Ihe ubiquitous allergen 
Nickel is a widespread element. It is one ol the main components ol magma in the 
earth's core. Many daily used objects, such as coins, keys, scissors, wrist watches, 
jewelry and blue jeans buttons contain nickel. Even so-called hypoallergenic jewelry 
contains considerable amounts ol nickel. Sweat and plasma were lound 10 be very 
ellective in releasing available nickellrom such jewelry, especially at low pH and 
alter prolonged contact [1 J. Nickel is also present in many sorts ol lood. Naturally 
rich in nickel content are nuts (walnut, peanut, hazelnut, al mond), bitter chocolate, 
oats, buckwheat, soy products and dried legumes. Finally, nickel is an essential 
component ol many enzym es in bacteria, plants, invertebrates and probably also 
higher animals [2J. 
The primary routes ol nickel exposure and uptake are ingestion in the general 
population, inhalation in the occupational setting, and, to alesser extent, release 
Irom surgical implants and dental prostheses. On average, daily dietary intake is 
150-250 ~lg leading to a normal nickel serum level ol 0.5-5 J.[g/L. Elimination is via 
urinary and biliary excretion with a hall-time ol -28 hours [3, 4J. Although uptake ol 
nickel via the stratum corneum, sweat ducts and hair lollicles ol the skin is impor-
tant in the induction and elicitation ol nickel allergic contact dermatitis (ACD), its 
contribution to overall nickel uptake is lairly small [4J. However, the skin can act as 
a reservoir lor nickel with a mean reten ti on time ol many months [5J. Although 
nickel concentrations in plasma and urine ol nickel allergic and non-allergic indi-
viduals are not dillerent, in occupationally exposed individuals they may be -10 
times higher [6J. 
As stated in chapter 1.2, the sensitization rate ol an allergen in a population is 
determined mainly by the combined effects ol the intensity ol exposure and its 
sensitizing potential [7J. Therelore, substances to which the human skin is Ire-
quently exposed bear a higher risk ol inducing ACD. For nickel, the combination ol 
a mild sensitizing potential and widespread exposure in the general population 
results in the high Irequency ol sensitization ol 10-20%. Moreover, sin ce (ear) 
piercing and wearing ol inexpensive jewelry has become very popular, the preva-
lence ol nickel sensitivity has also increased [1, 8, 9J. In many population-based 
and patient-based studies in Europe as weil as the United States, nickel, chro-
mium and cobalt were the highest ranking sensitizers [7J. Although a st rong clini-
cal association between nickel and cobalt allergy was lound [10J, immunological 
cross-reactivity could not be demonstrated. 
Nickel directly affe els Ihe immune syslem 
Metals, such as nickel, chromium, cobalt, gold, platinum, mercury and beryllium, 
are directly immunogenic and capable ol inducing a wide range ol pathologic and 
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non-pathologic conditîons including ACD, asthma, autoimmune disease and un-
der special conditions also immunological tolerance. Their immunogenicity de-
pends on the ability to lorm complexes with proteins, polysaccharides and even 
nucleic acids. The various actîons ol metals on the immune system and non-
specilic delense mechanisms include mostly inhibitory but also stimulatory el-
lects on phagocytosis, prolileration, cytokine production, synthesis ol antibodies, 
and ceU mediated immune reactions. Target ceUs are keratinocytes, macrophages, 
monocytes, dendritic ceUs, Band T Iymphocytes, natural kiUer ceUs and endothe-
lial ceUs [11]. At high (>1-10 mg Ni/m' air) concentrations, inhalation ol certain 
industriaUy used nickel compounds mayalso cause acute toxicity, and lung and 
nasal cancer [12, 13]. However, ol greatest public concern is nickel ACD. 
Among the substances capable ol inducing ACD, the metals nickel, chromium and 
cobalt are the most common. Nickel can in duce ACD via direct actions on many 
immunocompetent ceUs, including Langerhans ceUs, keratinocytes and endothe-
lial ceUs. A direct effect on keratinocyte viability and IL-1 production has been 
reported [5]. Nickel can also directly in duce endothelial expression ol adhesion 
molecules (lCAM-1, VCAM-1 and ELAM-1) and productîon ol IL-6 via activatîon ol 
the transcription lactor NFKB [14, 15]. FinaUy, nickel can directly modily the pep-
tide-HLA class 11 complex that is recognized by specilic T ceUs [16]. 
In the next two chapters, hyposensitizatîon and immunohistochemical analysis ol 
cytokines in nickel ACD will be discussed. 
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ABSTRACT 
Background: In allergie contact dermatitis (ACD) previously sensitized TeelIs cause 
skin damage. If an ubiquitous allergen like nickel is involved, no effective treatment 
is available. Down-regulation of this allergie response has been described alter anti-
gen presentation in the absence of adequate costimulatory signais. UV exposure 
can enhance such hyposensitization. 
Objective: The aim of th is study was to establish the capability of a hyposensi-
tization procedure to induce antigen-specific toleranee. 
Me!hods: Twenty-one patients with nickel ACD were randomly assigned 10 either a 
hyposensitized or control group. A schedule, consisting of UVB treatment and subcuta-
neous nickel sulfate administration (hyposensitization) or UVB only (control), was 
applied. During the ensuing two years, several clinical and immunologie features 
were monitored. 
Resul!s: During UVB treatment we observed a significant clinical improvement in 
both groups that persisted in the hyposensitized group. Except for increased slope 
varianees of specific Iymphocyte proliferation in time, no clear changes we re seen in 
the immunologie findings. 
Conclusion: Despite significant clinical improvement induced by UVB, hyposen-
sitization did not induce significant changes in the immunologie findings in patients 
with nickel ACD. 
INTRODUCTION 
The type of allergie contact dermatitis (ACD) most frequently diagnosed involves 
nickel allergy. Treatment of chronic ACD has been largely symptomatic because 
consistent avoidanee of skin contact with and dietary intake of nickel are ditficult to 
achieve. Allergen-specific T Iymphocytes are crucial in the pathogenesis of ACD. 
Nickel-specific T Iymphocyte clones have been isolated from peripheral blood of 
nickel-allergic patients [1-4]. When activated, these T Iymphocytes produce IL-2 and 
high levels of IFN-y [1, 4] and cause inflammatory skin injury. Prevention of skin 
injury may be obtained through inhibition of specific T cell activation (e.g. through 
hyposensitization). 
A state of specific toleranee or anergy has been described alter antigen presenta-
tion in the absence of costimulatory signals [5-7]. In both mice [8-21] and human 
beings [5, 22], UVB induces specific hyporesponsiveness when administered simulta-
neously with allergen. UV exposure (even suberythemagenic doses) has significant 
down-modulatory effects on T cell-mediated responses to contact allergens. In a 
previous study, we demonstrated a clear effect of UVB on patch test responses to 
nickel, possibly through depletion of Langerhans ce lis (LC) and induction of CD1 a' 
DR' antigen presenting ce lis (APC) [22]. 
Until now, hyposensitization treatment has been restricted to immediate hypersensitivi-
ty reactions such as to insect venoms and pollen. In view of the clear effects of UVB 
on LC and ACD, we designed a hyposensitization schedule that bypasses the highly 
sensitizing potentialof epidermal LC by combining UVB treatment with subcutaneous 
injection of nickel sulfate solutions. 
58 Chapter 2.2 
MATERlAL AND METHODS 
Patch tests 
Before the start of the study a European standard patch test series of contact allergens 
(van der Bend, Brielle, The Netherlands), including nickel sulfate, potassium dichro-
mate and cobalt chloride, was performed according to guidelines of the Internatio-
nal Contact Dermatitis Research Group. After 48 hours the patch chambers were 
removed. At 48 hours and 72 hours the skin reaction was scored as described 
earlier [23J. At the start of the study, patch tests with nickel, chromium and cobalt 
were repeated to obtain baseline values. Because of the risk of further sensitization 
or boostering, patch tests were not repeated. 
Patients 
Twenty-one patients allergic to nickel as judged by history and clinical signs of con-
tact allergy (predominantlyon the hands and face) indicating nickel as a likely cause, 
and confirmed by a patch test response of 2+ or greater to nickel sulfate were enrolled 
in and completed the study. All subjects were nonpregnant women. 
Each patient was randomly assigned to either the hyposensitized group, scheduled 
for UVB plus nickel sulfate administration, or to the control group, which was to 
receive only UVB treatmen\. The protocol and informed consent documents were 
approved by the committee on medical ethics of our hospita/. The hyposensilized 
group consisted of 12 women, 28 ± 5 years of age. Nine patients, 38 ± 16 years of 
age, formed the control group. 
UVB treatment 
A Waldmann UV1000 standing UV cabinet was used for UV treatmen\. All patients 
(hyposensitized and control groups) received UVB pretreatment during the first 3 to 
6 months. On the basis of skin type, exposure started at 5 to 10 mJ/cm2 three times 
a week and gradually increased, allowing only mild erythema. Nickel sulfate injections 
were started in the hyposensitized group as soon as a cumulative dose of 1.0 J/cm2 
was reached. At th is point, UV exposure was continued once a week until a cumulative 
dose of approximately 1.25 mJ/cm2 was reached. 
Hyposensitization procedure 
Sterile, pyrogen-free, solutions of 10",10'5,10", and 10.3 mol/L nickel sulfate were 
prepared. The lowest concentration equals the nickel concentration normally mea-
sured in body fluids [24-27J. In a manner similar to hyposensitization schedules 
used in type I allergy, weekly subcutaneous injections were started with 0.1 mi of the 
lowest nickel sulfate concentration in the arm. After each injection the patients were 
observed for at least 20 minutes. If possible, the next doses were subsequently 0.2, 
0.4,0.7 and 1.0 mi of the same concentration, and finally 0.1 mi of the next concentra-
tion. Doses were increased until either minimal local symptoms occurred or the 
highest concentration was reached. At th is point the maximal dose achieved was 
continued and the interval was gradually prolonged up to 1 month. The total duration 
of the nickel sulfate hyposensitization was 2 years. 
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Clinical evalua!ion 
The clinical follow-up period was 24 months. At three defined time poinls - at the 
start of Ihe study (month 0), al maximal UVB exposure (month 6), and al the end 
(month 18) of the hyposensitization treatment - clinical evaluation was done. The 
affected area of involved skin, severity (itching, papules, vesicles and fissure forma-
tion), frequency of symptoms, Iherapeutic need (use of corticosteroids and its 
potency), and a subjective quality of life assessment were scored on a standard 
evaluation form. With respect to clinical scores, the control group consisted of eight 
patients because we excluded one patient because of lack of clinical fOllow-up 
information. 
Lymphocyte prolifera!ion assays 
Lymphocyte proliferation assays (LPA) were performed as described earlier [23]. 
Lymphocyte proliferation was expressed as counts per minute (cpm). Stimulation 
indices (SI) (i.e. relative proliferation) were calculated by dividing specific by 
background proliferation.ln our laboratory an SI greater than 3 was considered to be 
indicative of prior Iymphocyte sensitization to nickel. 
Fluorescence-activated cell sorter immunophenotyping 
Peripheral blood samples were immunophenotyped with the monoclonal antibodies 
listed in Table I. Except for Iymphocyte function-associated antigen (LFA)-1/2 and 
BBA4, all monoclonal antibodies were directly conjugated to either fluorescein 
isothiocyanate (FITC) or phycoerythrin (PE). Measurement and analysis was done 
with a FACScan flow cytometer with Simulset, FACScan, Consort 30 and Lysis re-
search software (Becton Dickinson, San Jose, CA). Both absolute cell numbers per 
micro liter and percentages were calculated. 
Statistica I analysis 
Professional STATA 3.0 Statistics/Data Analysis (Computing Resource Center, Santa 
Monica, CA) and EGRET (version 0.26.6, 1991, Serc and Cytel, Seattle) were used 
for data analysis and statistical calculations. 
The change of the disease activity scores during treatment was analyzed, within 
each group, with the Wilcoxon signed-rank test. An exact trend test was used to 
compare the hyposensitized and control groups with regard to the distribution of the 
scores at the end of the study. 
The distributions of SI and cell counts were transformed to normal by taking natural 
log values. This enables use of parametrie statistical methods. The resulting distribu-
tions were checked for normality in normal plots. 
Linear regression was used to analyze time trends of Iymphocyte proliferation and 
activated T cell numbers during treatment [28]. The resulting slope values of both 
groups were compared in attest modified for unequal varianees (Welch test). Equality 
of varianees was tested in the varianee ratio test (Ftest). 
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Table I. Monoclonal antibodies used in th is study. 
Antibody CD code Souree 
(antigen recognized) 
Leu-4 (FITC/PE) CD3 BD 
Leu-3 (FITC/PE) CD4 BD 
Leu-1 CD5 BD 
Leu-2 (PE) CDS BD 
LFA1/2 CD11a CLB 
My4 CD14 CC 
Leu-11 c (PE) CD16 BD 
B1 (FITC) CD19 CC 
B4 (FITC) CD20 CC 
2A3 (PE) CD25 BD 
HLe-1 CD45 BD 
BBA4 CD54 BB 
Leu-19 (PE) CD56 BD 
L243 (PE) HLA-DR BD 
BB, British Biotechnology, Oxon, UK; BD, Becton Dickinson, Sunnyvale, CA; CLB, 
Central Laboratory of the Red Cross Blood Transfusion Service, Amsterdam, The 
Netherlands; CC, Coulter Clone, Hialeah, FL; FITC, fluorescein isothiocyanate; 
LFA, Iymphocyte function-associated antigen; PE, phycoerythrin. 
RESULTS 
Baseline values ol pateh tests and LPA 
The dislribulions of baseline values for bolh palch lesls and LPA in Ihe hyposensilized 
and conlrol groups were compared. Paleh lest scores and speeifie Iymphoeyle 
proliferalion were eomparable in bolh groups. In bolh Ihe hyposensitized and Ihe 
eonlrol groups, a palienl previously (before sludy) reaelive 10 niekel showed a negalive 
baseline value of Ihe paleh test al Ihe slarl of Irealmen\. However, LPA results showed 
Ihal Iymphoeyle reaelivily 10 niekel slill exisled. 
UVB dose 
Individual UVB doses ranged belween 5 and 50 mJ/em'. In bolh groups Ihe cumuIa-
live dose of 1.0 J/em' was reaehed within Ihe firsl 4 monlhs. 
Niekel sullate administration 
Mosi palienls loleraled a 100- 10 1000-fold inerease of Ihe niekel dose wilhin 3 
monlhs. In Iwo palienls Ihe maximum dose of 1.0 mi of 10' mol/L niekel sulfale was 
reached. Adverse effecls remained limiled 10 Iransienl loeal induralion Ihal developed 
al Ihe sile of injeelion wilhin 8 10 24 hours. These lesions were hislologieally 
eharaelerized by a perivaseular accumulation of mononuelear eells. To avoid Ihis 
reaclion, doses were lemporarily lowered. As a result, in some patienls doses varied, 
oeeasionally by 10-fold, because of variabie niekel lolerabilily. 
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Figure 1. Time course of disease activity scores in hyposensitized (Ieft panels) and control 
(right panels) groups with regard to affected area (A and B), severity (C and D), frequency 
(E and F) and therapy (G and H). 
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Clinical evalualion 
Figure 1 shows dot plots of the four disease activity scores in both groups at three 
time points: at the start of the study (month 0), during maximal UVB exposure (month 6), 
and at the end of the study (month 18). Overall, scores within both groups dropped 
during UVB treatment. This trend continued even after UVB exposure was stopped. 
In the hyposensitized group this led to p values of 0.0076, 0.0076, 0.065 and 0.045 
for the affected area, severity, frequency and therapy scores respectively. In the 
control group these p values were larger, namely 0.021, 0.021, 0.94 and 0.14, 
respectively. The change of the disease activity scores was most evident for the 
affected area and severity scores. However, between the hyposensitized and con trol 
groups no statistically significant score differences were found (p = 0.84, 0.33, 0.26 
and 0.40, respectively). 
Lymphocyte prolileration 
Specific Iymphocyte reactivity against nickel was monitored during the hyposen-
sitization therapy. Within each patient, some variation of SI was found during the 
2-year observation period. Neither SI nor net counts per minute values showed 
significant correlation with clinical scores. 
In figure 2, A, mean SI values and 95% confidence intervals of all patients within 
each group are plotted against duration of treatment. Mean proliferation indices over 
time varied between 10 and 30. No significant difference was seen between the 
groups.ln an attempt to characterize further the time course of Iymphocyte reactivity, 
slopes of individual time plots were calculated by linear regression analysis. The 
resulting slope values indicate ascending or descending trends of Iymphocyte 
reactivity with duration of treatment. However, neither positive nor negative slope 
values corresponded with clinical improvement. Figure 2, B, shows approximately 
equivalent mean slope values but increased slope variance in the hyposensitized 
group as compared with control subjects. This difference of variances was highly 
significant (/X0.001). 
Immunophenotyping ol peripheral blood mononuclear ce lis 
Numbers of B cells, TeelIs (including the subpopulations) and natural killer ce lis 
were within normal limits, comparable in both groups and fairly constant over time 
(Tabie 11). 
Table 11. Distribution of Iymphoeyte phenotypes. 
Cell type 
Lymphocytes 
Bcells 
T cells 
CD4> ce lis 
CDS>celis 
Natural killer ce lis 
Niekel allergie 
Hyposensitized Control 
2.0 (1.4-4.1) 
0.2 (O.OS-O.4) 
IA (1.1-3.2) 
1.1 (0.6-2.5) 
0.5 (0.3-1.0) 
0.2 (0.OS-0.3) 
1.3 (1.0-2.5) 
0.1 (0.05-0.2) 
1.1 (0.7-2.2) 
0.7 (0.5-1.4) 
0.3 (0.1-0.7) 
0.1 (0.1-0.2) 
Nonallergic 
contrals 
1.7 (1.1-2.6) 
0.1 (0.1 -0.2) 
1.2 (0.S-2.2) 
0.7 (004-1.5) 
0.4 (0.2-0.7) 
0.2 (0.06-0.6) 
Values are median absolute cell counts per milliliter; 95% confidence intervals shown in parentheses. 
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Figure 2. Level of nickel reactivity in time as measured by nickel-specific Iymphocyte prolifera-
tion: (A) mean SI values over time in all patients within each group. Bars represent 95% 
confidence intervals. (B) slop es of individual time plots as calculated by linear regression 
analysis .• hyposensitized group 0 control group. 
In an attempt to characterize lurther the nickel reactive Iymphocytes, we did 
flowcytometric analysis of peripheral blood mononuclear ce lis lor activated T cells 
with CD3/HLA-DR and CD3/CD25 double-staining. Actual double-positive cell 
numbers per microliter were calculated and plotted against time. Values ranged from 
10 to 1000 cellshtl in both groups. Figure 3 shows the time course of mean CD3'/IL-2 
receptor'(CD25') and CD3'/HLA-DR+ cell counts and 95% confidence intervals of 
all patients within each group. On average, CD25+ counts were 1.7 times higher than 
HLA-DR+ counts. As previously described [29J, co-expression of IL-2 receptor and 
HLA-DR on T ce lis is limited. Apparently these markers represent at least partially 
diflerent types or phases ol activation. The ave rage number of activated TeelIs was 
estimated at approximately 100 to 150 cellshtl (I.e. 5% to 20% of circulating TeelIs). 
These values are within normal limits. 
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LFA-1 a. and intercellular adhesion molecule-I expression of both peripheral blood 
Iymphocytes and monocytes was also measured. Lymphocytes showed a bimodal 
LFA-10; expression, tllat is, normal (LFA-1 ac) and high (LFA-10;*), mainly because 
of the expression of this molecule on TeelIs. During the study, these two levels of 
expression appeared to be inversely correlated. These time trends, however, did not 
match clinical disease activity. 
DISCUSSION 
Hyposensitization with contact allergens has previously been shown to be effective 
[30-34]. The present study describes monitoring of clinical and immunologie fea-
tures during such nickel hyposensitization. 
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Considerabie clinical improvement was observed during UVB pretreatment. In both 
groups this trend persisted even alter UVB withdrawal. No statistically significant 
diflerence between the groups was seen. 
Lymphocyte reactivity to nickel appeared to Iluctuate with time. Height ol SI showed 
no correlation with clinical scores. Discordance between clinical and in vi/ra findings 
has previously been described [35-40]. 
Overall, no significant change in the in vi/ro Iymphocyte reactivity to nickel was seen 
during the monitored period. However, time-trend analysis ol each patienl revealed 
a significantly larger slope variability within the hyposensitized group. lts meaning is 
not entirely clear. Possibly the effect of hyposensitization varies in different persons 
[21,41]. 
ActivatedT Iymphocyfes in peripheral blood, measured as CD3'/HLA-DR' and CD3'/ 
CD25' ce lis, remained within normal limits during trealment. II is conceivable thaI 
Ihe number of nickel-specific memory T Iymphocytes is too low 10 allow detection of 
changes in the peripheral circulation. 
As in Iype I hyposensitizalion, Ihe mechanisms by which clinical improvement might 
be explained, remain 10 be elucidated. Evidence is emerging th at besides LC and 
T Iymphocytes, keratinocytes are also actively involved in immunologic reactions in 
Ihe skin.lnsight into the process ol induction of central or peripheral tolerance, clonal 
anergy or active suppression is only beginning to appear [42-45]. Analysis of epidermal 
ce lis and Iymphocyles for Ihe presence and susceptibility of costimulatory lactors, 
such as adhesion molecules [46-48] and cyfokines [7, 49, 50], and the inlluence of 
immunomodulators, such as UV radiation on these, may provide more insight into 
th is process. 
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ABSTRACT 
Accurate and reproducible quantification of immunostaining is difficult. A number 
of different procedures have been described, producing results that cannot be 
easily compared. Computer-assisted image analysis (IA) may help to overcome 
some of these difficulties. However, reliable IA of immunostained slides requires 
sound knowledge of information theory and computer technology, besides famili-
arity with histology and immunohistochemistry (IHC). Moreover, while IA has been 
used successfully to quantify immunostained cytological preparations and sec-
ti ons of a number of other tissues, application of the technique to skin sections 
has rarely been described. 
We developed and validated a semiautomatic procedure (macro) for area mea-
surement by IA. The accuracy and reproducibility of th is area measurement proce-
dure were high, Le.less than 0.5% and 1 %, respectively. When compared to tradi-
tional grid-based area measurement, the mean values of both methods were simi-
lar but the standard deviation of IA was somewhat smaller. As an example, the IA 
area measurement procedure was applied to immunostained inflammatory skin 
sections. The computer-assisted IA allowed us to quantify immunostaining as cell 
counts per square millimeter of epidermal, dermal or infiltrate section area. 
INTRODUCTION 
Quantification of immunostaining is difficult. Firstly, reliable and reproducible 
immunohistochemistry (IHC) depends heavily on a variety of critical factors, such 
as time between biopsy and embedding, embedding medium, variation of section 
thickness, fixation, species, isotype and subtype of the primary and secondary 
anti body (Ab) and proper Ab and tissue controls [1]. Secondly, quantilication of 
IHC is done by widely different methods. The number of positively stained cells, for 
example, may be expressed per field [2], per unit of basement membrane [3], or 
as a fraclion of the largest positively stained cluster observed [4]. This obvious 
lack of standardized procedures may explain the poor reproducibility of many 
methods, the inter- and intraobserver variance and the difficult interpretation of 
the results obtained from different methods. 
Computer-assisted image analysis (IA) may seem a logical step to overcome some 
of these difficulties. However, reliable IA of immunostained slides requires sound 
knowledge of information theory and computer technology, besides of course 
familiarity with histology and IHC. Although IA has been applied to immunostained 
(single cell) cytological preparations and sections of tissues like bone marrow, 
Iymph nodes, brain, nerve tissue, breast, endometrium and cervix [5], application 
of the technique to immunostained skin sections has rarely been described. 
We describe a standardized, semiautomatic IA procedure to measure epidermal, 
dermal and infiltrate areas in inflammatory skin sections. As an example, the tech-
nique is applied to inflammatory skin sections that were immunostained for cytokines 
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and other markers ol inllammation. This method enabled us to quantily the num-
ber ol stained ce lis per square millimeter ol epidermal, dermal or inlillrate section 
area. 
PATIENTS AND METHODS 
Patients and controls 
Six ACD patients (Hospital Walcheren, Vlissingen, The Netherlands), 6 psoriatic 
patients (University Hospital Dijkzigt, Rotterdam, The Netherlands) and nine healthy 
controls, scheduled lor cosmetic breast or abdominal reduction surgery (Sint 
Franciscus Hospital, Rotterdam, The Netherlands), were enrolled in our study al-
ter inlormed consent. 
The presence and activity ol ACD was judged by history, clinical signs and a patch 
test (PT) response ol 2+ or greater. PTwere performed according to ICDRG guide-
lines with nickel sullate 5% in petrolatum in commercially available PT chambers 
(van der Bend, Brielle, The Netherlands). After 48 hours the PT chambers were 
removed. At 48 hours and 72 hours the skin reactions were scored as previously 
described [6]. Three millimeter punch biopsies were taken lrom positive PT, les ion al 
psoriatic and heallhy control skin. 
Tissue processing 
The skin biopsies were snap Irozen in Tissue-Tek3 O.C.T. compound (Miles Labo-
ratories, Elkhart, IN, USA) and stored at -80°C until lurther processing. Six mi-
crometer sections were pre pa red using a Jung Frigocut 2800E cryostat (Leica, 
Rijswijk, The Netherlands), mounted on 3' aminopropyllriethoxysîlane(APES)-
coated (A3648, Sigma Chemical Company, St. Louis, MO, USA) glass slides, and 
air-dried. Previous experiments had shown APES coating to give the lowest back-
ground staining. For optimal comparison, each slide contained normal, ACD and 
lesional psoriatic skin sections in duplo. Sections ol tonsil, thymus, spleen, cuta-
neous T celilymphoma (mycosis lungoides), bronchial tissue, and cytospin prepa-
rations ol stimulated and unstimulated peripheral blood mononuclear cells were 
included as additional tissue controls. 
Image analysis 
The IA hardware consisted ol a three chip charge-coupled device (3CCD) color 
videocamera (DXC-930, Sony, Tokyo, Japan) mounted to a Zeiss Axioplan light 
microscope (Zeiss, Oberkochen, Germany) at 10x magnificat ion and connected 
to a lrame grabber (Kontron Electronics, München, Germany) in a 80486 66 MHz 
personal computer. Automatic gain control was intentionally turned 011 lor optimal 
comparabîlity. Illumination was provided by a halogen light souree (Philips 7023, 
Philips, Eindhoven, The Netherlands), connected to a stabilized adjustable power 
supply (12V / 100W). Since the emission ol light sourees and the noise and sensi-
tivity ol CCD cameras are known to vary with temperature, and therelore may 
interfere with reliable measurement [7-9], all hardware was allowed a 1 hour warming 
period to minimize these unwanted thermal ellects. 
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Figure 1. Flow diagram of the macro for semiautomatic measurement of epidermal, dermal 
and infiltrate section areas. 
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The IA software consisted of the KS-400 v1.2 software package (Kontron Electro-
nies) running under Microsoft Windows. This macro-based IA software allows 
automatic execution of a user-defined sequence (macro) of image processing 
commands. Figure 1 is a flow diagram of the macro we developed for semiauto-
matic measurement of epidermal, dermal and infiltrate section areas. The proce-
dure is divided into three main parts: (1) calibration of the microscope and the 
CCD camera, (2) image acquisition and (3) image measurement. For optimal com-
parability, calibration and acquisition were done in a single session. 
Calibration 
Color calibration of the red, green and blue (RGB) channels of the CCD camera 
was done via white balance of a blank image. In addition, spatial calibration was 
done to allow conversion of pixels into mm'. However, because pixels are square 
instead of round, the distance between two pixels that touch diagonally is greater 
(..J2 at most) than their distance orthogonally. Thus, to enable accurate image mea-
surement, the resulting error should be corrected by the IA software [8J. We checked 
this correction by measuring a known 0.55xO.55 mm' grid at 0, 15, 45 and 60 
degrees angles of rotation, respectively. 
Image acquisilion 
The acquisition of all images was done in a single session. For each object image, 
a site-matched background (blank) image was captured. The captured area 
amounted to >50% of the total skin section area. Each frame was corrected for 
nonuniform illumination (shading correction) by subtraction of the background 
image from the object image. The resulting image was stored on optical disk in 
an uncompressed 24 bits tagged image file format (TIFF) with a spatial resolution 
of 756x512 pixels and a range of 256 values for each of the R, G, and B channels. 
Image measurement 
First, the contrast of each image was enhanced by linear normalization of the gray 
value histogram. Noise was then suppressed by the application of an edge pre-
serving 3x3 median filter [8J. Histologie artifacts (e.g. tissue folds and bubbles) 
were delineated and excluded from further analysis. Next, the hematoxylin coun-
terstained epidermal and infiltrate section areas were selected by interactively 
setting segmentation thresholds in the gray value histogram of the image. The 
number of small scattered segments was reduced by application of binary mor-
phologic operations, such as opening and closing. The resulting segments were 
labeled and their outer limits were visually checked by superimposing them on 
their corresponding original image. The surface area of each segment was then 
automatically calculated and stored. Finally, a hard copy was made for reference 
during cell counting (see quantification of immunostaining). A similar procedure 
was followed to measure the total area of the tissue section. This method appeared 
highly reproducible due to the characteristic gray value histogram of the image 
(Figure 2), with peaks corresponding to the darker infiltrate and epidermis and the 
lighter dermis, respectively. 
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Figure 2. Characteristic gray value histogram of inflammatory skin, shawing three peaks 
carrespanding ta the infiltrate (128·160), epidermis (192-224) and dermis (224-
256), respectively. 
The reproducibility of IA area measurement was assessed by measuring a single 
normal skin section 10 times. Individual measurements were spaced at least 1 
hour apart and every three successive measurements the microscope and CCD 
camera were turned off, postponing further measurements to the next dav. Addi-
tionaily, area measurement by IA was compared with the more traditional grid-
based method in 20 serial ACD skin sections (see results). 
Immunohistochemistry 
Antibodies and controls 
We used a number of Ab specific for cytokines and other markers ol inflammation. 
The Ab used in th is study and their sources are listed in Table I. The specificity of 
the primary and secondary Ab was checked by using a protein concentration-
matched non-relevant (third-party) monoclonal Ab, a pre-immune mouse IgG, and 
phosphate-buffered saline (PBS). 
Immunosupersensitive alkaline-phosphatase staining 
All incubations and washes were done in a Sequenza immunostaining center 
(Shandon Scientific Ltd, Cheshire, UK). The tissue sections were lixed in acetone 
(10 minutes at room temperature), washed once in PBS and washed twice in PBS 
with 1 % bovine serum albumin (BSA, Sigma Chemica I Company). Subsequently, 
the sections were preincubated with 10% normal rabbi! serum lor 10 minutes. 
Alter that, they were incubated with the primary monoclonal Ab lor 1 hour at room 
temperature, washed in PBS-BSA 1 % and incubated for 30 minutes with a 1 :50 
dilution of biotinylated rabbit anti-mouse immunoglobulin (Biogenex, San Ramon, 
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CA, USA) supplemented with 10% normal human serum. After washing twice in 
PBS, the sections were incubated lor 30 minutes with a 1 :50 dilution ol strep-
tavidin-alkaline phosphatase (Biogenex, San Ramon, CA, USA). Naphtol-AS-MX-
phosphate (0.30 mg/ml, Sigma Chemical Company) and new luchsine (160 mg/ml 
in 2 mol/L HCI, Chroma-Gesellschaft, Köngen, Germany) were used as a sub-
strate lor alkaline phosphatase (AP). Levamisol (0.25 mg/ml, Sigma Chemical 
Company) was added to block endogenous AP activity. Finally, sections were 
counterstained with Mayer's hematoxylin (Merck, Darmstadt, Germany) and 
mounted in Kaiser's glycerol-gelatin (Merck). 
Table I. Antibodies used in this study. 
Antibody / antigen Clone / code Species / isotype Cone (~g/ml) Souree 
CDla OKT6 MlgG, 10 ATC 
CD3 Leu-4 MlgG, 0.125 BD 
IL-la lC12.1 MlgG, 5.0 ONC 
IL-4' BMS129 MlgG, 5.0 BM 
IL-8' 52E8 MlgG, 1:5 
IFN-y MD-2 MlgG, 20 
ehymase MAB1254 MlgG, 0.10 CH 
control 1 9040 MlgG, 20 BD 
control 2 9050 MlgG" 20 BD 
seeondary Ab ZAOOO-4M RaMlgG-biotin 1 :50 BG 
'Kindly provided by Bender MedSystems, Vienna, Austria. 'Supernatant, kindly provided 
by Dr. M. Stieherling, University of Kiel, Kiel, Germany.' Kindly provided by Dr. P. van der 
Meyden, TNO Primate Centre, Rijswijk, The Netherlands. 
Ab, antibody; CD, cluster of differentiation; Cone, protein concentration; IL, interleukin; 
IFN, interferon; Mig, mouse immunoglobulin; RaM, rabbit anti-mouse. ATC, American Type 
Culture Coltection, RoekviIIe, MA, USA; BD, Becton Dickinson, San Jose, CA, USA; BG, 
Biogenex, San Ramon, CA, USA; BM, Bender MedSystems, Vienna, Austria; 
CH, Chemicon, Temecula, CA, USA; ONC, Oncogene Seienee Ine., Uniondale, NV, USA. 
Quantificatian af immunastaining 
Quantification ol the staining was done in duplicate by two independent observers 
(MS, JH) on direct light microscopic images at magnilications ol 1 Ox1 0 or 10x25 
(Leitz Dialux, Leica, Rijswijk, The Netherlands). Using the hardcopy ol the IA mea-
sured areas as arelerence, positive ce lis within the epidermis, inliltrate and der-
mis were counted and subsequently expressed as the number ol cells per mm2 ol 
the corresponding section area as measured by IA. CD3+ ce lis were calculated 
slightly different: the percentage ol positively stained inliltrate ce lis was deter-
mined. Cytokines causing diffuse staining were scored semi-quantitatively as shown 
in Table 11. 
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Table 11. Semiquantitative scores of staining intensity and 
stained area fraction. 
Score Staining intensity Stained area fraction (%l 
0 negative <20 
1 weak < 40 
2 moderate < 60 
3 st rong < 80 
4 very strong < 100 
Statistica I analysis 
Professional STATATM 4.0 Statistics I Data Analysis (Stata Corporation, College 
Station, TX, USA) was used lor data analysis and statistical calculations. For varia-
bies with a normal distribution, parametric statistica I methods were used, other-
wise non-parametric methods were applied. Coefficients of variation were calcu-
lated as the standard deviation (SO) divided by the mean times 100 percent [10J. 
Oifferences between the ACO, psoriatic and normal control groups were tested for 
significance using the non-parametric two-sample Wilcoxon Rank-Sum Test [11 J. 
RESULTS 
PT scores of the ACD palients 
All ACO patients were patch tested with nickel sulfate to in duce alocal elicitation 
reaction from which the ACO skin biopsies were taken. The PT scores, which are 
a measure ol disease activity, are shown in Table 111. All but one patient had a PT 
score of 2+ or greater. 
Table 111. Patch test scores of the ACD patients. 
Patient PT score 
+++ 
2 ++ 
3 ++ 
4 + 
5 +++ 
6 ++ 
Validation of image analysis for area measurement 
Figure 3 is a visual representation of the IA procedure lor measurement of section 
areas as depicted in Figure 1. The original image (A) of an ACO skin section was 
converted into a binary image (B) by setting a threshold in the gray value histo-
gram. After that, the number of small scattered segments in the binary image was 
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reduced by applying binary morphologic operations as iIIustrated in image (C). 
Finally, the ouler limits of the epidermal and infiltrate segments were superim-
posed on Ihe original image to enable visual verification of the procedure (D). 
Figure 3. Visual representation of the image analysis procedure for measurement of sec-
tion areas (see Figure 1), showing (A) original object image of a contactallergic 
skin section, (B) binary image after thresholding of the gray value histogram, 
(C) binary image after binary morphologic operations, and (0) the epidermal 
and infiltra!e segments as deduced from the binary image, labeled and super-
imposed on the original object image. (10x) 
Accuracy and reproducibility 
The accuracy of IA area measurement and its sensitivity to orientation was checked 
by measuring a grid of known dimensions at various angles of rotation. The result-
ing deviations from the actual value were smalI, i.e. between -0.44 and +0.23 
percent. At 10x magnification of the microscope objective, a standard image sized 
756x512 pixels corresponded to 1.202 mm' section area. 
The reproducibility of our IA area measurement procedure was calculated from 
repeated measurement of a single normal skin section. The resulting coefficients 
of variation were smalI, i.e. below 1.0 percent (data not shown). 
Variation of serial skin section areas 
To assess the section-to-section variation, serial ACD, psoriatic and normal skin 
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sections were measured by IA. In Figure 4, the resulting epidermal, dermal, infil-
trate and total section areas are shown for 20 serial ACD skin sections. For epider-
mal, dermal and total section areas, the coefficients of variation (SD as a percent-
age of the mean) were 7.4-8.6 percent. However, for infiltrate section areas the 
coefficient of variation was much larger, i.e. 17 percent. This is probably due to the 
irregular dimensions and scatter of infiltrate cell clusters as compared to the rather 
constant epidermal and dermal section areas. 
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Figure 4. Varialion of epidermal (elosed squares), infillrale (open squares), dermal (elosed 
eircles) and lolal (open cireles) seclion areas as measured by image analysis in 
20 serial eonlaelallergie skin sections (sections no. 13, 14 and 20 were excluded 
as Ihey eonlained large arlifacls). 
Comparison of area measurements by IA and grid 
Area measurement by IA was compared with the traditional grid-based method in 
20 serial ACD and psoriatic skin sections. Table IV shows the distributions of epi-
dermal and infiltrate section areas for both methods and of their absolute and 
relative differences. As psoriatic epidermis is much thicker than ACD and normal 
epidermis, the total section area of psoriatic skin was al most identical to the epi-
dermal section area. Therefore, for psoriatic skin only the epidermal section area 
is listed. The mean epidermal and mean infiltrate section areas of both ACD and 
psoriatic skin were quite similar for the two methods. However, the SD of ACD 
epidermal section areas as measured by the grid-based method was somewhat 
larger. The SD of psoriatic epidermal and ACD infiltrate section areas were much 
larger and no differences between the IA and grid-based methods were noted 
here. The agreement between both methods was determined by analysis of the 
distribution of the differences [11 J. The mean difference, which is an estimate of 
the ave rage bias of one method relative to the other, ranged between -4 and + 11 % 
(relative difference). The SD of the differences, which is an estimate of the indi-
vidual agreement between both methods, was 6 and 11 % (relative difference) for 
psoriasis and ACD, respectively. 
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Table IV. Comparison of IA and grid-based measurement of epidermal and infiltrate 
section areas in 20 serial ACD and psoriatic skin sections. 
IA Grid-based t. (absolute) t. (relative) 
ACD 
Epidermis 0.15 ± 0.01 0.13 ± 0.02 0.02 ± 0.02 0.11 ±0.11 
Inliltrate 0.19 ± 0.04 0.17 ± 0.04 0.02 ± 0.02 0.10 ± 0.10 
Psoriasis 
Epidermis 0.37 ± 0.08 0.39 ± 0.08 -0.02 ± 0.03 -0.04 ± 0.06 
Values are mean areas in mm' ± SD. The relative difference (t.) is calculated as the 
difference divided by the mean of bath methods. ACD, allergie contact dermatitis; IA, 
image analysis. 
Application ol IA to IHC-stained inflammatory skin sections 
Application ol IA area measurementto immunostained inflammatory skin sections 
is iIIustrated in Table V lor COl a, C03 and chymase, three commonly used inflam-
matory markers specilic lor Langerhans cells, TeelIs and mast cells, respectively. 
Table V. Inflammatory markers in ACD, psoriatic and normal skin. 
Localization CDla CD3 Chymase 
ACD 
Epidermis 110 (53-380) 19 (0-230)' 0(0-0) 
Infiltrate 230 (35-510)' 24 (6.1-34)' 210 (100-270)' 
Dermis 14 (2.3-210) ND 24 (20-37) 
Psoriasis 
Epidermis 56 (13-77) 86 (21-120)' 4.3 (0-20)h 
Infiltrate 360 (130-680)b 28 (22-34)' 130 (0-280)' 
Dermis 32 (1.8-99) 150 (110-220) 36 (0-43) 
Normal 
Epidermis 71 (27-210) 0(0-3.8) o (0-3.5) 
Dermis 14 (5.5-38) 6.7 (5.0-14) 25 (11-36) 
'p~0.0043; b p~0027; , p~0.024; , p~0.028; , p~0.0019; , p~0.0034; 9 p~0.0027; 
h p~0.024; , p~O.046. P values were calculated in comparison with normal skin. 
Values are median cell counts per mm'. Minimum and maximum values are 
shown in parentheses. CD3' infiltrate cells are expressed as the percentage 
of positively stained infiltrate area. ACD, allergie contact dermatitis; CD, cluster 
of differenlialion; ND, na data available. 
The numbers ol COl a' (Langerhans) cells in ACO and psoriatic inliltrates were 
significantly larger than in normal skin. C03' (T) cell numbers were significantly 
increased in the epidermis and inliltrates ol both ACO and psoriatic skin. Chymase' 
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mast ce lis were significantly increased in the infiltrates of both inflammatory skin 
diseases. 
Additionally, the Tables VI and VII show the results of visual densitometry of immuno-
staining of markers specific for the prainflammatory cytokine interleukin(IL)-1a, 
the chemokine IL-8 and the regulatory cytokines IL-4 and interferan(IFN)-y. These 
diffusely staining markers could not be quantified in areliabie and repraducible 
way by IA. 
Table VI. Inflammatory cytokines in the epidermis of ACO, psoriatic 
and normal skin. 
Localization IL-la IL-B 
ACD 
SB area fraction 4 (4-4) 0(0-0) 
SB intensity 1 (1-2) 0(0-0) 
SPG area fraction 4 (0-4) 2.5 (2-4) 
SPG intensity 1 (1-2) 3 (1-3) 
SC area fraction 4 (1-4) o (0-2) 
Psoriasis 
SB area fraction 4 (4-4) 0(0-0) 
SB intensity 1 (1-1)' o (0-0) 
SPG area fraction 3.5 (0-4) 3 (0-4) 
SPG intensity 1 (0-1) 1.5 (0-3) 
SC area fraction NO NO 
Normal 
SB area fraction 4 (4-4) 0(0-0) 
SB intensity 3 (1-4) 0(0-0) 
SPG area fraction 4 (4-4) 3 (1-4) 
SPG intensity 2 (1-2) 2 (1-4) 
SC area fraction 4 (4-4) 1 (0-2) 
, p~0.032. P values were calculated in comparison with normal skin. Val-
ues are median scores. Minimum and maximum values are shown in 
parentheses. ACO, allergie contact dermatitis; IL, interleukin; NO, na data 
available; SB, stratum basale; SC, stratum corneum; SPG, stratum 
spinosum and granulosum. 
The intensity of IL-1a staining of the suprabasal keratinocytes was significantly 
decreased in psoriatic skin. This seemingly paradoxical finding can be explained 
by dilution of the staining due to the increased epidermal thickness and the high 
percentage of IL-1a: cells in psoriatic epidermis. A similar trend was seen in ACD. 
IL-8 staining was localized in the stratum spinosum and granulosum but not in the 
basal or suprabasallayer as has been reported by some authors [12, 13]. For IL-8, 
no significant differences between the inflammatory and norm al contral skin were 
seen. 
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Table VII. Regulatory cylokines in Ihe epidermis and infillrales of ACD, 
psorialic and normal skin. 
Localizalion IL-4 IFN-y 
ACO 
Epidermis - area fraclion 0(0-4) o (0-1) 
- inlensily 0.5 (0-1) 1 (0-2) 
Infiltrale - inlensily 2 (1-4) 2 (1-3)' 
Psoriasis 
Epidermis ~ area fraction 4 (0-4) ND 
- inlensily 1 (0-1) ND 
Infillrale - inlensily 2 (1-2) ND 
Normal 
Epidermis - area fraction 3 (0-4) o (0-1) 
- inlensity 1 (0-2) o (0-1) 
Infillrate - intensily 3 (0-3) 1 (0-3) 
, p=0.046. P values were calculated in comparison with normal skin. Val-
ues are median scores. Minimum and maximum values are shown in 
parentheses. ACD, allergie contact dermatitis; IFN, interferon; IL, 
interleukin; ND, no dala available. 
The intensity ol IFN-y staining ol inliltrate cells was signilicantly increased in ACD 
compared with normal skin. No signilicant dillerences were seen lor IL-4. 
DISCUSSION 
The continuously dropping cost ol computer hardware and the evolution ol soft-
ware towards easier, more intuitive graphical user interfaces has brought com-
puter-assisted IA within the reach ol al most every IHC researcher. However, reli-
able IA ol immunostained slides requires sound knowledge ol inlormation theory 
and computer technology, besides ol course lamiliarity with histology and IHC. We 
investigated the suitability ol IA area measurement lor application to immunostained 
inflammatory skin sections. The accuracy and reproducibility ol IA area measure-
ment was high, i.e. deviations ol less than 0.5% and 1.0%, respectively. When 
compared to traditional grid-based area measurement, the mean values ol the 
areas as measured by both methods were similar but the standard deviation was 
somewhat smaller lor IA (Tabie IV). However, as the large section-to-section varia-
tion (Figure 4) may have troubled these results, the distribution ol the differences 
between both methods was also analyzed. The mean difference was at most 11 % 
ol the measured area (Tabie IV). As an example, the IA area measurement proce-
dure was applied to immunostained inflammatory skin sections (Tabie V). The 
procedure could also easily be modilied to give a measure ol spongiosis (a valu-
able parameter in inllammatory skin disease) by calculating the binary closed 
minus unclosed epidermal section area. 
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IA was used bya number of authors to acquire more consistent data, a.o. for cell 
counting and densitometric analysis of cytokine production at the single ceillevel 
[14-17]. When compared to the classical methods, like the use of grids and fjelds, 
IA of immunostained tissue enables accurate, reproducible and objective image 
measurement with minimal human interaction, less field selection or sampling 
bias, lower risk of errors due to manual copying of data and reasonable speed of 
execution [5, 7, 18, 19]. Additional advantages of digitized IHC images include 
degradation-free storing and copying (as opposed to deterioration of the original 
sections on glass slides), the opportunity to correct for slight image defects and 
the ability to do structural and statistical analysis of the image and three dimen-
sional (30) reconstruction of serial sections. An excellent review on quantitative IA 
was written by Oberholzer et al. [20]. More extended information can be found in 
textbooks on IA such as the ones by Russ [8] and Castleman [9]. 
Quantification of immunostaining by computer-assisted IA has been reported bya 
number of authors [7, 19,21] and is said to have several advantages over more 
traditional methods: it is more objective, less laborious and faster than visual esti-
mation and, like confocal laser microscopy, it preserves morphologic information 
when compared to biochemical assays and flow cytometry. However, in practice 
the use of computer-assisted densitometry for quantification of immunostaining of 
cytokines requires rigorous standardization of IHC (e.g. thickness of sections, 
mounting substance, permeabilization, type of fixation, species and isotype of 
antibody), microscopy (e.g. light level and focus of the microscope) and of IA (e.g. 
choice of segmentation thresholds in RGB or HSL color space). Also, IA cannot 
eradicate the difficulties associated with quantification of cytokines that cause 
diffuse staining. Jagoe et al. have criticized uncontrolled thresholding, particularly 
in singlemodal image histograms, showing significant intra- and interobservervaria-
ti on in the range of gray values labeled as 'positively stained' [22]. The importance 
of a well-defined and objective quantification-protocol, explained in detail in the 
methods section, cannot be overestimated. In our hands and with available hard-
and software, direct quantification of immunostaining intensity of cytokines in 
inflammatory skin sections proved unreliable. 
In conclusion, IA is a useful and exciting addition to IHC. Although quantification of 
immunostaining intensity by IA remains difficuIt and requires thorough standard-
ization of both IHC and IA, the IA procedure we describe enables measurement of 
inflammatory skin section areas, that is more accurate, reproducible and objective 
than conventional area measurement methods. 
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Inlroduction 
Anti-epileptic drugs (AED) are lor more than one reason an important group ol 
drugs with respect to adverse drug reactions. Long-term use, multi-drug therapy, 
structural similarity (cross-reactivity; mimicry), and a relative lack ol alternatives, 
make the occurrence ol adverse reactions to AED a difficult condition. Moreover, 
the choice ol an AED may be largely determined by the incidence ol the adverse 
effects as the effectiveness ol most AED is comparable [1 J. 
Roughly three to 30 percent ol skin eruptions due to AED (depending on the source) 
are reported to have an allergic origin [2-8J. In practice, many severe reactions, 
which are Irequently accompanied by lever, impaired liver and renal lunction, ap-
pear to be immunologically mediated [9-14J. For some life-threatening skin reac-
tions (e.g. Stevens-Johnson syndrome and toxic epidermal necrolysis), AED are 
among the most important perpetrators [15, 16J. Therelore, research into the mecha-
nisms underlying these conditions is ol great practical importance. 
The AED carbamazepine, phenytoin, barbiturates and valproate are Irequently 
used and responsible lor the majority ol adverse drug reactions [1, 17J. Recently, 
however, new AED like vigabatrin, lamotrigin, oxcarbazepine, lelbamate and 
gabapentin have appeared. These drugs are claimed to match good ellectiveness 
to rare adverse effects [18-20J. Since these drugs have been available for only a 
lew years, lurther experience with these drugs in a larger population is needed to 
prove th is claim to be true or lalse. 
Clinical manileslations ol adverse reaclions 10 anli-epileplic drugs 
Skin ras hes are the most pronounced adverse reactions to AED, besides lever, 
Iymphadenopathy, hematological abnormalities and impaired liver lunction. The 
diversity ol dermatological appearances is summarized in Table I [6, 21]. 
Table I. Skin eruptions due to anti-epileptie drugs. 
- maculopapular exanthema 
- urticaria 
- eczemataus reactions 
- pruritus 
- erythema exsudativum multiforme / Stevens-Johnson syndrome 
- exfoliative dermatitis 
- drug induced lupus erythematosus 
- alopecia 
- lichenoid eruptions 
In general, the risk ol adverse drug reactions, both allergic and non-allergic, in-
creases with age due to physiological changes ol pharmacodynamics and -kinet-
ics [15, 22J, and as a result ol age-related risk lactors, like concurrent disease and 
exposure [23-26J. 
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A number ol specilic AED and their accompanying skin rashes will be discussed 
in some detail below. 
Carbamazepine (CBZ) 
The long-standing experience with CBZ has provided a rich literature about the 
skin rashes it may induce. Skin ras hes have been reported in 3 to 20 percent ol 
patients using CBZ [3, 4, 7, 8J. The variability ol the data is partly due to differ-
ences in study design, and the delinition ol the rashes included. Erythematous, 
morbilliform and urticarial eruptions as weil as purpura are the most Irequently 
reported. Toxic epidermal necrolysis (TEN) and exloliative dermatitis have also 
been described. Eczema, photoreactivity, drug-induced lupus erythematosus (LE), 
erythema exsudativum multilorme and pustular reactions are less Irequently en-
countered [21, 27, 28J. Hematological abnormalities like thrombocytopenia and 
leukopenia, and liver lunction disorders are also commonly reported [7, 29, 30J. 
The severe anti-convulsant hypersensitivity syndrome (AHS), described below in 
greater detail, can also be induced by CBZ [31J. Cross-reactivity between CBZ 
and the more recently introduced oxcarbazepine has been described, especially 
in patients with severe skin eruptions [18, 19, 32J. 
Phenytoin 
A transient maculopapular exanthema is commonly seen during the lirst three 
weeks alter the onset ol phenytoin therapy. Pseudolymphomatous reactions have 
also been described. During long-term use gingival hyperplasia and even acrome-
galic leatures may develop due to excessive prolileration ol libroblasts. Erythema 
exsudativum multilorme, toxic epidermal necrolysis, drug-induced LE and lixed 
drug eruptions are also commonly seen [16, 27, 28J. Phenytoin can also induce 
AHS. 
Valproate 
Transient exanthemas are occasionally reported during initial valproate treatment. 
Induction ol drug-induced LE and haematological abnormalities, like thrombocy-
topenia and macrocytosis, have also been described. Usually these symptoms 
disappear alter dose reduction or cessation ol the drug [13, 28, 33J. 
Barbiturates 
Fixed drug eruptions, especially ol the glans penis, are commonly reported during 
barbiturate treatment. Allergic reactions, like immunologically mediated urticaria 
and serum sickness, are seen less Irequently. However, latal cases ol exloliative 
dermatitis and erythema exsudativum multilorme, as weil as toxic epidermal 
necrolysis, purpura and photoreactivity have also been reported. Barbiturates can 
also in duce AHS. Phenobarbital and benzodiazepines have, unlike the above-
mentioned AED, not been reported to induce LE with characteristic clinical and 
laboratory abnormalities[13, 27, 28J. 
Clinical manifestations of the anti-convulsant hypersensitivity syndrome (AHS) 
Especially aromatic AED, like phenytoin, CBZ and the barbiturates can in duce 
Allergie ADR to anti-epileptie drugs 93 
AHS [34]. The syndrome usually starts with lever alter a mean period ol th ree 
weeks ol drug intake. Next, Iymphadenopathy and skin rashes oeeur, that may 
vary lrom mild exanthemas to liIe threatening skin eonditions like taxie epidermal 
neerolysis. Subsequently, damage to internal organs, like hepatitis (50%), nephri-
tis (10%) and hematologieal abnormalities (a.o. atypieal Iymphoeytosis and eosi-
nophilia) develop. Pseudolymphoma mayalso be part ol the syndrome [12]. Usu-
ally, eessation ol the eausative drug does not lead to prompt disappearanee ol the 
disorder and prednisone therapy is required. 
Pathogenesis of adverse reaetions 10 anti-epileptie drugs 
The pathogenesis ol adverse reaetions to AED may be based on immunologieal 
or non-immunologieal responses to the drug itself or one or more ol its (reaetive) 
metabolites. 
Individual (genetie) diversity in the metabolism ol AED may eause aeeumulation ol 
taxie metabolites [35, 36]. For example, eyelie AED, like phenytoin, phenobarbital 
and CBZ, are metabolized by eytoehrome P-450 in the liver. In this proeess 
epoxides are lormed whieh can be reaetive or induee an immune response [10]. 
Generally, these epoxides are broken down by epoxide hydrolases. Deficieney ol 
these enzymes can lead to adverse effects due to aeeumulation, especially in the 
case ol phenytoin. The underlying mechanism is probably idiosynerasy, a qualita-
tively abnormal, unexpected response to a drug, differing lrom its pharmacologic 
aetions [23]. 
Concurrent treatment with phenytoin, eimethidin and glueocorticoids, as some-
times used lor epilepsy due to intraeranial proeesses, may eau se thromboeytope-
nia. This can be aseribed to aceumulation ol toxie metabolites as a result ol 
downregulation ol the epoxide-hydrolases by glueoeortieoids [37]. 
As CBZ is known to induce its own detoxilication enzym es, adverse effects due to 
toxic metabolites can usually be prevented by gradual introduction ol the drug. 
However, reactive metabolites, lormed lrom CBZ by the myeloperoxidase(MPO)-
system ol activated leukocytes, have been reported as a possible cause ol agranu-
locytosis and lupus erythematosus [38]. In the metabolic pathway ol oxcarbazepine 
(OCBZ, a CBZ-derived AED) na epoxides are thought to be lormed. This may 
explain why adverse effe cts due to OCBZ are Ie ss Irequently seen. However, the 
blood level ol concomitant drugs may ri se il OCBZ substitutes CBZ, as the lormer 
does not induce detoxification enzym es. 
Immune media/ed reactions 
AED can influence bath antigen(Ag)-dependent and Ag-independent immune re-
activity. They may induce allergie reaetions, auto-immunity, pseudolymphomatous 
reaetions, and non-specilie changes ol the humoral and cellular immune response 
[12-14,39]. 
Drug allergy can be defined as an immunologieally mediated reaction in which the 
drug acts as an allergen. For proper induction ol an allergie drug reaction, most 
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AED need to bind to carrier molecules (glycoproteins) lirst. Subsequently, the hap-
ten-carrier complex or 'complete Ag' is presented to T cells by Ag presenting cells. 
If the Ag is recognized, prolileration and lormation ol memory T cells lollows. As ol 
now the patient is sensitized and renewed contact with the allergen may lead to an 
allergic reaction according to one or more immunological reaction types originally 
described by Coombs and Geil. These reaction types were described in greater 
detail in the chapters 1.1 and 1.3. In addition, drug-induced adherence between 
leukocytes and keratinocytes may be an important initial step in the pathogenesis 
ol immunological cytotoxicity [40, 41]. 
Diagnosis of adverse reactions 10 anti-epileptic drugs 
Routine laboratory tests cannot (yet) reliably predict the likelihood ol drug allergy 
in a single patient [42]. Nevertheless, the distinction between allergy and non-
immunological reactions is ol great importance lor luture drug use. 
Clinically, serious reactions can often be recognized on the basis ol simultaneous 
occurrence ol skin eruptions, lever and involvement ol internal organs [43]. 
Although epicutaneous patch tests are sometimes considered to be ol little use lor 
detection ol allergy to systemically used drugs, they are delinitely uselul lor detec-
tion ol allergy to CBZ (and possibly other AED) [8, 34, 44, 45]. Additionally, the 
Iymphocyte prolileration assay (LPA), if correctly performed, is an important tech-
nique to confirm immunological reactivity [34, 45]. To avoid lalse-negative test 
results, it is recommended to perform the LPA at least 2 months after the period of 
clinical disease [34, 45]. 
In patients with a genetic deliciency ol detoxification enzym es, accumulation ol 
reactive metabolites can be detected by a cytotoxicity test [10]. In this test, Iym-
phocytes ol a patient are exposed in vi/ra to toxic epoxides preformed by cyto-
chrome P-450. II epoxide hydrolases are delicient in these Iymphocytes, cell death 
can occur as a result ol accumulation of toxic epoxides. The enzyme deficiency 
can then be quantilied as a percentage of cytotoxicity. Routine use ol this test is 
not recommended since the prevalence of genetic enzyme deficiency is low and 
the costs of the cytotoxicity test are high [36]. 
Therapy 
In most cases ol adverse reactions to AED, prompt withdrawal (if possible) of the 
causative drug will halt the response. The AHS may, however, remain weil after 
stopping the causative drug. 
If drug allergy is likely, an alternative non-cross-reactive AED should be sought. 
The newly developed AED, representing additional therapeutic possibilities with 
possibly lewer adverse reactions, may lighten this task. The risk of 'status epilepticus' 
is not high il adequate alternative drug therapy is instituted [6]. 
Especially allergic drug reactions may require additional treatment. Antihistamines 
may be helplul to control pruritis. Effective treatment of drug-induced serum sick-
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ness may require the use of corticosteroids and antihistamines. Corticosteroids 
are also needed for severe or progressive drug eruptions. Severe reactions like 
anaphylaxis require the combined use of corticosteroids, antihistamines and 
sympaticomimetics. 
Desensitization has been successful for allergy to bee and wasp venom and some 
drugs (e.g. penicillin and insulin). The mechanism of desensitization is unciear but 
generation of 'blocking' IgG antibodies and gradual and subclinical mast cell de-
granulation have been suggested [26]. The procedure is not without risk and should 
only be tried if no alternative is available [24, 46]. Reports of successful clinical 
hyposensitization with CBZ have been sporadic [47-49]. This may be due to differ-
ences in the allergic reaction types involved in allergy to CBZ as opposed to al-
lergy to bee or wasp venom. 
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ABSTRACT 
Purpose: Five to 20% ol patients discontinue antiepileptie drug (AED) therapy 
beeause ol adverse reaetions. Carelul reintroduetion, however, may be eonsidered il 
true drug allergy ean be ruled out. Delinitive assessment ol sueh immunologieally 
mediated reaetions requires demonstration ol either specific antibodies or sensi-
tized Iymphoeytes. 
Methods: We investigated whether skin pateh tests (PT) and in vi/ra Iymphoeyte 
prolileration assays (LPA) were suitable lor deteetion ol allergy to earbamazepine 
(CBZ) and the possibly eross-reaetive oxearbazepine (OCBZ). Data ol 65 patients 
displaying a wide range ol possibly allergie side effects to CBZ were available lor 
analysis. CBZ users without any side effects and heallhy volunteers served as eontrols. 
Both PT and LPA were done with CBZ, OCBZ and three metabolites [CBZ-lO,11-
epoxide (CBZ-E), 1 O-monohydroxy-CBZ (MHD), and 1 O,11-dihydroxy-CBZ (DIOL)J. 
Results: Positive PT with CBZ were seen in 20% and with OCBZ in 14% ol the 
patients. Positive LPA resulls with CBZ and OCBZ, respeetively, were lound in 40 
and 19%. Both tests were positive in 14 and 7% ol the patients. Cross-reaetivity to 
OCBZ was seen in - 40% ol CBZ-reaetive patients in both PT and LPA. 
Conclusion: These data iIIustrate the additional value ol LPA in the de!ection ol 
CBZ allergy while showing !hat a major par! ol side effects !o CBZ and OCBZ is not 
immunologieally media!ed, aeeording to PT and LPA. 
INTRODUCTION 
Discontinuation ol antiepiiepUe drug (AED) intake beeause ol possibly allergie side 
effee!s is necessary in 5-20% ol pa!ients [1-5J. In some cases these reaeUons are 
even lile !hreatening [6-9J. Espeeially severe adverse reaeUons are thought to be 
immunologieally mediated [10-15J. 
Carelul analysis ol adverse drug reactions is needed !o de!ermine their nature as 
th is will inlluence luture drug adminis!ra!ion [16J. Cautious readministration may 
even be eonsidered il true (immunologically mediated) drug allergy ean be ruled out. 
Rechallenge may eonfirm the allergie nature ol adverse effects, but it bears the risk 
ol severe reaetions [17J. Therelore, sale and reliable methods are urgently needed 
to make a elear distinetion between drug allergy and non-allergie responses. More-
over, reeognition ol eross-reaetivily may help in seleeting an allernative drug. Skin 
pateh tests (PT) and Iymphoeyle prolileration assays (LPA) have previously been 
advoeated to establish the immunologie basis ol adverse reaetions [4, 8, 18-26J. 
Most studies have been performed by using a limited number ol me!abolites and a 
small number ol patients usually with severe symptoms. For thorough evaluation ol 
!he test it is essential !o test a large number ol individuals eomprising a wide spec-
trum ol clinical signs and symptoms ol possibly allergie nature. We report the results 
ol parallel skin PT and LPA lor the detection ol earbamazepine (CBZ) allergy and 
oxearbazepine (OCBZ) eross-reaelÎvity. All eurrently available me!abolites we re tested 
using a large number ol patients reeeiving CBZ therapy with a wide range ol side 
effects. We have studied allergy to CBZ as i! is widely used and weil doeumented to 
eause allergie eutaneous eruptions in 3-20% ol its users [1-4, 21, 27, 28J. 
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METHODS 
Patients 
Data from 65 patients with epilepsy displaying a wide range of side effects to CBZ 
were collected for analysis. Skin rashes consisted of mild maculopapular, urticarial, 
erythematous, exfoliative and eczematous skin reactions. Systemic manifestations 
included fever, hematologic abnormalities (Ieukocytopenia and thrombocytopenia), 
Iymphadenopathy and impaired liver function. Fifteen CBZ users without adverse 
effects and six healthy individuals served as controls. 
Clinical evaluation 
A standardized checklist was used for documentation of age and gender of the 
patient, clinical signs and symptoms of the adverse reaction and its treatment, duration 
of prior CBZ intake, current medication, and previous allergies or atopy of the patient 
and his or her family. 
Patch tests 
Patch tests (PT) were performed according to international standard procedures 
[29J. Pure CBZ, its main metabolite CBZ-1 0, 11-epoxide (CBZ-E, GP49.023), 
oxcarbazepine (OCBZ, GP47.680), its active metabolite 10-monohydroxy-CBZ (MHD, 
GP47.779) and the common metabolite 10, 11-dihydroxy-CBZ (DIOL, CGP10.000) 
as weil as ground CBZ (Tegretol") and OCBZ (Trileptal®) tablets (Ciba Geigy, Basel, 
Switzerland) were used. Figure 1 depicts these metabolites in the metabolic pathway 
ol CBZ and OCBZ [30J. Of all substances 5 milligrams was retained in PT chambers 
(van der Bend, Brielle, The Netherlands) with 50 111 ethanol 70% and applied to the 
left side of the back. After 2 days the chambers were removed and the skin reaction 
was scored at 48 and 72 hours. 
Lymphocyte proliferation assays 
Sodium-heparinized venous blood samples were drawn belore application of the PT. 
Peripheral blood mononuclear cells (PBMC) were isolated lrom these samples by 
using Ficoll-Paque (density 1.077 g/cm3; Pharmacia, Uppsala, Sweden) density-
gradient centrifugation. After washing, cells were suspended in complete RPMI1640 
medium (supplemented with 20 mM Hepes, L-glutamine, antibiotics and 15% heat-
inactivated pooled human serum), and seeded at 2x1 05 cells/well in 96 wells round-
botlom culture plates (Faleon, San Jose, CA, USA). Stock solutions of CBZ, OCBZ 
and the three metabolites were pre pa red at concentrations of 5-15 mg/ml in pure 
ethanol (pro analysi 99.8%, Merck, Darmstadt, Germany). Previous testing showed 
that final concentrations ol 5, 10 and 15 Ilg/ml in culture medium were optima!. The 
levels are grossly comparable to usual serum levels. Tetanus toxoid (3 U/mi, RIVM, 
Bilthoven, The Netherlands) was used as a positive contro!. Alter 6, 7 and 8 days, 
respectively, 0.5 ~ICi 3H-TdR (Amersham International, Amersham, UK) was added 
to each weil. After 8 hours, cells were harvested by using an automatic cell harvester 
(Skatron, Lier, Norway). Tritiated thymidine incorporation was measured with a 
BetaPlate liquid scintillation counter (LKB Wallac, Turku, Finland). All cultures were 
done in quadruplicate. Lymphocyte proliferation was expressed as counts per mi-
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nute (cpm). Stimulation indices (SI; i.e. relative proliferation) were calculated bydividing 
maximum specific proliferation by background proliferation. SI >3 were considered 
indicative of prior Iymphocyte sensitization. Values between 3 and 10 were considered 
low positive, those > 10, high positive. 
Statistical analysis 
Professional STATA 3_0 Statistics/Data Analysis (Computing Resource Center, Santa 
Monica, CA, USA) was used for data analysis and statistical calculations. Means 
and standard deviations were calculated from quadruplicate cultures. Differences 
between the patient and control groups were tested for significance using the Wilcoxon 
Rank-Sum Test for numerical data and X' and Fisher's exact tests for categorical 
data. Spearman's rank correlation coefficients were calculated as a measure of 
association between parameters [31, 32J 
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RESULTS 
Clinical evaluation 
The clinical leatures ol the patients and controls are summarized in Table I. The 
median duration ol prior CBZ intake was 1 month. Skin rashes including mild 
maculopapular, urticarial, erythematous, exloliative and eczematous skin reactions 
constituted a major part ol the reactions [overall 60 (92%) ol 65 cases]. Systemic 
manilestations such as lever, hematologie abnormalities (Ieukocytopenia and 
thrombocytopenia), Iymphadenopathy or impaired liver lunction were documented 
in 14 (22%) ol 65 cases. These rather high Irequencies reil eet bias due to selective 
relerral. 
Table I. Clinical features of patients and controls tested for CBZ allergy. 
No. of patients 
M/F-ratio 
Age (yr)' 
Drug intake prior to side efteets (mo)' 
Skin reactions 
Systemie manifestationsb 
Patients with 
side efteets 
65 
1:2.0 
31 (4-82) 
1 (0.1-240) 
92% 
22% 
Controls 
21 
1:1.9 
28 (19·68) 
0% 
0% 
'median (range); 'lever, hematologie abnormalities, Iymphadenopathy or impaired 
liver funetion; CBZ, earbamazepine. 
Patch tests 
The concordances belween patch tests with pure CBZ and OCBZ on the one hand 
and ground Tegretol and Trileptal tablets on the other, were 95 and 92%, respectively, 
the tablets giving slightly more positive tests. In Table 11, the results ol PT with CBZ 
and OCBZ among patients with side effects and controls are summarized. The 
dillerenee between both groups was not statistically significant (CBZ: p=O.4; OCBZ: 
p=0.19). Positive PTwith CBZ and OCBZ were lound in 12 (20%) of 61 and 8 (14%) 
0159, respectively. Cross-reactivity to OCBZ was lound in live (45%) ol 11 ol CBZ-
reactive cases. When metabolites ol CBZ and OCBZ were also taken into account, 
the frequency increased to 55 percent. No side effects ol the patch tests were notieed. 
Lymphocyte prolileration 
In Figure 2, results of the LPA among suspected patients and controls are summarized. 
Stimulation indices varied between 0.1 and 100. Highly significant diflerences were 
seen with CBZ, CBZ-E and OCBZ (p=0.0038, p=0.0020 and p=0.0010, respectively). 
Reactivity to CBZ-E was comparable to its precursor CBZ. OCBZ displayed an 
inhibitory effect on the proliferation of PBMC in vi/ra, as it frequently gave rise to 
SI <1. Stimulation with OCBZ was also significantly less than with MHD, its active 
metabolite. In vi/ra Iymphocyte reactivity to CBZ and OCBZ was found in 26 (40%) 
0165 and 12 (19%) ol 64, respectively. Among the controls, one patient using CBZ 
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showed low reactivity to CBZ. For MHD an SI cut-alf level >3 may be desirable./n 
vi/ro cross-reactivity to OCBZ was seen in 10 (40%) 01.25 of CBZ-reactive cases. 
This value increased to 73% if metabolites of bath drugs were also taken into 
account. 
Table 11. Distribution of skin PT reactions to CBZ and OCBZ among patients 
with side effects to CBZ and controls. 
Drug PT-scorea Patients with Controls 
side effects 
CBZ' 49 10 
+ 3 0 
++ 8 1 
+++ 1 0 
OCBZ' 51 11 
+ 5 0 
++ 2 0 
+++ 1 0 
'patch test score according to international guidelines; 'p~0.40; , p~0.19; CBZ, 
carbamazepine; OCBZ, oxcarbazepine; PT, patch test; lPA, Iymphocyte 
proliferation assay. 
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Figure 2. Distributions of stimulation indices (SI) with carbamazepine (CBZ, p~0.0038), its 
metabolite CBZ-10, 11-epoxide (CBZ -E, p~0.0020), the common metabolite 10, 11-dihydroxy-
CBZ (DIOl, p~0.56), the OCBZ metabolite 10-monohydroxy-CBZ (MHD, p~0.26) and 
oxcarbazepine (OCBZ, p~0.0010) among patients with side effects (open circles) and controls 
(elosed cireles). Medians are represented by horizontal lines. 
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Table 111 shows PT and LPA results for CBZ and OCBZ. Simultaneous positivity in 
both tests was seen in eight (14%) of 59 with CBZ and four (7%) of 56 with OCBZ. 
The correlation between the results of PT and LPA, although statistically significant, 
was rather low (r=0.39, p=0.0022) for both CBZ and OCBZ. 
Table 111. Pateh test and LPA for CBZ and OCBZ. 
Pateh test Totals 
+ 
CBZLPA 
SI <; 3 33 3 36 
SI >3 15 8 23 
Total 48 11 59 
OCBZLPA 
SI <; 3 41 3 44 
SI> 3 8 4 12 
Total 49 7 56 
LPA, Iymphoeyte proliferation assay; CBZ, earbama-
zepine; OCBZ, oxearbazepine; SI, stimulation index. 
In Figure 3 the distribution of the sensilization period (i.e. time between start ol CBZ 
use and the oecurrence ol side effects) and its relation with CBZ-specilic Iympho-
cyte prolileration is depicted. Almost all reactions associated with a positive LPA 
were seen within the lirst 3 months ol drug intake. Ol the reactions appearing after 3 
months, only one resulted in low reactivily in the LPA. 
30 
SJ = CBZ-specific proliferation 
• Sb 30 
1110-30 
0.5 3 6 12 24 
interval (monlhs) 
Figure 3. Distribution of sensitization period and its relation with earbamazepine-speeifie 
Iymphoeyte proliferation (white: negative LPA; light grey: low positive; dark grey: high positive; 
blaek: very high positive). 
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Figure 4 shows the distribution of the test interval (i.e. time between the occurrence 
of side effects and performance of LPA) and its relation with CBZ -specific Iymphocyte 
proliferation. CBZ-specific Iymphocytes could be detected between one month and 
as long as 10 years after the initial sensitization. Very high in vitra reactivity to CBZ 
(81::>30) was not seen until 3 months after clinically active drug reactions. 
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Figure 4. Distribution of test interval and its relation with CBZ-specific Iymphocyte proliferation 
(white: negative LPA; light grey: low positive; dark grey: high pasitive; black: very high pasitive). 
DISCUSSION 
In clinical practice, frequently the dilemma exists wh ether to stop drug intake if allergy 
to that drug is suspected. As the severity of allergie responses tends to increase 
af ter repeated booste ring, it is vital to stop drug intake as early as possible until the 
nature of the adverse reaction is unraveled. If true drug allergy can be ruled out, 
reintroduction may be considered. The choice of an alternative drug may be helped 
by in vitra detection of cross-reactivity. A safe and reliable method is therefore needed 
to detect allergie responses and cross-reactivity. With AED, long-term use, combi na-
tion therapy, structural similarity (cross-reactivity), and a relative lack of alternatives, 
stress the need for such diagnostic tests. One of the principal in vitra assays to 
assess cell-mediated immune reactivity is the antigen-specific LPA. Our study 
concerned the parallel use of skin PT and LPA with all available metabolites for the 
detection of CBZ allergy in a large group of patients with a wide range of side effects 
during CBZ therapy. 
We found 20% positive PT to CBZ, whereas in vitra Iymphocyte proliferation was 
positive in 40%. Among the CBZ-using controls one low-positive 81 was seen. 
Experience with the LPA in nickel allergy has shown that th is may imply early 
subclinical sensitization. 
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The stabie 10, 11-epoxide of CBZ (not an arene oxide) has been thought to be 
responsible for many adverse reactions including immunologically mediated reactions. 
However, we did not see either a larger number of positive tests or a higher reactivity 
with CBZ-E as compared to CBZ. This confirms previous in vivo and in vi/ra 
observations [11, 33J. The role of other short-lived epoxides of CBZ, which are known 
to be lormed in vivo [34J, remains unclear because these metabolites have not been 
available for testing. 
OCBZ has previously been described as equally effective as CBZ, but with a bet!er 
tolerability and a favarable interaction profile, possibly due ta its different metabolism 
[30, 35-43J. In vi/ra, however, OCBZ was found ta inhibit Iymphocyte proliferation. 
The rapid in vivo metabolism of OCBZ into MHD may explain th is discrepancy. 
In vivaand in vitracross-reactivity ol OCBZ in CBZ-reactive patients has been reported 
in 15-25% [21, 40J. With regard to chemical cross-reactivity between aromatic AED, 
Irequencies as low as 0 and as high as 80% [11, 12J have been described. We lound 
- 40% cross-reactivity in both PT and LPA. 
The finding ol a sensitization period with a maximum of 3 months is in line with 
previous studies [2, 3, 11, 16J and stresses the diagnostic importance ol this temporal 
relation. The distribution of the test interval showed a 'relractory period' of - 1 month, 
during which false-negative test results may occur. The interval appears to be longer 
after strong sensitization. Such a refractory period has been noted belore and was 
ascribed to 'impaired Iymphocyte responsiveness' [20J. However, we propose that 
selective recruitment of antigen-specific Iymphocytes into target organs, transiently 
leading to low specific T cell numbers in the peripheral blood, is the cause of this 
phenomenon. Remarkably, with drug-allergic hepatic injury, quite the opposite was 
recently described, resulting in an advice to test within 1-3 weeks after onset of the 
event and retest lor negative result after 3-6 months [44J. 
Finally, a Ilowchart for diagnosing AED allergy is proposed in Figure 5. Test 
characteristics ol both PT, LPA and cytotoxicity assays have been taken into ac-
count. The chart starts with a suggestive history or physical examinalion or both 
providing areasonabie working diagnosis. The importance of clinical inlormation as 
a starting point lor further investigation needs to be stressed. Clinical criteria helpful 
in distinguishing allergic from other adverse reactions have been reviewed elsewhere 
[9, 16, 45J. Patch testing, il possible with both the pure drug as weil as the used 
formulation, is th en suggested as a quick and cheap first step. LPA can then be done 
if a patient with a suspect history has a negative PT. As cytotoxic reactions are 
probably not detected in our tests, an assay that detects deliciency ol detoxification 
enzymes will be needed to recognize these reactions [11, 12J. The combination of 
serious adverse effects with both negative PT and LPA results may call for such an 
in vitra cytotoxicity assay. 
Af ter this approach several diagnostic categories are possible: non-allergic reaction 
or allergic reaction with or without a deficiency of detoxification enzym es. Therapeutic 
options include (a) choice of an alternative non-cross-reactive anti-epileptic drug, 
(b) repetition ol the diagnostic sequence if false-negative results are suspected, 
(c) carelul reintroduction of the drug involved, and (d) in some sporadic cases, il no 
alternative is available, desensitization [46-49J. 
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Figure 5. Suggested flowchart for diagnosing antiepileptic drug allergy. 
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ABSTRACT 
A 6-year-old Caucasian girl experienced a generalized erythematous skin rash during 
carbamazepine therapy. In the next lour days the eruption worsened into erythroderma 
with lever and generalized Iymphadenopathy. Routine laboratory studies revealed 
increased serum levels ol liver enzymes and eosinophilia. Immunologie reactivity to 
the anticonvulsant carbamazepine was conlirmed both in vivo and in vi/ra by patch 
tests and Iymphocyte prolileration assays, respectively. 
INTRODUCTION 
The anticonvulsant hypersensitivity syndrome (AHS) is generally characterized by 
lever, skin rash, Iymphadenopathy and hepatitis that develop between th ree weeks 
to three months after initiation ol antiepileptic drug therapy, especially aromatic 
agents. Cutaneous manilestations are variabie and include erythema, a maculo-
papular eruption, erythema multilorme and even exloliative dermatitis. Immuno-
logie mechanisms are thought to play a major role in the pathogenesis ol this 
syndrome, but are rarely verilied by appropriate testing. We combined clinical and 
immunologie analyses to conlirm immunologie reactivity to the anticonvulsant 
carbamazepine in our patient. Although the term 'hypersensitivity' is widely used, 
we preIer the word 'allergie' as it indicates an underlying immunologie mecl1anism 
whereas 'hypersensitivity' does not. 
CASE REPORT 
A 6-year-old Caucasian girl was admitted lor a generalized skin eruption with lever, 
abdominal pain, vomiting and diarrhea ol two weeks duration. As scarlet lever was 
suspected, oral penicillin V therapy was given, but without elleet. Next, oral celuroxim 
was given lor lour days. Nevertheless, the rash evolved into an erythroderma and 
the patient had a lever ol 39°C. She suffered several epileptic insults and relused to 
drink. Carbamazepine 400 mglday had been started lor partial epilepsy lour weeks 
earlier. 
Clinical examination revealed a pulse rate ol 112/minute, blood pressure 110170 
mm Hg, proper hydration and consciousness, occipitallymphadenopathy, palpable 
liver and spleen, and generalized blue-red erythema ol the skin and conjunctivae 
with edema ol the hands, leet and periorbital areas (Figure 1). The conjunctivae 
were red but the mucous membranes were not involved. 
Laboratory data 
Relevant study results included hemoglobin 7.7 mmolil (normal 6.8-8.1 mmolil); 
white blood cell count 35.8x10'IL (normal 4.0-10x10'/L) with eosinophilia 
1.35x10'IL (normal 0.050-0.250x10'/L); aspartate aminotranslerase 81 UIL (nor-
mal <30 UIL); alanine aminotranslerase 59 UIL (normal <30 UIL); alkaline phos-
phatase 122 UIL (normal 80-225 UIL); y-glutamyl translerase 113 UIL (normal <30 
UIL); lactate dehydrogenase 1359 UIL (normaI160-360 UIL); creatinine 51 mmolil 
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A 
Figure 1. Erythema, edema and purpura of the hands (A), Ihe feet (S) and exfoliative der-
matitis with perioral crusts (C). 
(normaI25-50 mmol/L); C3 0.73 giL (normal 0.83-1.59 giL); C, 0.08 giL (normal 0.15-
0.50 giL). Olher lesls were normat. Viral and baclerial cullures and serology were all 
negalive. 
Diagnosis and treatment 
Kawasaki disease was ruled oul, as only Ihree oul ol six classic crileria were presenl. 
Fever, edema and erythema, lollowed by sealing ol Ihe exlremilies, and hyperemie 
conjunclivae were presenl; redness ol Ihe tips and oropharynx, polymorphous 
exanlhema wilh largellesions, and cervicallymphadopalhy were nol. 
Carbamazepine was suspecled as a possible eau se, so il was slopped and replaced 
wilh oxcarbazepine. Oxcarbazepine is widely used oulside Ihe Uniled Slales. lis 
efficiency and chemical slruclure are similar 10 Ihose ol carbamazepine, and cross-
reaclivily has been reporled in 15-25% ol palienls [1-3J. The girl's erylhema and 
sealing disappeared, her lemperalure dropped, and laboralory parameiers improved. 
However, after 10 days Ihe rash reappeared wilh similar clinical and laboralory charac-
lerislics and she experienced a remarkable loss ol hair. Oxcarbazepine was slopped 
and phenyloin was sla ried, and wilhin Ihree weeks Ihe rash disappeared. After Iwo 
monlhs, palch lesls (PT) and Ihe in vi/ra Iymphocyle prolileralion assay (LPA) were 
done 10 conlirm an immunologie basis lor Ihe skin eruplion. Palch lesls were 
performed according 10 inlernalional slandard procedures [4J wilh pulverized lablels 
ol carbamazepine, oxcarbazepine (Tegrelol andTrileplal, Ciba Geigy, Basel, Swilzer-
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land) and phenytoin (Diphantoine; Katwijk, Katwijk, The Netherlands). Five milligrams 
of each substance was retained in PT chambers (van der Bend, Brielle, The Nether-
lands) wilh 50 ~tI ethanol 70% and applied to the left side of the back. Previous 
tesling of 80 subjects showed Ihis concenlralion 10 be nonirritaling (Troost, 
unpublished observations). After Iwo days Ihe chambers were removed and Ihe skin 
reaclion was scored al 48 and 72 hours. The PT was positive with all three anti-
epileplic drugs (Figure 2). 
Figure 2. Positive patch test results with carbamazepine, oxcarbazepine and phenytoin. 
In vitra LPA was performed wilh carbamazepine (CBZ), ils main metabolite CBZ-
10, 11-epoxide (CBZ-E, GP49.023), oxcarbazepine (OCBZ, GP47.680), ils melabolile 
10-monohydroxy-CBZ (MHD, GP47.779) and Ihe common melabolile 10, 11-di-
hydroxy-CBZ (DIOL, CGP1O.000)[5] as weil as phenyloin (PH EN). Previous lesting 
in allergie and nonallergie CBZ -users showed thai 5 to 15 Ilg/ml were optimal in vitro 
concentrations for CBZ and metaboliles, and 2.5 10 50 ~!g/ml for PH EN (Troosl, 
unpublished observalions). These concenlralions are grossly comparable wilh Ihe 
usual serum levels of Ihese drugs. Telanus toxoid (3 U/mi, RIVM, Bilthoven, 
The Nelherlands) was used as a positive control. 
Stimulation indices (SI, Le. relative proliferalion) were calculaled by dividing maxi-
mum specific proliferalion by background proliferalion. An SI above 3 was consi-
dered indicative of prior Iymphocyte sensitization. Lymphocyle reactivily 10 CBZ and 
its main metabolile CBZ-10, 11-epoxide was found, bul not 10 OCBZ or PHEN. The 
results of PT and in vitra LPA are summarized in Table I. 
AHS with exfolialive dermatitis was considered Ihe mosllikely diagnosis. Phenyloin 
was Ih en insliluled and was weil loleraled. 
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Table I. Clinical response 10, and resulls of, palch lesls and Iympho-
cyle proliferalion assays wilh several anli-epileplic drugs. 
Drug Clinical Tesl resulls 
response PT LPA (SI') 
Carbamazepine ++ ++ 14.2 
CBZ -epoxide NO NO 5.8 
Oihydroxy-CBZ NO NO 1.3 
Monohydroxy-CBZ NO NO 2.1 
Oxcarbazepine ++ ++ 2.3 
Phenytoin +++ 2.3 
'An SI above 3 is considered positive. PT, palch lesl; LPA, Iymphocyte 
proliferalion assay; NO, nol done. 
DISCUSSION 
Carbamazepine is an aromatic anti-epileptic drug that is widely administered and 
weil documented to cause allergic skin eruptions in 3% to 20% ol users [1, 6-11 J. 
Exloliative dermatitis was reported in 2.5% to 10% ol dermatological reactions to 
CBZ [10, 12, 13J. Less Irequently the rash is part ol the AHS. The syndrome is 
characterized by lever, rash, Iymphadenopathy, and hepatitis, usually occurring within 
three weeks to three months alter the start ol drug therapy. Other possible leatures 
are hematologic abnormalities, nephritis, edema, especially ol the lace, conjuncti-
vitis, pharyngitis and allergic pneumonitis. 
Severe adverse reactions are thought to be immunologically mediated [12, 14-18J. 
Carelul analysis ol these reactions is therelore necessary to determine their nature, 
as th is influences luture drug administration. Cautious readministration may be consi-
dered il true (immunologically mediated) drug allergy can be ru led out. Clinical crite-
ria helplul in distinguishing allergic lrom other adverse reactions are reviewed 
elsewhere [19-21 J. The temporal relationship between start ol drug intake and appea-
rance ol allergic symptoms is olten the most vital inlormation in determining the 
causative agent. Although challenge tests may conlirm the allergic nature of adver-
se effects, they bear the risk ol severe reactions [22J. Skin PT and LPA can be 
performed salely to establish the immunologic basis ol the effects [1, 11, 23-32J. In 
addition, detection ol cross-reactivity may help in choosing an alternative drug. 
Our patient was probably sensitized !wice: first to CBZ and alter another sensitization 
period of 10 days to OCBZ. Although PHEN cross-reactivity has been described, 
th is drug was weil tolerated by our patient. Patch tests conlirmed the reactivily to 
both CBZ and OCBZ, but showed a positive skin reaction to PHEN as weil. In vi/ra, 
however, no Iymphocyte reactivity to PHEN was detected. Therelore, the patch test 
may have been a false positive result due to excited skin syndrome. This could not 
be confirmed, however, as the parents ol the child relused lurther testing. The patient 
was diagnosed as having AHS due to CBZ. 
In vi/ro LPA conlirmed reactivily to CBZ and CBZ-1 0, 11-epoxide. This stabie epoxide 
is thought to be responsible for many adverse reactions, including the immunologi-
cally mediated reactions. 
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Previously, OCBZ was described as equally effective as CBZ and better tolerated, 
and having a lavorable interaction prolile, possibly due to its different metabolism 
[3, 5, 33-40J. In vivo and in vi/ra cross-reactivity ol OCBZ was reported in 15% to 
25% in CBZ reactive patients [1, 3J. Even higher Irequencies are se en after serious 
skin eruptions [12J. Our patient showed reactivity to both CBZ and OCBZ, clinically 
as weil as with PT; however, in vi/ra Iymphocyte reactivity to OCBZ was absent. The 
rapid in vivo metabolism ol OCBZ and the significant inhibition ol in vi/ra Iymphocyte 
prolileration caused by OCBZ in many other patients may explain th is discrepancy. 
A combined clinical and laboratory study to assess lurther the performance ol PT 
and LPA in detecting CBZ allergy and OCB cross-reactivity in a large group ol subjects 
taking CBZ is currentiy in review lor publication elsewhere. 
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ABSTRACT 
Pleurisy ol initially unknown origin was lound in a patient who was treated with 
bromocriptine lor Parkinson's disease lor 6 years. At presentation, bilateral pleural 
thickening existed th at caused severe restriction ol pulmonary lunction. There were 
an elevated erythrocyte sedimentation rate, polyclonal hypergammaglobulinaemia, 
increased levels ol acute phase proteins and anaemia. After withdrawal ol the 
bromocriptine the patient's complaints as weil as the laboratory parameters markedly 
improved. Further loss ol pulmonary lunction did not occur. However, the pleural 
thickening did not resolve, not even upon subsequent corticosteroid treatment, 
probably due to librosis. Together, these lindings strongly suggest a causative role ol 
bromocriptine. The results ol the laboratory studies suggested an immunopathogenetic 
mechanism, but in vitra Iymphocyte-prolileration studies and skin patch tests with 
bromocriptine were negative. Bromocriptine should be considered as a cause ol 
pleurisy. The drug must be stopped immediately upon the occurrence ol pleural 
thickening in order to prevent impairment ol pulmonary lunction. In addition, periodic 
laboratory and X-ray studies in patients on long-term bromocriptine treatment should 
be considered. 
INTRODUCTION 
Pleurisy can be a manilestation ol a large number ol dillerent clinical entities, such 
as inlectious, malignant or autoimmune diseases or toxic conditions. Here we report 
on a case ol bilateral pleurisy associated with the use ol bromocriptine lor Parkinson's 
disease. 
CASE REPORT 
A 66-year-old man suffering lrom mild Parkinson's disease lor 15 years was admitted 
in September 1993 because ol progressive thoracic discomiort, dry cough and 
dyspnoea that had existed lor 7 months. An involuntary weight loss ol 5 kg had 
occurred in th is period. Neither the patient nor his lamily had a history ol pulmonary, 
cardiac or other systemic diseases. He had been a heavy smoker but stopped smo-
king 20 years ago. He denied occupational exposure to asbestos. His medication 
consisted ol bromocriptine (10-15 mg daily since 1987), levodopa-carbidopa and 
baclolen. 
Physical examination disclosed no abnormalities other than bilaterally slightly 
dimmed percussion ol the latero-basal thorax with line inspiratory crackles, but 
was otherwise unremarkable. The temperature was 37.3°C. Laboratory studies 
showed a normochromic, normocytic anaemia, an elevated erythrocyte sedimen-
tation rate and CRP concentration (Fig. 1) as weil as increased levels ol the acute-
phase proteins haptoglobin (3.4 gil, normal range 0.4-2.5 gil) and lerritin (473 mg/l, 
normal range 30-240 mg/l). Analysis ol the serum protein spectrum revealed in-
creased levels ol arglobulins and a polyclonal hypergammaglobulinaemia. 
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IgG, IgA and IgM concentrations were 25.4 gil (normal range 8.0 - 18.0 gil), 4.84 gil 
(normal range 0.9 - 4.5 gil) and 1.26 gil (normal range 0.6 - 2.8 gil), respectively. 
The white-blood-cell count was just below the upper norm al limit (9.8 x 109/1, 72% 
neutrophils, 20% Iymphocytes, 8% monocy1es). Autoantibodies (ANA, anti-ds-DNA, 
rheumatoid factors) were not detectable. Arterial blood gas analysis was normal. 
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Figure 1. Laboratory parameters (ESR, the concentration of C-reactive protein and 
haemoglobin) during bromocriptine treatment (15 mg daily) after withdrawal of this drug and 
during prednisone treatment (20 mg daily). 
Figure 2. Chest X-ray films 3 years before (A), during 4 (8) and 6 (C) years of treatment with 
bromocriptine for Parkinson's disease. 
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The chest X-ray showed bilateral laterobasal pleural thickening with partial com-
pression atelectasis ol the left lung (Fig. 2c). A previous chest X-ray made in 1984 
because ol transient coughing was normal (Fig. 2a). The chest X-ray made in 1991, 
also because ol transient coughing, showed only blunting ol the costo-phrenic sinuses, 
a pleural streak in the midfield ol the lelt lung and smaU pleural adhesions above the 
right diaphragm and beside the apex ol the heart (Fig. 2b). Further investigations or 
lollow-up chest X-ray studies wem not carried out at that time. The lindings on the 
present X-ray wem conlirmed by CT-scan. Neither parenchymal abnormalities ol the 
lungs nor enlarged thoracic or abdominal Iymphomas nor retroperitoneal librosis 
wem present. Pleural fluid could not be obtained by puncture and was not 
demonstrated by subsequent echography. Pulmonary lunction tests showed a 
restrictive disorder (TLC 66%, FRC 61 % ol the predicted value) without airway 
obstruction. 
Further aetiological studies including bronchoscopy with transbronchial biopsy, cul-
tures ol the sputum and PPD-skin test wem all unremarkable. In the meantime the 
complaints ol the patient worsened as did the results ol the laboratory studies: the 
ESR and CRP concentration rose lurther, and the haemoglobin concentration lurther 
decreased (Fig. 1). Because ol several reports that suggested arelation between 
pleuropulmonary disease and the use ol bromocriptine [1-9] we conducted in vivo 
and in vitro immunological studies to conlirm bromocriptine hypersensitivity as the 
aetiological lactor in our patient. Skin patch tests and in vitro Iymphocyte-proliferation 
studies using the patient's peripheral blood mononuclear ceUs were carried out with 
different concentrations ol bromocriptine mesylate (final concentrations ranging Irom 
0.2 to 125 nglml; therapeutic plasma concentration in Parkinson's disease patients 
ranging lrom 0.4 to 1.3 ng/ml). Both tests were negative with positive response to 
con trol antigens. 
Notwithstanding these results, we discontinued the bromocriptine medication by 
tape ring it off in 2 weeks time. Four weeks alter the bromocriptine had been completely 
stopped, the patient reported a substantial improvement ol the thoracic discomiort, 
disappearance ol the dry cough, reduction ol dyspnoea and a weight gain ol 3 kg. 
The laboratory abnormalities also improved (Fig. 1). The IgG concentration in the 
serum decreased slightly to 21.8 gIl. Although the complaints and laboratory 
abnormalities lurther declined in the next months, they remained at a lower level and 
the X-rays ol the chest showed no improvement. Therelore, prednisone 20 mg daily 
was instituted. Within 6 weeks, the remaining thoracic discomiort and dyspnoea 
completely resolved. Laboratory parameters normalized (Fig. 1), including the 
hypergammaglobulinaemia (lgG and IgA concentrations declined to 14.8 and 2.84 
gil, respectively). However, neither the chest X-ray and the CT-scan nor the pulmonary 
lunction tests (TLC 68%, FRC 61 % ol the predicted value) showed any improvement. 
The corticosteroid therapy is currently being tape red off without any sign ol reactivation 
ol the inflammatory process. 
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DISCUSSION 
Long-term bromocriptine therapy has been used world-wide over the past two decades 
in large numbers ol patients.lndications lor bromocriptine include Parkinson's disease, 
prolactinoma and acromegaly. More recently, it has been used in inflammatary 
diseases such as arthritis psoriatica [10J and iridocyclitis [11], and in immuno-
suppressive regimens alter transplantation [12, 13J, because bromocriptine interleres 
with the intracellular signalling ol several cytokines [14J. However, to our knowiedge, 
to date, only 30 cases ol bromocriptine-induced pleurisy have been described in the 
English language medical literature [1-9, 15J. This suggests that pleurisy is a rare 
complication ol the use ol bromocriptine. Alternatively, it is also possible that 
bromocriptine is olten not recognized as a causative agent in patients with pleurisy. 
Upon introduction ol bromocriptine, initial studies on the salety ol this drug described 
pleurisy in 6 out ol 123 patients treated [1J. The daily doses in that study were 
substantially higher than those used nowadays and ranged lrom 30 to 100 mg. This 
might explain the relatively high Irequency ol pleurisy in those patients. However, 
mare recently pleurisy was also lound in 2 out ol 62 patients with Parkinson's disease 
taking less than 30 mg daily in a prospective 5-year lollow-up study on the use ol 
bromocriptine [15J. Similar to our patient, all patients described until now were men 
over 50 years ol age treated lor Parkinson's disease. In all cases complaints and 
abnormalities in laboratory and X-ray investigations developed alter 1-5 years ol 
treatment with bromocriptine in daily doses ol at least 15 mg. Retrospectively, it 
might be argued that the mild abnormalities present on the chest X-ray film ol our 
patient in 1991 were also caused by bromocriptine. 
In addition, pleural effusion with non-specific Iymphocytic pleocy1osis was Irequently 
described [1-9, 15J. Our patient, however, had no detectable amounts ol Iluid in the 
pleural cavity. Presumably, he had a more advanced stage ol pleurisy with organisation 
and subsequent fibrosis ol the pleural exudate that had been present earl ier in the 
disease. The poar response to withdrawal ol bromocriptine and the subsequent 
institution ol prednisone therapy, as indicated by the X-ray studies and pulmonary 
lunction tests, support this hypothesis. 
The striking relation between the withdrawal ol bromocriptine in this patient and 
those described previously [1-9J and the improvement ol the clinical and laboratary 
lindings provides strong circumstantial evidence lor a causative role ol bromocriptine 
in the development ol pleurisy. However, the pathogenesis is unclear. Idiosyncrasy 
cannot be ruled out, but the increased levels ol acute-phase proteins and the 
polyclonal hypergammaglobulinaemia suggest that immunological mechanisms might 
be operating. To our knowledge we are the lirst to address this possibility by 
immunological studies. Delinite prooi is lacking as the skin tests and Iymphocyte 
stimulation tests were negative. This might be due to the lact that bromocriptine 
does not provoke an immune reaction directly, but merely acts like a hapten, which 
together with pleural determinants lorms the antigen ic stimulus lor immunologically 
mediated injury.ln addition to pleural librosis, bromocriptine has also been implicated 
in the development ol retroperitoneal librosis with similar abnormalities in laboratory 
studies, suggesting a common pathogenetic mechanism [4,15-18J. Fibrotic 
inflammatory disorders ol the pleura and retroperitoneal librosis have also been 
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described during the long-term use ol the alkylated ergot derivative, methysergide, 
which has a molecular structure related to that ol bromocriptine [19-21]. Direct prooI 
that methysergide plays a causative role in these disorders is also lacking, but the 
abnormalities remit!ed alter withdrawal ol the drug, as we described lor bromocriptine. 
In conclusion, bromocriptine should be considered as a causative agent when pleurisy 
occurs, even il the daily dose is low. In such cases the drug should be stopped and 
corticosteroid treatment is possibly beneficial in order to prevent lormation ol 
irreversible pleural thickening with impairment ol pulmonary lunction. In addition, 
periodic laboratory and X-ray studies in patients on long-term bromocriptine therapy 
are recommended. 
ACKNOWLEDGMENTS 
Sandoz Pharma AG is acknowledged for their kind gift ol purilied bromocriptine-
mesylate and lor inlormation on adverse reactions to bromocriptine. 
REFERENCES 
1. Rinne UK. Pleuropulmonary changes during longterm bromocriptine treatment for 
Parkinson's disease. Lancet 1981;1:44. 
2. LeWitt PA, Calne DB. Pleuropulmonary changes during longterm bromocriptine treatment 
for Parkinson's disease. Lancet 1981;1:44-45. 
3. Ward CD, Humby MD. Pleuropulmonary and retroperitoneal fibrosis associated with 
bromocriptine treatment. J Neurol Neurosurg Psychiatry 1987;50:1706-1707. 
4. Hely MA, Morris JG, Lawrence S, Jeremy R, Genge S. Retroperitoneal fibrosis, skin 
and pleuropulmonary changes associated with bromocriptine therapy. Aust NZ J Med 
1991 ;21 :82-84. 
5. Tornling G, Unge G, Axelsson G, Noring L, Granerus AK. Pleuropulmonary reactions in 
patients on bromocriptine treatment. Eur J Respir Dis 1986;68:35-38. 
6. Wiggens J, Skinner C. Bromocriptine induced pleuropulmonary fibrosis. Thorax 
1986;41 :328-330. 
7. McElvany NG, Wilcox PG, Churg A, Fleetham JA. Pleuropulmonary disease during 
bromocriptine treatment of Parkinson's disease. Arch Intern Med 1988;2231-2236. 
8. Kinnunen E, Viljanen A. Pleuropulmonary involvement during bromocriptine treatment. 
Chest 1988;94: 1 034-1 036. 
9. Todman DH, Oliver WA, Edwards RL. Pleuropulmonary fibrosis due to bromocriptine 
treatment for Parkinson's disease. Clin Exp Neurol 1990;27:79-82. 
10. Weber G, Frey H. Zur Behandlung der Psoriasis arthropathica mit Bromocriptin. Z Hautkr 
1986;61 :1456-1466. 
11. Hedner LP, Bynke G. Endogenous iridocyclitis relieved during treatment with 
bromocriptine. Am J Ophtalmol 1985;100:618-619. 
12. Carrier M, Wild J, Pelletier LC, Copeland JG. Bromocriptine as an adjuvant to cyclosporin 
immunosuppression after hearttransplantation. Ann Thorac Surg 1990;49:129-132. 
13. Wilner ML, EHinger RB, Koyle MA, Rosenthal JT. The effect of hypoprolactinemia alone and 
in combination with cyclosporin on allograft rejection. Transplantation 1990;49:264-267. 
14. Reber PM. Prolactin and immunomodulation. Am J Med 1993;95:637-644. 
128 Chapter 3.4 
15. Hely MA, Morris JGL, Reid WGJ, O'Sullivan DJ, Williamson PM, Rail D, Broe GA, Margrie S. 
The Sydney multi-centre study of Parkinson's disese: a randomised, prospective five 
year study comparing low dose bromocriptine with low dose levodopa-carbidopa. 
J Neurol Neurosurg Psychiatry 1994;57:903-910. 
16. Herzog A, Minne H, Ziegier R. Retroperitoneal librosis in a patient with macroprolactinoma 
treated with bromocriptine. Br Med J 1989;298:1315. 
17. Bowler JV, Ormerod IE, Legg NJ. Retroperitoneal fibrosis and bromocriptine. Lancet 
1986; 1 :466. 
18. Demonet JF, Rostin M, Dueymes JM, loulalen A, Montastruc JL, Rascol A. 
Retroperitoneal fibrosis and treatment of Parkinson's disease with high doses of 
bromocriptine. Clin Neuropharmacol 1986;9:200-201. 
19. Dunn JM, Sloan H. Pleural effusion and fibrosis secondary to Sansert administration. 
Ann Thorac Surg 1973;15:295-298. 
20. Hindle W, Posner F, Sweetnam MT, Tan RSH. Pleural effusion and librosis during treatment 
with methysergide. Br Med J 1970;1:605-606. 
21. Graham JR. Cardiac and pulmonary librosis during methysergide therapy for headache. 
Am J Med Sci 1967;254:1-12. 
CHAPTER 4 
GENERAL DISCUSSION 
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This thesis describes the application ol immunological insights and techniques to 
improve the diagnosis, treatment and lollow-up ol inflammatory skin diseases, in 
parlicular allergic contact dermalilis (ACD) and allergic drug eruptions.ln th is last 
chapter, the most important lindings and conclusions ol the previous chapters will 
be discussed in a broader sen se and in the light ol recent developments in re-
search on allergic and inflammatory skin disease. The ligure on the cover is ex-
plained and some concluding remarks are made about the immune syslem ol the 
skin, manipulalion ol the immune syslem (hyposensitization and tolerance induc-
tion) and diagnostic tests lor drug allergy. Suggestions lor lurther research are 
also given. 
In both ACD and allergic drug eruplions, the skin is the target organ ol immuno-
logical reactivity to an allergen. The figure on the cover is a schematic representa-
tion ol human skin exposed to antigens (Ag) or allergens Irom inside the body, like 
most drugs (the tablet in the figure), and lrom outside the body, such as contact 
allergens (the metal ring in the ligure). A migrating T cell, specific lor the Ag in 
question or an unrelated Ag, is depicted strategically at the border between epi-
dermis and dermis. 
4.1 The immune system of the skin 
The knowledge about the cells, mediators and mechanisms that are involved in 
allergic skin reactions has increased vastly in the last two decades and it will 
continue to increase in the nexl. Therelore, it seems inevitable lor invesligators 
th at concepts, that were up-to-date at the start ol their study, will be partly out-
dated when the study linishes. This thesis is no exceplion 10 thaI. Nevertheless, 
chapter 1 attempts to review the current insights into the ce lis and cytokines that 
are involved in cutaneous inflammalion. Although this thesis is lor the most part 
about 'cellular aspects' ol Iymphocytes and keralinocytes, various other resident, 
recruited and/or recirculating skin cells, that make up the Skin Immune System 
(SIS) [1], deserve lurther study. Especially Langerhans ce lis (LC) are promising 
targets lor immunomodulation. Cytokine production proliles are another topic ol 
intense research and studies on apoptosis mayalso provide clues lor luture im-
munotherapy. 
In the chapters 1 and 2, ACD was described as a typical T helper type 1 response. 
This is, however, an oversimplification. Although many inlectious, autoimmune and 
allergic diseases have been described as typical T helper type 1 or type 2 re-
sponses [2], the original paradigm cannot entirely account lor the true complexity 
ol the in vivo situalion [3]. The role that T cells, cytokines and other ellector cells 
play in a certain disease may not always lall easily into the discrete T helper type 1 
or 2 pattern. Indeed, based on cytokine production patterns, other CD4+ T helper 
effector phenotypes (a.o. ThOA, ThOB and Th3) and also CD8' cytotoxic T cell 
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subsets (Te1 andTe2) have been deseribed [4J.ln various diseases, both T helper 
type 1 and 2 responses are present. Many responses are also mediated by 
eytokines produeed by eells other than T helper type 1 or 2 (e.g. keratinoeyte-
produeed IL-1 and IL-6, masteell and eosinophil-produeed IL-4, NKeeli-produeed 
IFN-yand maerophage-produeed IL-12).ln addition, the eell types, eytokines and 
their ellects in one stage ol a disease may be eompletely different in another. For 
example, atopie dermatitis is initially a T helper type 2 reaetion but after 24-48 
hours the T helper type 1 eytokine proliIe dominates. Thus, analogous to the elassi-
lieations based on the immune reaetion types I-IV [5J or on CD4/CD8-ratios, over-
simplilieation may be uselul lor didaetie and meehanistie purposes but in most 
in vivo eonditions the processes are more complex. 
4.2 Manipulation of the immune system 
Hyposensitization and to/erance induction 
In chapter 2.1, nickel was shown to be ubiquitous. lts presence in many objects lor 
daily use and in lood makes effective avoidance virtually impossible. That is the 
main reason lor our attempts to hyposensitize nickel ACD patients. Some investi-
gators believe th at an allergy that has al ready developed is irreversible [6J as op-
posed to primary induction ol Ag-specific tolerance, which prevents the subse-
quent development of an allergy to that Ag. However, the tendency of some aller-
gies to fade away over a period of many years proves that down regulation is 
possible. Also, lor type I allergy, the efficacy of hyposensitization has already been 
proven. Therelore, we believe the question is not whether it is possible, but how it 
should be done. 
According to generally accepted concepts, tolerance is acquired by elonal dele-
ti on (after ubiquitous Ag presentation), elonal inaetivation (after Ag presentation 
without appropriate co-stimulatory signais) and possibly also through active sup-
pression (suppressor T cells). Chapter 2.2. is the lirst published report of a clinical 
hyposensitization procedure using ultraviolet B (UVB) and subcutaneous nickel 
sulfate administration to induce Ag-specific tolerance in patients with nickel ACD. 
It is based on publications by Kripke [7, 8J and derived Irom analogous hyposensi-
tization procedures used in type I allergy, such as to pollen. UVB is now known to 
act on various cells ol the SIS, including epidermal LC, keratinocytes and T Iym-
phocytes, and on chromophores, such as DNA and trans-urocanic acid [9-11J. The 
net results of UVB on the SIS, that have been reported, are local and systemic 
immunosuppression, possibly mediated via IL-10 and TNF-o:. When UVB expo-
sure is lollowed by application ol a contact allergen, a subsequent allergen-
specilic ACD reaction is suppressed [8J. In our hyposensitization study, low dose 
UVB and subcutaneous nickel sulfate injections were administered to nickel ACD 
patients. The nickel sulfate doses were raised from 10-6 to 10-3 mol/L and its Ire-
quency was on ce a week until the highest concentration was reached and once a 
month in the subsequent follow-up period. The hyposensitization treatment was 
monitored using clinical disease activity scores and immunological parameters, 
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such as in vitro reaclivily 10 nickel in Ihe Iymphocyte prolileration assay (LPA) and 
Ilow cylomelric analysis ol Ihe expression ol the adhesion molecules LFA-l Ct; and 
ICAM-l on peripheral blood mononuciear cells (PBMC), and ol activated CD3+/ 
HLA-DR+ and CD3+/IL-2 receptor' T cells. Although Ihe clinical parameters studied 
improved signilicantly, no changes were seen in the immunological parameters 
evaluated. Possible explanations lor these findings include (1) the changes in-
duced were 100 small 10 delect, (2) the size ol Ihe group was too small to delect 
any changes, (3) the immunological lollow-up parameiers were inappropriate, and 
(4) the hyposensitization procedure is nol yel optima!. Suggestions lor lurther re-
search inciude repetition ol the procedure in a larger group, Ihe use ol epidermal 
LC as antigen presenting cells in the in vitro LPA, the lollow-up ol other immuno-
logical parameiers, such as delection ol cylokine production profiles alter aller-
gen-specilic T cell stimulation and expression ol costimulatory lactors, and olher 
hyposensitization procedures, lor example via Ihe oral roule [12J. Oral exposure 10 
nickellrom dental braces was lound to reduce sensitization upon subsequenl ear 
piercing in a large relrospective study [6J. Combination ol CsA and B7-1/B7-2-
blocking agents has also been reported as an effective melhod to induce T cell 
anergy and Ihus complete immunosuppression [13J. In addition, gamma delta 
T cells have recently been reported 10 play a pos si bie role in downregulation ol 
ACD and high-dose Ag tolerance [14, 15J. 
In chapter 2.3, an attempl was made 10 sludy in vivo cytokine production alter 
Ag-specilic stimulation (patch tesl) Ihrough immunohistochemistry ol ACD skin 
sections. However, reliable and reproducible quantification ol cytokine slaining 
proved extremely dilficull. Although image analysis (IA) was demonslrated 10 be a 
valid and uselul method to improve quantification of immunoslained inflammatory 
skin biopsies, it could not circumvenl the difficulties associated with quantification 
of cytokines Ihal cause diffuse staining. A limited study is currently done 10 see 
whether IA density measurement of positively stained section areas corresponds 
with the results ol traditional visual densitometric scoring syslems. The IA proce-
dure used in Ih is sludy is analogous 10 well-described melhods used in flow 
cylometric analysis. First, the 'red range' is selecled via Ihresholding of Hue in 
HSL color space. Alter that, Ihe resulting image is gray translormed and exclusion 
limits are set on the histogram of the negative control section (slained with an 
isolype-matched control Ab). These limits are then applied to the corresponding 
immunoslained sections, effectively leading to sublraction ol the negative contro!. 
The linal image is visually checked to contain only the positively stained section 
areas. The sizes of these section areas are measured and compared to visual 
estimations. The results ol this study wil! clarify whelher IA can also be used to 
estimate staining intensity, besides section area measuremenl. 
4.3 Diagnostic tests for allergy 
In chapler 3.1, clinical manilestations and diagnostic aspects ol allergie adverse 
drug reactions (ADR) caused by anti-epileptic drugs (AED) were reviewed. It was 
stated Ihat in Ihe case ol AED, the search for the drug that caused the ADR and a 
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suitable alternative drug is complicated by the long-term use, multi-drug therapy, 
structural similarity (cross-reactivity; mimicry) and the relative lack ol alternatives. 
Also, the relevanee and importance ol the distinction between allergy and non-
immunological reactions lor luture drug choice was stressed. The epicutaneous 
PT and the in vitra LPA were suggested to conlirm immunological reactivity to 
AED [16, 17]. In chapter 3.2, the suitability ol skin PT and in vitra LPA lor detection 
ol allergy to C8Z and the possibly cross-reactive oxcarbazepine (OC8Z) was in-
vestigated in patients on C8Z, displaying a wide range ol possibly allergie side 
effects. True allergy lor C8Z and OC8Z was lound in up to 40% and 20% ol the 
patients with suspected reaetions, respectively. The PT and the LPA did not al-
ways denote the same patients as being allergie. Therelore, these tests should be 
considered additive instead ol mutually exclusive, as depicted in the Ilowchart lor 
diagnosing allergy to AED at the end ol chapter 3.2. In the chapters 3.3 and 3.4 we 
described how the PT and the LPA were used to support the diagnosis ol drug 
allergy in two case reports on exloliative dermatitis due to C8Z and on bromo-
criptine-induced pleurisy, respectively. In the first case, immunological reactivity 
was conlirmed, in the second it was not. 
As the LPA is done completely in vitra, it is very sale. However, its main drawbacks 
are that extensive controls and large cell numbers are needed lor every Ag tested, 
and that it takes about one week to get interpretable results. In addition, its read-
out concerns the overall prolileration ol P8MC, not ol specific TeelIs. A more 
appropriate readout might be the cytokine production prolile alter Ag-specilic stimu-
lation. Also, the LPA could be modified to incorporate antibody production and 
cytotoxicity aspects. Cross-reactivity between C8Z and phenytoin is another issue 
that needs lurther study [17, 18]. lts main problem, however, is that reliable detec-
tion ol immunological cross-reactivity between these drugs requires C8Z allergie 
subjects without prior phenytoin intake or phenytoin allergie patients without prior 
exposure to C8Z. In practice, this proves to be a serious problem as prior medica-
tion is not always properly known and record ed. 
In conclusion: (1) hyposensitization ol nickel ACD patients via low dose UV8 ex-
posure and subcutaneous nickel sullate injections induced a signilicant improve-
ment ol clinical ACD parameters, but needs lurther relinement and verilication by 
appropriate immunological parameters, (2) quantilication ol immunostained inllam-
matory skin sections was improved by computer-assisted IA area measurement, 
and (3) suspected drug allergy to the anti-epileptic drugs C8Z, OC8Z and pheny-
toin could be conlirmed by parallel in vivo and in vitra detection ol immunological 
reactivity to the drug via PT and LPA, respectively. 
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SUMMARY 
This thesis is about the application ol immunological insights and techniques to 
improve the diagnosis, treatment and lollow-up ol inflammatory skin diseases, in 
particular allergie contact dermatitis and allergie drug eruptions. 
In chapter 1.1 the cells and cytokines th at are involved in cutaneous inflammation 
are discussed. Firstly, the various resident, recruited and I or recirculating skin 
cells, that make up the so-called Skin Immune System, are summarized. The Skin 
Immune System includes keratinocytes, Langerhans ce lis, melanocytes, Iympho-
cytes, cells lrom the monocyte I macrophage lineage, granulocytes, mast cells 
and endothelial ce lis. Secondly, cytokines (smalI, soluble polypeptide molecules 
that are produced by virtually every cell type in response to exogenous stimuli) are 
discussed. Cytokines interact with specific receptors on the cell membrane or 
inside cells to mediate intercellular or intracellular communication. A number ol 
cytokines important in the induction and regulation ol cutaneous inflammation are 
summarized, along with their stimuli, producer ce lis, target cells and ef/ects. 
Finally, the classilication ol immune responses according to Geil and Coombs is 
summarized lor a betler understanding ol the immune reactions at work in the 
various inflammatory skin diseases. 
Contact dermatitis is a world-wide disorder and a major cause ol occupational 
disease. Estimates ol its prevalenee in the general population range between 1 % 
and 10%. Two dillerent types can be distinguished, i.e. allergie and irritant contact 
dermatitis. In chapter 1.2, clinical, epidemiological and immunological aspects ol 
allergie contact dermatitis are discussed. Allergie contact dermatitis is seen most 
Irequently among young women, between 20 and 30 years ol age. It is an inflam-
matory skin disease that results lrom repeated contact with contact allergens or 
sensitizers. Allergie contact dermatitis is very persistent as even occasional con-
tact with allergens is sufficient to maintain the condition. The occurrance ol allergie 
contact dermatitis is tightly correlated with the presence or absence ol certain risk 
lactors. Precise details on the Irequency and type ol exposure, the type ol allergen 
involved, the risk lactors present and the localization ol the eczema are ol great 
practical importance lor estimating the prognosis. However, the search lor the 
causal contact allergen(s) in individual allergic contact dermatitis patients is not a 
light task, especially il allergy to multiple allergens exists. Patch tests and the in 
vitro Iymphocyte proliferation assay may be ol help here. The combination ol a 
positive exposure history and a positive patch test lor the same allergen is highly 
signilicant lor the clinical diagnosis ol allergic contact dermatitis. To date, avoid-
ance ol allergen exposure seems to be the only truly ef/ective measure. Immuno-
logically, allergie contact dermatitis can be characterized as a classical type IV or 
delayed type hypersensitivity reaction. This reaction is mediated by TeelIs previ-
ously sensitized to one or more contact allergens. Substances capable ol inducing 
allergie contact dermatitis are generally low molecular weight chemically reactive 
compounds, called haptens. They penetrate the skin and bind to skin proteins to 
lorm a complete antigen, capable ol inducing an immune response. Nickel, chro-
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mium and cobalt are among the most frequent contact allergens. The sequence of 
events leading to allergic contact dermatitis, after initial and subsequent repeated 
exposure to a reactive hapten, is described as two phases, (1) the induction or 
acquisition phase and (2) the elicitation or expression phase. In the afferent limb, 
antigen is taken up, processed and presented in the groove of HLA class 11 on the 
surface of antigen presenting cells. After migration to the regional Iymph no des, 
the HLA-peptide complex on the antigen presenting cell can be recognized by the 
T cell receptor of specific T cells, leading to their activation. In the efferent limb the 
previously sensitized antigen-specific CD4+ T helper type 1 cells and CD8+ cyto-
toxic T cells migrate to the skin where they may get activated upon renewed anti-
gen presentation. Release of cytokines and chemokines like interferon-y, tumor 
necrosis factor-~, interleukin-3, granulocyte-macrophage colony-stimulating fac-
tor, macrophage inflammatory protein and monocyte-chemotactic and activating 
factor leads to recruitment and activation of other T cells, specific for unrelated 
antigens, and macrophages which amplify the inflammatory response. 
Chapter 1.3 discusses clinical, epidemiological and immunological aspects of al-
lergic drug reactions, a small but important part of the broad range of adverse 
drug reactions. Reported frequencies of adverse drug reactions (allergic and 
nonallergic) range from 0.3% to 30% per drug treatment. In general, the risk of an 
allergic adverse drug reaction is between 1 % and 3%. An adverse drug reaction 
can be considered allergic if it is mediated by antigen-specific immunological mecha-
nisms, i.e. via antibodies or Iymphocytes. Drug allergy may mimic many diseases, 
ranging from mild to even fatal conditions. The majority of allergic adverse drug 
reactions, however, involve the skin and are consequently also termed allergic 
drug eruptions. The likelihood of allergic adverse drug reactions is tightly corre-
lated with the presence or absence of certain risk factors. 
Although drug allergy is often suspected, it is rarely properly analyzed. Discrimi-
nation between allergic and other adverse drug reactions is essential since it influ-
ences future drug administration. Incorrect labeling of a patient as allergic may 
lead to substitution of beneficial medication for other, possibly less effective, more 
dangerous and/or more expensive drugs. If an allergic adverse drug reaction is 
suspected, the offending drug should be discontinued as soon as possible, usu-
ally before extensive diagnostic exploration can be done. Several diagnostic tests 
have been suggested. However, the lack of a 'golden standard' for the diagnosis of 
allergic adverse drug reactions seriously hampers the proper validation of such 
tests. In vi/ra tests, such as the Iymphocyte proliferation assay, are likely to be the 
safest alternatives to rechallenge. 
Allergic adverse drug reactions mayor may not follow the allergic reaction types 
as described by Coombs and Geil. Chemical reactivity, a drug-related risk factor, 
is crucial since it determines the likelihood that a drug wil! bind to a carrier mole-
cule. As most drugs have a low molecular weight, they cannot induce an immune 
response on their own. Frequently, the drug itself or one of its (mostly reactive) 
metabolites first needs to bind covalently to carrier molecules, like proteins, glyco-
proteins and sometimes polysaccharides or cell membranes, turning it into a mul-
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tivalent complete allergen. Certain drugs induce allergic adverse drug reactions 
more Irequently than others. Commonly used allergenic drugs are antibiotics (in-
cluding p-Iactam penicillins, cephalosporins and sullonamides), anti-epileptic drugs, 
anesthetics (including muscle relaxants and thiopental), hormones (a.o. insulin), 
immunoglobulins and vaccines. 
The various immunological techniques used in this thesis are put into perspective 
in chapter 1.4. Their purpose, technical procedure, possibilities and limitations 
are discussed. The patch test, the Iymphocyte prolileration assay and Ilow cytometric 
analysis were used lor monitoring immunological parameters during hyposensiti-
zation treatment ol nickel allergic contact dermatitis patients. The patch test and 
the Iymphocyte prolileration assay were also used and validated to support the 
diagnosis ol allergic adverse drug reactions to the anti-epileptic drug carbamazepine 
and its metabolites, and to bromocriptine. Immunohistochemistry and computer-
assisted image analysis were used lor detection ol cytokines and other markers ol 
inflammation in inflammatory skin sections. 
Chapter 2.1 locuses on nickel as a contact sensitizer. The combination ol a mild 
sensitizing potential and widespread exposure ol nickel in the general population 
results in the high Irequency ol sensitization ol 10-20%. Many objects that are 
Irequently used in daily lile contain nickel, e.g. coins, keys, scissors, wrist watches, 
jewelry (a.o. earrings) and blue jeans buttons. Being a trace element, nickel is also 
present in many sorts ol lood, such as nuts (walnut, peanut, hazelnut, almond), 
bitter chocolate, oats, buckwheat, soy products and dried legumes. The primary 
routes ol nickel exposure and uptake are ingestion in the general population, in ha-
lation in the occupational setting, and, to alesser extent, release Irom surgical 
implants and dental prostheses. Although uptake ol nickel via the stratum cor-
neum, sweat ducts and hair lollicles ol the skin is important in the induction and 
elicitation ol nickel allergic contact dermatitis, its contribution to overall nickel up-
take ol the body is lairly smalI. However, the skin can act as a reservoir lor nickel 
with a mean retention time ol many months. Metals, such as nickel, chromium, 
cobalt, gold, platinum, mercury and beryllium, are directly immunogenic and ca-
pable ol inducing a wide range ol pathological conditions including allergic contact 
dermatitis, asthma and autoimmune disease, but can, under special conditions, 
also induce immunological tolerance. Nickel induces allergic contact dermatitis 
via effects on many immunocompetent cells, including Langerhans cells, kera-
tinocytes and endothelial cells. 
Chapter 2.2 is the first published report ol a clinical hyposensitization procedure 
using ultraviolet Band subcutaneous nickel sullate administration to induce anti-
gen-specilic tolerance in patients with nickel allergic contact dermatitis. The incen-
tive lor th is study was the linding that the development ol allergy could be down-
regulated il the antigen was presented in the absence ol adequate costimulatory 
signais, as can be induced by ultraviolet B exposure. Twenty-one patients with 
nickel allergic contact dermatitis were randomly assigned to either a hyposen-
sitized or control group. A schedule, consisting ol ultraviolet B treatment and 
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subcutaneous nickel sulfate administration (hyposensitization) or ultraviolet B only 
(control), was applied. During the ensuing two years, several clinical and immuno-
logical features were monitored. During ultraviolet B treatment we observed sig-
nificant clinical improvement in both groups that persisted in the hyposensitized 
group. However, no dear changes were seen in the immunological parameters 
evaluated. 
Allergic contact dermatitis is studied widely by immunostaining of skin biopsies. 
Accurate and reproducible quantification of immunostaining is difficult. A number 
of dissimilar procedures have been reported, producing results that cannot be 
easily compared. In chapter 2.3, image analysis is demonstrated as a valid and 
useful method to improve quantification of immunostained inflammatory skin biop-
sies. A semiautomatic procedure (macro) for area measurement by image analy-
sis was developed and validated. The technique allowed quantification of 
immunostaining as cell counts per square millimeter of epidermal, dermal or infil-
trate section area. The accuracy and reproducibility of the image analysis area 
measurement procedure was high, i.e. the deviations were less than 0.5% and 
1 %, respectively. When compared to traditional grid-based area measurement, 
the mean values of both methods were similar. 
Chapter 3.1 discusses clinical manifestations and diagnostic aspecls of allergic 
adverse drug reactions caused by anti-epi lept ic drugs. Skin ras hes are the most 
pronounced adverse drug reactions to anti-epileptic drugs, besides fever, Iymph-
adenopathy, hematological abnormalities and impaired liver function. In the case 
of anti-epileptic drugs, the search for the drug that caused the adverse reaction 
and a suitable alternative drug is complicated by the long-term use, multi-drug 
therapy, structural similarity (cross-reactivity; mimicry) and the relative lack of al-
ternatives. Carbamazepine, phenytoin, barbiturates and sodium valproate are re-
sponsible for the majority of adverse drug reactions to anti-epileptic drugs. AI-
though routine laboratory tests cannot reliably predict the likelihood of drug allergy 
in a single patient, epicutaneous patch tests and the in vi/ra Iymphocyte prolifera-
tion assay can be used to confirm immunological reactivity to anti-epileptic drugs. 
Such distinction between allergy and non-immunological reactions is of great im-
portance for future drug use. 
Five to 20% of patients discontinue anti-epileptic drug therapy because of adverse 
reactions. However, careful reintroduction may be considered if true drug allergy 
can be ruled out. Definitive assessment of such immunologically mediated reac-
tions requires demonstration of either specific antibodies or sensitized Iympho-
cytes. In chapter 3.2, the suitability of skin patch tests and in vi/ra Iymphocyte 
proliferation assays for detection of allergy to carbamazepine and the possibly 
cross-reactive oxcarbazepine was investigated. Sixty-five patients on carba-
mazepine, displaying a wide range of possibly allergic side effects, carbamazepine 
users without any side effects and healthy volunteers were tested. Both patch 
tests and Iymphocyte proliferation assays we re done with carbamazepine, 
oxcarbazepine and three metabolites (carbamazepine-1 0, 11-epoxide, 10-mono-
Summary 141 
hydroxy-carbamazepine and 10, 11-dihydroxy-carbamazepine). Positive patch tests 
with carbamazepine were seen in 20% and with oxcarbazepine in 14% of the 
patients. Positive Iymphocyte proliferation assay results with carbamazepine and 
oxcarbazepine were found in 40 and 19% of the patients, respectively. Both tests 
were positive in 14 and 7% of the patients, respectively. Cross-reactivity to 
oxcarbazepine was seen in approximately 40% of carbamazepine-reactive pa-
tients in both patch tests and Iymphocyte proliferation assays. 
In chapter 3.3, a case of exfoliative dermatitis due to carbamazepine allergy is 
described. The patient is a 6-year-old Caucasian girl who experienced a general-
ized erythematous skin rash during carbamazepine therapy. The eruption wors-
ened into erythroderma with fever and generalized Iymphadenopathy in the next 
four days. Routine labo ra tory studies revealed increased serum levels of liver en-
zymes and eosinophilia. Immunological reactivity to carbamazepine was confirmed 
both in vivo and in vi/ra by patch tests and Iymphocyte proliferation assays, re-
spectively. 
Chapter 3.4 describes a possible case of bromocriptine-induced pleurisy. The pleu-
risy of initially unknown origin was discovered in a patient who was treated with 
bromocriptine for Parkinson's disease for 6 years. At presentation, bilateral pleural 
thickening existed that caused severe restrietion of pulmonary function. Labora-
tory tests revealed an elevated erythrocyte sedimentation rate, polyclonal hyper-
gammaglobulinaemia, increased levels of acute phase proteins and anaemia. Af-
ter withdrawal of the bromocriptine the patient's complaints as weil as the labora-
tory parameters markedly improved. However, the pleural thickening did not re-
solve. Although these findings strongly suggested a causative role of bromocriptine, 
the in vitro Iymphocyte proliferation assay and the skin patch test with bromocriptine 
were negative. 
Finally in chapter 4, the figure on the cover is explained and some concluding 
remarks are made about the immune system of the skin, modulation of the im-
mune system via hyposensitization and tolerance induction, and diagnostic tests 
for drug allergy. In this chapter, the experimental and clinical studies described in 
this thesis are discussed in the light of recent developments in research on aller-
gie and inflammatory skin disease. 
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SAMENVATTING 
Dit proefschrift beschrijft de toepassing van immunologische inzichten en technie-
ken ter verbetering van de diagnose, behandeling en follow-up van inflammatoire 
huidziekten, in het bijzonder allergisch contacteczeem en allergische genees-
middelenerupties. 
In hoofdstuk 1.1 worden de cellen en cytokinen, die betrokken zijn bij cutane 
ontsteking, besproken. Eerst worden de diverse residente, gerekruteerde en 
recirculerende cellen in de huid, die gezamenlijk het zogenaamde Skin Immune 
System vormen, besproken. Het Skin Immune System omvat keratinocyten, 
Langerhans cellen, melanocyten, lymfocyten, cellen van de monocyt/macrofaag-
lijn, granulocyten, mestcellen en endotheelcellen. Daarna worden cytokinen (kleine 
oplosbare polypeptiden die door vrijwel elk celtype worden geproduceerd als reactie 
op exogene prikkels) besproken. Cytokinen binden aan specifieke receptoren op 
de celmembraan of binnenin de cel en verzorgen zo de inter- en intracellulaire 
communicatie. Een aantal cytokinen die een belangrijke rol spelen bij het ontstaan 
en de regulatie van cutane ontsteking, worden samengevat tezamen met hun 
stimuli, cellulaire oorsprong, doelwitcellen en effecten. Tenslotte wordt de indeling 
van immuunreacties volgens Geil en Coombs besproken om de immuunreacties, 
die bij de diverse inflammatoire huidziekten optreden, beter te kunnen begrijpen. 
Contacteczeem is een wereldwijd voorkomende aandoening en een belangrijke 
veroorzaker van beroepsziekten. Schattingen van de prevalentie in de algemene 
populatie liggen tussen 1 % en 10%. Er kunnen twee verschillende vormen worden 
onderscheiden, nl. allergisch en orthoergisch (irritant) contacteczeem. In hoofd-
stuk 1.2 worden klinische, epidemiologische en immunologische aspecten van 
allergisch contacteczeem besproken. Allergisch contacteczeem komt het meest 
voor bij jonge vrouwen in de leeftijdsgroep van 20 tot 30 jaar. Het is een inflammatoire 
huidziekte die het gevolg is van herhaald contact met contactallergenen of 
sensibilisatoren. Allergisch contacteczeem is een zeer hardnekkige aandoening 
daar zelfs incidenteel contact met het allergeen voldoende is om de aandoening 
te onderhouden. Het voorkomen van allergisch contacteczeem is nauw gecorre-
leerd met de aan- of afwezigheid van bepaalde risicofactoren. Nauwkeurige infor-
matie over de frequentie en het type van blootstelling, het type allergeen, de aan-
wezigheid van risicofactoren en de lokalisatie van het eczeem zijn van groot prak-
tisch belang om de prognose te kunnen beoordelen. De zoektocht naar het oorza-
kelijke contactallergeen in individuele allergisch contacteczeem patiënten is ech-
ter geen sinecure, zeker bij polyvalente allergie. Patch tests en in vi/ra lymfocyten 
proliferatie assays kunnen hierbij van nut zijn. Het gezamenlijk voorkomen van 
een anamnese, die positief is voor blootstelling aan een allergeen, en een posi-
tieve patch test voor hetzelfde allergeen is van groot belang voor de klinische 
diagnose van allergisch contacteczeem. Tot nu toe lijkt vermijding van expositie 
aan het allergeen de enige effectieve maatregel te zijn. Immunologisch kan aller-
gisch contacteczeem worden gekarakteriseerd als een klassieke type IV of delayed 
type hypersensitivity reactie. Dit reactietype wordt veroorzaakt door T cellen die 
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gesensibiliseerd zijn tegen één of meer contactallergenen. De stoffen die in staat 
zijn om allergisch contacteczeem te induceren, zijn meestal chemisch reactieve 
componenten met een laag molecuulgewicht, ook wel haptenen genoemd. Zij 
dringen de huid binnen, binden aan eiwitten en vormen een compleet antigeen 
dat in staat is een immuunrespons te induceren. Nikkel, chroom en kobalt behoren 
tot de meest voorkomende contactallergenen. Het ontstaan van allergisch contact-
eczeem, na de eerste en daarna herhaalde blootstelling aan een reactief hapteen, 
wordt veelal beschreven in twee fasen, en wel (1) de inductie- of acquisitiefase en 
(2) de eli citatie- of expressiefase. In de afferente route wordt antigeen opgeno-
men, geprocest en gepresenteerd in de groeve van HLA klasse 11 moleculen op 
het oppervlak van antigeen presenterende cellen. Na migratie naar de regionale 
lymfklieren kan het HLA-peptide complex op de antigeen presenterende cellen 
worden herkend door de T cel receptor van specifieke T cellen, hetgeen leidt tot 
hun activering. In de efferente route migreren de gesensibiliseerde antigeen-spe-
cifieke CD4+ T helper type 1 cellen en CD8' cytotoxische T cellen naar de huid, 
waar zij bij hernieuwde presentatie van het antigeen geactiveerd kunnen worden. 
Afgifte van cytokinen en chemokinen, zoals interferon-y, tumor necrosis factor-p, 
interleukine-3, granulocyte-macrophage colony-stimulating factor, macrophage 
inflammatory protein en monocyte-chemotactic and activating factor, leidt tot re-
krutering en activering van andere T cellen, die specifiek zijn voor andere anti-
genen, en macrofagen waardoor de ontstekingsreactie wordt versterkt. 
Hoofdstuk 1.3 bespreekt klinische, epidemiologische en immunologische aspec-
ten van allergische geneesmiddelenreacties, die een klein maar belangrijk deel 
van het brede spectrum van bijwerkingen van geneesmiddelen vormen. De gerap-
porteerde frequentie van geneesmiddelenreacties (allergisch en niet-allergisch) 
ligt tussen 0.3% en 30% per behandeling met een geneesmiddel. In het algemeen 
is het risico op een allergische geneesmiddelenreactie 1 % tot 3%. Een genees-
middelenreactie kan als allergisch worden beschouwd als deze wordt gemedieerd 
door antigeen-specifieke immunologische mechanismen, zoals antistoffen en 
lymfocyten. Geneesmiddelenallergie kan veel ziekten, in ernst variërend van mild 
tot zelfs fataal, nabootsen. De meerderheid van de allergische geneesmiddelen-
reacties betreffen echter de huid en worden daarom ook wel allergische 
geneesmiddelenerupties genoemd. De kans op een allergische geneesmiddelen-
reactie is nauw gecorreleerd met de aan- of afwezigheid van bepaalde risico-
factoren. 
Hoewel geneesmiddelenallergie vaak wordt vermoed, wordt deze zelden goed 
geanalyseerd. Onderscheid tussen allergische en andere geneesmiddelenreacties 
is van groot belang aangezien het toekomstige medicatiebeleid erdoor wordt be-
paald. Het foutief als allergisch bestempelen van een patiënt kan er namelijk toe 
leiden dat nuttige medicatie wordt vervangen door andere, mogelijk minder effec-
tieve en / of duurdere geneesmiddelen. Indien een allergische geneesmiddelen-
reactie wordt vermoed, moet het betreffende geneesmiddel zo snel mogelijk wor-
den gestaakt, vrijwel altijd vóórdat uitgebreide diagnostiek kan worden verricht. 
Enkele diagnostische tests zijn geopperd. Echter, het gebrek aan een 'gouden 
standaard' voor de diagnose allergische geneesmiddelenreactie belemmert een 
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goede validering van zulke tests. In vi/ra tests, zoals de lymfocyten proliferatie 
assay, zijn de veiligste alternatieven voor rechallenge. 
Allergische geneesmiddelen reacties kunnen al of niet volgens de allergische 
reaclietypen zoals door Geil en Coombs beschreven, verlopen. De chemische 
reactiviteit van een stof is een cruciale geneesmiddel-gerelateerde risicofactor 
omdat deze de kans, dat een geneesmiddel aan een carrier bindt, bepaalt. Aange-
zien de meeste geneesmiddelen een laag molecuulgewicht hebben, kunnen zij 
zelfstandig geen immuunrespons induceren. Vaak moet het geneesmiddel zelf, of 
een van zijn (veelal reactieve) metabolieten, eerst covalent binden aan carrier-
moleculen, zoals eiwitten, glycoproteïnen en soms polysacchariden of cel-
membranen, waardoor een multivalent compleet allergeen ontstaat. Bepaalde 
geneesmiddelen induceren vaker een allergische geneesmiddelen reactie dan 
andere. Veel gebruikte allergene geneesmiddelen zijn antibiotica (inclusief de 
p-Iactam penicillinen en sulfonamiden), anti-epileptica, anaesthetica (inclusief de 
spierverslappers en thiopental), hormonen (o.a. insuline), immunoglobulinen en 
vaccins. 
De verschillende in dit proefschrift gebruikte immunologische technieken worden 
in perspectief geplaatst in hoofdstuk 1.4. Hun doel, technische procedure, moge-
lijkheden en beperkingen worden besproken. De patch test, lymfocyten proliferatie 
assay en flowcytometrische analyse werden gebruikt voor het vervolgen van 
immunologische parameters tijdens hyposensibilisatie van nikkel allergisch contact-
eczeem patiënten. De patch test en lymfocyten proliferatie assay werden tevens 
gebruikt en gevalideerd ter ondersteuning van de diagnose allergische genees-
middelenreactie door het anti-epilepticum carbamazepine en zijn metabolieten, en 
door bromocriptine. Immunohistochemie en computer-assisted image analysis wer-
den gebruikt voor de detectie van cytokinen en andere ontstekingsmarkers in huid-
coupes van patiënten met inflammatoire huidziekten. 
Hoofdstuk 2.1 richt zich op nikkel als contactallergeen. De combinatie van een 
mild sensibiliserend vermogen en de omvangrijke blootstelling aan nikkel in de 
algemene bevolking resulteren in de hoge sensibilisatiefrequentie van 10-20%. 
Veel voorwerpen voor dagelijks gebruik, zoals geld, sleutels, scharen, horloges, 
sieraden (bijv. oorbellen) en metalen knopen aan spijkergoed, bevatten nikkel. Als 
sporenelement is nikkel ook aanwezig in veel voedingsmiddelen, zoals noten (wal-
noot, pinda, hazelnoot, amandel), pure chocolade, haver, boekweit, sojaprodukten 
en gedroogde groenten. De belangrijkste wegen van blootstelling en opname van 
nikkel zijn via de voeding in de algemene populatie, via inhalatie in bepaalde be-
roepsgroepen en in mindere mate vanuit chirurgische implantaten en tand-
heelkundige prothesen. Hoewel de opname van nikkel via het stratum corneum, 
de zweetklieren en de haarfollikels van de huid belangrijk is voor de inductie en 
elicilatie van nikkel allergisch contacteczeem, is de bijdrage daarvan aan de totale 
nikkelopname van het lichaam vrij gering. De huid kan echter wel als een reservoir 
voor nikkel fungeren met een gemiddelde retentietijd van vele maanden. Metalen 
als nikkel, chroom, kobalt, goud, platina, kwik en beryllium zijn direct immunogeen 
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en kunnen een scala van pathologische aandoeningen veroorzaken, waaronder 
allergisch contacteczeem, astma en autoimmuunziekten, maar kunnen, onder 
speciale omstandigheden, ook tolerantie induceren. Nikkel induceert allergisch 
contacteczeem via effecten op diverse immunocompetente cellen, onder andere 
Langerhans cellen, keratinocyten en endotheelcellen. 
Hoofdstuk 2.2 is de eerste gepubliceerde beschrijving van een klinische hypo-
sensibilisatieprocedure, waarbij ultraviolet B licht en subcutane toediening van 
nikkelsulfaat is gebruikt om antigeen-specifieke tolerantie in patiënten met nikkel 
allergisch contacteczeem te induceren. De aanzet tot deze studie werd gevormd 
door de bevinding dat het ontstaan van een allergie kon worden verminderd door 
het betreffende antigeen aan te bieden in afwezigheid van adequate costimulatie, 
zoals door ultraviolet B kan worden geïnduceerd. Eenentwintig patiënten met nik-
kel allergisch contacteczeem werden random toegewezen aan de hyposensi-
bilisatie- of de controlegroep. Een behandelingsschema werd toegepast bestaande 
uit ultraviolet B-expositie en subcutane toediening van nikkelsulfaat (hyposensi-
bilisatiegroep) of uitsluitend ultraviolet B-expositie (controlegroep). Gedurende de 
daaropvolgende twee jaar werden diverse klinische en immunologische parame-
ters vervolgd. Tijdens de ultraviolet B-behandeling werd significante klinische ver-
betering in beide groepen gezien, welke bleef voortbestaan in de hyposensi-
bilisatiegroep. Er werden evenwel geen duidelijke veranderingen in de immuno-
logische parameters gezien. 
Allergisch contacteczeem wordt vaak bestudeerd via immunohistochemie op 
huidbiopten. Precieze en reproduceerbare kwantificering van immunohisto-
chemische aankleuring is moeilijk. Een aantal verschillende procedures zijn be-
schreven, waarvan de resultaten onderling moeilijk vergelijkbaar zijn. In hoofd-
stuk 2.3 wordt image analysis gedemonstreerd als een valide en bruikbare me-
thode ter verbetering van de kwantificering van immunohistochemisch gekleurde 
coupes van ontstekingshuid. Een semi-automatische image analysis procedure 
(macro) voor meting van oppervlak werd ontwikkeld en gevalideerd. Deze tech-
niek maakte het mogelijk om immunohistochemische aankleuring te kwantificeren 
als het aantal positieve cellen per vierkante millimeter epidermaal, dermaal of 
infiltraatoppervlak. De precisie en reproduceerbaarheid van deze image analysis 
procedure voor meting van oppervlakken was hoog, d.w.z. de afwijkingen waren 
kleiner dan respectievelijk 0.5% en 1 %. Bij vergelijking met traditionele oppervlakte-
meting met rasters bleken de gemiddelde waarden van beide methoden equiva-
lent. 
Hoofdstuk 3.1 bespreekt klinische manifestaties en diagnostische aspecten van 
allergische geneesmiddelenreacties veroorzaakt door anti-epileptica. Huiderup-
ties zijn de meest uitgesproken verschijnselen, naast koorts, Iymfadenopathie, 
hematologische afwijkingen en gestoorde leverfunctie. Bij anti-epileptica wordt de 
zoektocht naar het veroorzakend medicament en een geschikt alternatief nog be-
moeilijkt door een vaak langdurig gebruik, combinatietherapie, structurele ver-
wantschap (kruisreacties, mimicry) en een relatief tekort aan alternatieven. 
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Carbamazepine, fenytoïne, barbituraten en natriumvalproaat zijn verantwoordelijk 
voor de meerderheid van de allergische geneesmiddelenreacties door anti-
epileptica. Hoewel routine laboratoriumtesten de waarschijnlijkheid van genees-
middelenallergie in een individuele patiënt niet betrouwbaar kunnen voorspellen, 
zijn de patch test en de in vitro lymfocyten proliferatie assay wel bruikbaar ter 
bevestiging van immunologische reactiviteit tegen anti-epileptica. Een dergelijk 
onderscheid tussen allergie en niet-immunologische reacties is van groot belang 
voor het toekomstig medicatiebeleid. 
Vijf tot 20% van de patiënten staken de behandeling met anti-epileptica vanwege 
bijwerkingen. Voorzichtige herintroductie kan echter worden overwogen indien een 
echte geneesmiddelenallergie kan worden uitgesloten. Voor definitieve bepaling 
van zulke immunologisch gemedieerde reacties is het aantonen van specifieke 
antistoffen of gesensibiliseerde lymfocyten vereis\. In hoofdstuk 3.2 wordt de 
geschiktheid van de patch test en de in vitro lymfocyten proliferatie assay onder-
zocht voor de detectie van allergie door carbamazepine en het mogelijk kruis-
reagerende oxcarbazepine. Zesenvijftig carbamazepine-gebruikende patiënten met 
een breed scala van mogelijk allergische bijwerkingen werden getest, evenals 
carbamazepine-gebruikers zonder bijwerkingen en gezonde vrijwilligers. Zowel de 
patch test als de lymfocyten proliferatie assay werden gedaan met carbamazepine, 
oxcarbazepine en drie metabolieten (carbamazepine-l 0, ll-epoxide, 10-mono-
hydroxy-carbamazepine en 10, ll-dihydroxy-carbamazepine). Een positieve patch 
test met carbamazepine werd gezien bij 20% en met oxcarbazepine bij 14% van 
de patiënten. Positieve lymfocyten proliferatie assay resultaten met carbamazepine 
en oxcarbazepine werden gevonden bij respectievelijk 40% en 19% van de patiën-
ten. Beide testen waren positief bij respectievelijk 14% en 7% van de patiënten. 
Kruisreactiviteit tegen oxcarbazepine werd gezien bij ongeveer 40% van de 
carbamazepine-reactieve patiënten, zowel in de patch test als de lymfocyten 
proliferatie assay. 
In hoofdstuk 3.3 wordt een casus van exfoliatieve dermatitis door carbamazepine-
allergie beschreven. De patiënt is een 6-jarig Kaukasisch meisje dat een gegene-
raliseerde erythemateuze huideruptie doormaakte tijdens gebruik van carba-
mazepine. In de daaropvolgende 4 dagen verergerde de huideruptie tot 
erythrodermie met koorts en gegeneraliseerde Iymfadenopathie. Routine labora-
toriumonderzoek leverde verhoogde serumconcentraties van leverenzymen en 
eosinofilie op. Immunologische reactiviteit tegen carbamazepine werd in vivo en in 
vitra bevestigd door respectievelijk de patch test en de lymfocyten proliferatie assay. 
Hoofdstuk 3.4 beschrijft een casus van een mogelijk door bromocriptine veroor-
zaakte pleuritis. De pleuritis, door aanvankelijk onbekende oorzaak, werd gevon-
den bij een patiënt die reeds 6 jaar werd behandeld met bromocriptine wegens de 
ziekte van Parkinson. Bij presentatie was bilateraal pleuraverdikking aanwezig, 
die ernstige beperking van de longfunctie veroorzaakte. Bij laboratoriumonderzoek 
werden een verhoogde bezinkingssnelheid van de erythrocyten, een polyklonale 
hypergammaglobulinemie, verhoogde serumconcentraties van de acute fase ei-
witten en anemie gevonden. Na het staken van bromocriptine werd duidelijke verbe-
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tering van zowel klinische als laboratoriumparameters gezien. De pleuraverdikking 
verdween echter niet. Hoewel deze bevindingen sterk wijzen op een oorzakelijke rol 
van bromocriptine, waren zowel de in vi/ra lymfocyten proliferatie assay als de patch 
test met bromocriptine negatief. 
Tenslotte wordt in hoofdstuk 4 de figuur op de omslag verklaard en worden en-
kele afsluitende opmerkingen gemaakt over het immuunsysteem van de huid, de 
modulatie van het immuunsysteem door hyposensibilisatie en de inductie van to-
lerantie, en diagnostische tests voor geneesmiddelenallergie. In dit hoofdstuk 
worden de in dit proefschrift beschreven experimentele en klinische studies be-
sproken in het licht van recente ontwikkelingen in het onderzoek van allergische 
en inflammatoire huidziekten. 
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3D three dimensional ETAF epidermal cell-derived 
Ab anti body (-bodies) thymocyte activating 
ACD allergie contact dermatitis factor 
ADE allergie drug eruption(s) ESR erythrocyte sedimentation 
ADR adverse drug reaction(s) rate 
AED anti-epileptic drug(s) FB libroblast(s) 
Ag antigen(s) FACS fluorescence-activated 
AHS anticonvulsant hypersensi- cell sorter 
tivity syndrome FITC fluorescein isothiocyanate 
ANA antinuclear antibody(ies) FRC free residual capacity 
AP alkaline phosphatase GM-CSF: granulocyte-macrophage 
APAAP alkaline-phosphatase- colony-stimulating factor 
anti-alkaline-phosphatase h hour(s) 
APC antigen presenting cell(s) Hb hemoglobin 
APES 3' aminopropyllriethoxy- 'H-TdR triliated thymidine 
silane HE haematoxylin eosin 
BSA bovine serum albumin HETE hydroxy-eicosa-
C complement tetraenoic acid 
CBZ carbamazepine HLA human leukocyte antigen 
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CCD charge-coupled device HS human serum 
CD1 cluster of differentiation-1 Hu human 
CD contact dermatitis IA image analysis 
CGRP calcitonin gene-related ICAM intercellular adhesion 
peptide molecule 
CLA cutaneous Iymphocyte- lCD irritant contact dermatitis 
associated antigen ICDRG international contact 
cpm counts per minute dermatitis research group 
CRP c-reactive protein ICE interleukin-1 ~ converting 
CS corticosteroid(s) enzyme 
CT computer tomography IFN interferon 
DC dendritic cell(s) Ig immunoglobulin(s) 
DIOL 10,11-dihydroxy-CBZ IHC immunohistochemistry 
DNA deoxyribonucleic acid IL interleukin 
DTH delayed type IL-1ra interleukin-1 receptor 
hypersensitivity antagonist 
EN endothelial cell(s) IP-10 IFN-y-inducible protein 1 ° 
EC epidermal cell(s) KC keratinocyte(s) 
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EDN eosinophil-derived factor 
neurotoxin LC Langerhans cell(s) 
EGF epidermal growth factor LE lupus erythematosus 
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LPA Iymphocyte proliferation RNA ribonucleic acid 
assay(s) RPMI RosweIl Park Memorial 
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LT leukotriene(s) SALT skin-associated Iymphoid 
MBP major basic protein tissue 
MCAF monocyte-chemotactic SD standard deviation(s) 
and activating factor SEM standard error(s) of the 
MCP monocyte-chemotactic mean 
protein SI stimulation index(-ices) 
MC mast cell(s) SIS skin immune system 
MCrc tryptase and chymase posi- SLE systemic lupus 
tive mast cell(s) erythematosus 
MHC major histocompatibility SOM somatostatin 
complex SP substance P 
MHD 10-monohydroxy-CBZ TcR T cell receptor(s) 
Mig mouse immunoglobulin TEN toxic epidermal necrolysis 
MIP macrophage inflammatory TGF transforming growth factor 
protein Th T helper 
MPO myeloperoxidase TIFF tagged image file format 
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NK natural killer TNF tumor necrosis factor 
NKA neurokinin A TPA 12-0-tetradecanoyl-
NF nuclear factor(s) phorbol-13-acetate 
NSAID non-steroidal anti- UV ultraviolet 
inflammatory drug(s) VCAM vascular cell adhesion 
OCBZ oxcarbazepine molecule 
OD optica I density VLA very late activating 
p probability antigen 
PAF platelet activating factor WBC white blood cell(s) 
PBMC peripheral blood 
mononuclear cell(s) 
PBS phosphate-buffered saline 
PDGF platelet-derived growth 
factor 
PE phycoerythrin 
PG prostaglandin(s) 
PHEN phenytoin 
PMA phorbol myristate acetate 
PPD purified protein derivative 
PT patch testIs) 
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